- - - --------------------------------------------------------------------------------
- - - --------------------------------------------------------------------------------
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K
(MARK ONE)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
EXCHANGE ACT OF 1934 (FEE REQUIRED)
FOR THE FISCAL YEAR ENDED JUNE 30, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 (NO FEE REQUIRED) FOR THE TRANSITION PERIOD
FROM _________ TO __________
COMMISSION FILE NUMBER 333-1926
DOCTORS HEALTH, INC.
(FORMERLY DOCTORS HEALTH SYSTEM, INC.)
(Exact name of registrant as specified in its charter)
MARYLAND 52-1907421
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or organization) Identification No.)
10451 MILL RUN CIRCLE, 10TH FLOOR
OWINGS MILLS, MARYLAND 21117
(410) 654-5800
(Address including zip code, and telephone number, including
area code, or registrant's principal executive offices)
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
None
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
None
Indicate by check mark whether the Registrant (1) has filed all Reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such Report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes (x) No ( )
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10 K. (X)
State the aggregate market value of the voting stock held by non-affiliates
of the Registrant: $6,720,150.
Indicate the number of shares outstanding of each of the Registrant's
classes of common stock.
<TABLE>
<CAPTION>
CLASS OUTSTANDING AT SEPTEMBER 22, 1997
- - - --------------------------------------------------------------------------------- ---------------------------------
<S> <C>
CLASS A COMMON STOCK, PAR VALUE $.01 PER SHARE 810,000 SHARES
CLASS B COMMON STOCK, PAR VALUE $.01 PER SHARE 2,664,010 SHARES
</TABLE>
DOCUMENTS INCORPORATED BY REFERENCE
Not Applicable
- - - --------------------------------------------------------------------------------
- - - --------------------------------------------------------------------------------
<PAGE>
FORWARD LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS
FORWARD LOOKING STATEMENTS. Certain statements in this document that are
not historical facts are hereby identified as "forward looking statements."
Doctors Health, Inc. ("Doctors Health" or the "Company") cautions readers that
such "forward looking statements" including, without limitation, those relating
to the Company's future business prospects, revenues, working capital,
liquidity, capital needs, interest costs and income, are necessarily estimates
reflecting the best judgment of the Company's senior management and involve a
number of assumptions, risks and uncertainties. Accordingly, actual results may
differ materially from those suggested by the "forward looking statements". Such
"forward looking statements" should, therefore, be considered in light of
various important factors, including those set forth below and others set forth
from time to time in the Company's reports and registration statements filed
with the Securities and Exchange Commission (the "SEC"). These "forward looking
statements" are found at various places throughout this document.
In particular, the discussions herein under "Item 1. Business" and "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations" are susceptible to risks and uncertainties discussed below. The
Company, through its senior management, may from time to time make "forward
looking statements" about the matters described herein or other matters
concerning the Company. The Company disclaims any intent or obligation to update
"forward looking statements".
FACTORS THAT MAY AFFECT FUTURE RESULTS. The health care industry, in
general, and the medical management business, in particular, are in a state of
significant flux. This, together with the circumstance that the Company has a
relatively short operating history, makes the Company particularly susceptible
to various factors that may affect future results such as risks relating to the
Company's growth strategy; identification of growth opportunities; dependence on
HMO enrollee growth; the capitation nature of the Company's revenues;
difficulties inherent in controlling the utilization of health care services and
health care costs; exposure to professional liability; and uncertainties
regarding the changes in and enforcement of government laws and regulations. For
a more detailed discussion of these factors and their potential impact on future
results, see the applicable discussions herein.
2
<PAGE>
PART I
ITEM 1. BUSINESS
GENERAL
The Company is a physician driven managed care and medical management
company which conducts its business through a network consisting of primary care
physicians ("PCPs"), specialists, hospitals and other health care providers (the
"Network"). As of June 30, 1997, the Network included 2,657 physicians in the
state of Maryland and Northern Virginia, including approximately 197 PCPs, 189
obstetrician-gynecologists and 2,271 specialists.
The Company's primary focus is managing physician networks, consisting of
individual and small groups of physicians organized by the Company into medical
groups, existing physician networks, independent practice associations ("IPAs")
and independent physician groups. The Network is designed to give the Company
access to, and increase its bargaining power for, managed care contracts and to
provide health maintenance organizations ("HMOs") and other prepaid health
insurance plans (collectively, the "Payors") with a single-source of
well-managed health care providers.
The Company's overall strategy is to deliver health care at a cost which is
less than the revenues it receives under Global Capitation Contracts with Payors
(the "Global Capitation Contracts"). The Global Capitation Contracts obligate
the Company to provide primary care, specialist, hospital and other services to
enrollees (persons entitled to health care services through their employers or,
with respect to elderly persons, through the federal government's Medicare
program) of Payors (the "Global Capitation Contracts"). Enrollees are sometimes
referred to as capitation lives. The Company seeks to ensure the delivery of
high quality, cost-effective health care by (i) delivering preventive medical
care services to reduce high-cost, acute care episodes; (ii) arranging for the
cost-effective delivery of health care services through managed care contracting
arrangements with various health care providers; and (iii) managing certain
medical cases to seek favorable treatment results for patients. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations."
As a managed care company, the Company negotiates and enters into Global
Capitation Contracts, pursuant to which (i) Payors pay the Company a fixed
amount per month based on the number of enrollees who have selected a PCP in the
Network and (ii) the Company pays the health care providers within the Network,
or those having other contractual arrangements with the Company for providing
the required medical care. The Company also receives a management fee derived
from revenues earned by certain physician medical groups it has organized (the
"Core Medical Groups") pursuant to certain long-term management agreements
between the Core Medical Groups and the Company ("PSO Agreement"). The PCPs who
have affiliated with the Company designate the Company as their agent for the
purpose of negotiating Global Capitation Contracts and other managed care
contracts.
As a medical management company, the Company coordinates the delivery of
medical care by the various health care providers in the Network. Through a care
management department consisting of physicians, nurses, social workers and other
staff, the Company seeks to promote the wellness of patients, control costs, and
encourage patient satisfaction through the delivery of medical management
services. Such medical management services include case and disease management,
utilization review and quality management services.
THE MANAGED HEALTH CARE INDUSTRY
Physicians have traditionally provided medical care on a fee-for-service
basis, which provides few incentives for the efficient utilization of resources
and has contributed to increases in health care costs that are significantly
higher than historical inflation rates. Concerns over the accelerating cost of
health care have caused employers, individuals and the federal and state
governments to turn to HMOs and other forms of managed care in an attempt to
manage health care costs more effectively. The Company believes that overall
enrollment in HMOs will continue to increase due to the fact that HMOs generally
offer lower overall premium costs than traditional health insurance which
reimburses physicians on a fee-for-service basis.
Health care in the United States historically has been delivered through a
fragmented system of health care providers, including individual or small groups
of PCPs and specialists. In an effort to manage their costs and minimize their
risk, Payors are shifting from fee-for-service payments for physicians and are
increasingly utilizing "capitation" arrangements. Under capitation arrangements,
physicians receive a fixed monthly fee per assigned patient (referred to as an
"enrollee") and agree to provide certain health care services required by such
enrollee. Under these arrangements, physicians assume the risk that they will be
able to provide medical care at costs less than the capitation payment. The
Company believes that traditional PCPs and small group specialty practices are
at a disadvantage in a managed care environment because they have high operating
costs, little bargaining power with Payors and little or no information or data
regarding utilization of health care
3
<PAGE>
services or the total health care costs of treating their patients, and
therefore are unable to assess the business risks of managed care.
As a result of these trends, PCPs and specialists have begun to abandon
traditional practices in favor of affiliating with larger organizations, such as
the Company, to negotiate capitation rates and incentive payments with Payors,
and to provide management and other services to physicians to manage the
economic risk involved in providing health care.
STRATEGY
The Company believes the evolution of managed care in the health care
industry has created an opportunity to provide health care more efficiently and
profitably than is possible under the traditional "fee-for-service" or "HMO
network" models. The Company's Network and its medical management services have
enhanced the Company's bargaining power to negotiate Global Capitation Contracts
with Payors. The key elements of this strategy are as follows:
NETWORK DEVELOPMENT. The Company has constructed the Network by entering
into various affiliation arrangements with PCPs, specialists, hospitals and
other health care providers in the Baltimore and Washington metropolitan areas,
Northern Virginia and surrounding regions to enable it to assume risk under
Global Capitation Contracts for certain health care services. Through these
affiliation arrangements, the Company obtains the right to negotiate and execute
managed care contracts on behalf of individual physicians, independent IPAs and
medical groups, and PCPs who have sold their practice assets to the Company and
become employed by a Core Medical Group.
EFFECTIVELY MANAGE THE DELIVERY OF MEDICAL CARE. The Company believes that
much of the high cost of health care and patient dissatisfaction with health
care outcomes is caused by excessive utilization of high cost services and the
lack of incentives in the health care system to help patients avoid high-cost,
episodic care. Accordingly, the Company coordinates the delivery of health care
services among the physicians, hospitals, and other providers within the Network
to (i) focus on wellness and health promotion programs managed by the Company
and individual PCPs, (ii) reduce specialist and other provider costs through
early and effective care management services; and (iii) reduce medical costs,
particularly inpatient, costs through more efficient utilization of alternative
medical care strategies such as outpatient or home care, where medically
appropriate.
MEDICARE MANAGED CARE. An important element of the Company's strategy is
the enrollment of Medicare-eligible persons in the Medicare managed care plans
with which the Company contracts. Compensation rates for Medicare patients are
considerably higher than for non-Medicare patients, reflecting the greater
historical expense of providing care to Medicare patients. Accordingly, an
important component of the Company's strategy is to (i) obtain access to
significant numbers of Medicare patients through various contractual
arrangements with Payors and PCPs; (ii) convert Medicare fee-for-service
patients of the PCPs to Medicare managed care plans; and (iii) attract new
Medicare patients to enroll in Medicare HMOs with whom the Company contracts.
ATTRACTIVE TO PHYSICIANS. The Company seeks to be attractive to physicians,
and particularly to PCPs. The Company is dedicated to the creation of
professionally managed networks that facilitate physicians focusing on the
practice of medicine using clinical protocols and procedures developed in
cooperation with fellow physicians and other sources. The Company's strategy is
to have a network structure that allows physicians greater access to managed
care contracts and hospital case management than they could obtain
independently.
ACQUISITION PROGRAM
As of June 30, 1997, the Company had obtained the right to negotiate and
execute managed care contracts for 197 PCPs through agreements with individual
PCPs, independent IPAs and independent medical groups and through acquisitions
of assets of the medical practices of PCPs who became employees of a Core
Medical Group.
In February 1997, Company completed the merger of Medtrust Medical Group,
Inc., an IPA based in Springfield, Virginia, into Doctors Health of Virginia,
Inc., a subsidiary of the Company. This transaction resulted in the creation of
an IPA consisting of PCPs providing medical care throughout Northern Virginia
and a network of specialist physicians. As of June 30, 1997, the Company had
entered into contracts with approximately 61 PCPs and 136 specialists who had
been members of the Medtrust Medical Group, Inc.
Also during fiscal year 1997, the Company and a 37-member physician group
terminated a joint contracting arrangement by mutual consent.
4
<PAGE>
The Company expects it will continue to expand its Network primarily by
entering into managed care contracting arrangements with individual physicians,
independent IPAs and existing practice groups in which such physicians agree to
serve managed care patients through the Company's Global Capitation Contracts.
In addition, the Company is pursuing acquisition and expansion opportunities in
the Baltimore and Washington metropolitan area, other regions in the State of
Maryland, the Commonwealth of Virginia and surrounding regions. While the
Company also expects to add physicians to its Core Medical Groups by acquiring
their assets, expansion by asset acquisitions is expected to play a smaller role
in the Company's expansion strategy.
OPERATIONS
The Company's operations consist of (i) negotiating Global Capitation
Contracts and other risk arrangements with Payors; (ii) developing and
implementing medical management services to enrollees and Payors, including
physician credentialing, care management, utilization review/referral
management; (iii) developing a network of physicians and other health care
providers, including the execution of managed care contracting agreements with
individual physicians, independent groups and IPAs; and (iv) providing
traditional practice management to PCPs who practice medicine through the Core
Medical Groups.
MANAGED CARE CONTRACTING. The Company negotiates for and enters into Global
Capitation Contracts with Payors to provide health care services to their
enrollees. As of June 30, 1997, the Company had 8,199 capitation lives covered
by its Global Capitation Contracts. Of these capitation lives, 4,943 capitation
lives participated in the Company's commercial Global Capitation Contracts and
3,256 capitation lives participated in the Company's Medicare Global Capitation
Contracts.
The Company has entered into two Medicare Global Capitation Contracts and
one commercial Global Capitation Contract with Payors, and is negotiating Global
Capitation Contracts with additional Payors who conduct business in the
Baltimore and Washington metropolitan area, Virginia and surrounding regions.
The Company has entered into a memorandum of understanding to enter into a
Medicare Global Capitation Contract with NYLCare Health Plans of the
Mid-Atlantic, Inc. ("NYLCare") which will add approximately 11,000 Medicare
lives to the Company's Global Capitation Contracts (See "Business--Recent
Developments") Global Capitation Contracts typically obligate the Company to
provide and pay for all physician services (except for negotiated carve-outs)
and, in certain contracts, hospital and ancillary services for a percentage of
the premium or a fixed capitation payment. The payment from a Payor to the
Company is typically calculated based on the number of enrollees of the HMO who
have selected the Company's PCPs. Such Global Capitation Contracts generally
have terms of approximately one year and, after the initial term, are renewable
for one-year terms unless canceled by either party. In its Payor contracts, the
Company currently attempts to assume risk for all services, except mental health
and pharmacy. Eye care, home health and durable medical equipment also may be
carved out of the Company's risk due to more competitive terms for these
services being available to Payors based on their existing national
relationships. The Payor in each contract also retains a percentage of the
premium to perform marketing, enrollment and certain administrative services.
The Company also is party to certain capitation contracts pursuant to which
the Payor compensates the Company only for primary care medical services
("Gatekeeper Capitation Contracts"). The Company derives no earnings from the
Gatekeeper Capitation Contracts and will attempt to convert the managed care
lives in such commercial gatekeeper contracts to Global Capitation Contracts
when possible. (See "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Source of Revenues").
The Company's commercial Global Capitation Contract with Free State Health
Plan, Inc., a subsidiary of Blue Cross-Blue Shield of Maryland ("Free State"),
terminated during fiscal year 1997, but the Company and Free State have orally
agreed to continue to conduct business pursuant to such contract until the
parties complete negotiations for the terms of a new agreement. In addition, the
Company's Medicare Global Capitation Contract with Health Care Corporation of
the Mid-Atlantic, a subsidiary of Blue Cross-Blue Shield of Maryland, ("HCCMA")
terminated during fiscal year 1997, but the Company and HCCMA have orally agreed
to conduct business pursuant to such contract until the parties complete
negotiations for the terms of a new agreement. The Company's Medicare Global
Capitation Contract with Chesapeake Health Plan, a subsidiary of United Health
Care of the Mid-Atlantic, became effective on June 1, 1996 and continues
thereafter unless terminated by either party.
MEDICAL MANAGEMENT. The Company believes the most successful approach to
managing capitation risk and the costs associated with that risk is through the
care management process. Care management seeks to promote the wellness of
patients, control costs, encourage patient satisfaction and to coordinate and
integrate the health care services provided by the Company's Network. The
Company's care management program consists of credentialing, utilization review,
referral management, case management, disease management and quality management.
These programs seek to improve and preserve the
5
<PAGE>
quality of health care services provided by the Company's Network and control
the cost of medical care. Under two of the Company's Global Capitation
Contracts, Payors have delegated to the Company utilization review and care
management. The Company employs 13 care management personnel with medical
director, nursing, social work, case management and other patient care
management experience. All of the Company's care management staff are either
physicians, registered nurses or licensed social workers.
CREDENTIALING. All PCPs and specialists in the Network must complete the
Company's credentialing process. In accordance with the Company's credentialing
policies and procedures, these physicians submit a comprehensive application to
the Company's credentialing staff. The application materials are reviewed by the
Company and submitted to an external credentialing verification organization,
which provides primary source verification of information submitted in the
application. The application is then submitted to the Company's physician
credentialing committee and Medical Director for approval. The Company believes
its credentialing process helps ensure the quality of the PCPs and specialists
in the Network and promotes the quality of care provided to patients.
REFERRAL AND UTILIZATION MANAGEMENT. The Company also performs referral and
utilization management. Referral and utilization management encourages PCPs in
the Network to provide cost-effective, quality care by emphasizing preventive
medicine and by eliminating unnecessary tests, procedures, surgeries,
hospitalizations and referrals to specialists. The Company's utilization
management staff reviews for medical appropriateness selected referrals by PCPs
in the Network under the Company's Global Capitation Contracts to other
providers for the use of ancillary services, and for inpatient hospital
admissions. The Company utilizes health care management guidelines that are
widely accepted in the health care industry to review referrals for clinical
appropriateness. The Company shares the guidelines with physicians and prepares
and provides other educational programs regarding utilization and referrals,
including comparative data, to the PCPs. The PCPs provide information regarding
referrals to the Company's utilization management staff which reviews referrals
for services not provided by such PCPs. The Company's utilization management
coordinator and Medical Directors perform a network assessment and
appropriateness review. Utilization and referral management is a critical
component of the Company's operations because it promotes the effective and
efficient use of medical resources, controls the cost of medical care, and
contributes to the Company's ability to negotiate and obtain favorable shared
risk arrangements with Payors.
DISEASE MANAGEMENT PROGRAM. The Company promotes wellness and seeks to
avoid hospitalizations, reduce length of in-patient stays, and otherwise reduce
costs associated with high-frequency and high-cost chronic patient conditions
through its disease management program. The Company's program is currently
focused on three of the most expensive and debilitating ailments suffered by
patients: congestive heart failure, diabetes and asthma. The disease management
process involves physicians and employees from many of the Company's
departments, including utilization management, case management, education
specialists, physician liaisons and contracting. The Company gathers data and
other information regarding these conditions, such as morbidity and mortality
statistics, length of stay and hospital admission rates, and other data related
to the cost of care associated with such conditions. The Company also identifies
patients participating in its Global Capitation Contracts that are at risk or
suffering from one of these conditions. Physicians design a recommended
disease-specific medical approach, and the Company's employees involved in
disease management, using the resources of many of the Company's departments,
develop a plan to provide cost-effective, high quality care to patients
suffering from these chronic diseases. Specifically, the Company establishes
utilization and referral parameters, develops specialized pharmaceutical and
nutritional programs, provides education to patients, monitors specific cases
and provides patient support.
The Company develops its clinical protocols in consultation with physicians
and other sources. Physicians in the Company's Network remain free to diverge
from the protocols when they determine that it is medically appropriate to do
so. The Company's contracts with physicians and other health care providers
expressly state that the Company will not interfere with the physician's
relationship with and responsibility to the patient. While the clinical
protocols and procedures may assist the physician in providing cost-effective
and high quality care, the physician remains free and has the duty under all of
the Company's contracts to treat patients as he or she deems necessary, and not
to discriminate against patients covered by the Company's managed care plans.
CASE MANAGEMENT PROGRAM. The Company's case management program also focuses
on patient satisfaction and cost savings by identifying patients whose diagnoses
will require significant medical care. The Company's staff of case managers
coordinate all aspects of the care of such patients, including development of a
care plan in coordination with the patient's PCP. The care plan includes
evaluating whether a particular treatment is appropriate, whether there are
alternate sites to provide the treatment, and the availability of community
resources to meet treatment needs. Management believes effective case management
will assist PCPs and other health care professionals to slow the progression of
the disease, ensure patient
6
<PAGE>
compliance with the required treatment, reduce hospital admissions and lengths
of stay, as well as improve patient satisfaction. The Company believes that
integrated health care, with the PCP at its core, is both less expensive and
provides better health care for the vast majority of patients.
QUALITY MANAGEMENT PROGRAM. In order to help ensure the quality of health
care services to patients and manage the costs of health care, the Company's
care management department administers a quality management program which
monitors patient satisfaction and the quality of medical records. The care
management department conducts reviews of random samples of cases to monitor
consistency with the Company's policies and procedures regarding referral
management, utilization management and case management. The Company's care
management department has developed and implemented its policies and procedures
in compliance with the standards as specified by certain national accreditation
organizations for the health care industry.
NETWORK DEVELOPMENT. Consistent with the Company's primary care-driven
strategy, the Company establishes contractual arrangements with PCPs through (i)
independent IPAs and independent medical groups; or (ii) consolidation of
physicians in Core Medical Groups through asset purchase and employment
transactions. The Company focuses on arrangements because it allows physicians
the opportunity to retain control of many business and clinical aspects of their
medical practices while providing them with management services that assist the
physician in providing better patient care outcomes at a reasonable cost.
INDEPENDENT PRACTICE ASSOCIATIONS. The Company has expanded its Network by
contracting with physicians in a variety of ways through IPAs in which
individual PCPs authorize the IPA to negotiate managed care contracts on their
behalf and the IPA then authorizes the Company to negotiate such contracts on
behalf of the IPA. In some cases, the Company contracts with or through an
existing IPA, while in other cases the Company assists physicians who may wish
to establish an IPA. The preferred models utilized by the Company involve IPAs
with exclusive arrangements, pursuant to which a physician is obligated to
conduct all managed care contracting through the Company, or non-exclusive
arrangements, pursuant to which a physician may contract for managed care with
others but agrees to take all patients referred by the Company, or other
contractual arrangements which may involve a physician contracting for managed
care through others or choosing to accept or deny patients referred by the
Company.
CORE MEDICAL GROUPS. Since the Company's inception, sole proprietors or
small medical groups have organized to conduct group medical practices as Core
Medical Groups affiliated with the Company. Each Core Medical Group is comprised
of a group of physicians under common management and is designed to provide a
full and coordinated spectrum of medical services to patients and meet Payors'
needs. The Core Medical Groups have been formed in five geographic markets in
Maryland. As of June 30, 1997, 88 PCPs were participating in the Company's
Network as employees of five Core Medical Groups.
In typical Core Medical Group transactions, the Company purchases from a
PCP or medical group of PCPs certain medical practice assets as well as contract
rights under certain business contracts of the medical practice and assumes
specified liabilities or obligations. The PCP receives a combination of cash and
Class B Common Stock of the Company, the amount of which is determined by
negotiation between such PCP and the Company.
Such PCPs enter into Employment Agreements with the Core Medical Group with
a term of 10 years. The Company provides managed care contracting and practice
management services to the Core Medical Groups (and indirectly to its
Physicians) pursuant to 30 year PSO Agreements (with automatic, renewable 10
year terms) entered into between the Company and each Core Medical Group. The
Company's structure and the clinical independence of the Core Medical Groups
enable the Core Medical Groups' member physicians to retain their autonomy
through their ownership interests in the Core Medical Groups and control over
clinical decisions.
CONTRACTING WITH SPECIALISTS, HOSPITALS AND OTHER HEALTH CARE PROVIDERS.
The Company contracts with specialists, hospitals and other providers of health
care services to complete the Network.
CONTRACTING WITH SPECIALISTS. The Company contracts with specialist
physicians for the provision of services to the Company and its affiliated PCPs
in a variety of ways, typically consisting of contractual arrangements involving
discounted fee-for-service or sub-capitation compensation arrangements. As of
June 30, 1997, the Company had approximately 2,271 specialists (including
obstetrician-gynecologists) in its Network pursuant to various contractual
arrangements.
CONTRACTING WITH HOSPITALS AND OTHER PROVIDERS. The Company contracts with
hospitals ("Participant Hospitals") to participate in the Network through
Hospital Managed Care Agreements ("Hospital Agreement") pursuant to which the
Company will agree to make the hospital the referral hospital of choice for
specified categories of managed care patients and
7
<PAGE>
specified categories of service. Each Participant Hospital must meet cost and
quality standards and agree to cooperate with the Company in the implementation
of utilization review, to include pre-admission guidelines and processes,
patient care and cost tracking, information exchanges and management reporting
systems and the development of innovative pricing arrangements. Certain
arrangements with hospitals in Maryland require the approval of the Maryland
Health Services Cost Review Commission, which approval has been granted on a
case by case basis. The Company has entered into Hospital Agreements with the
University of Maryland Medical System, St. Joseph Medical Center, Inc., Suburban
Hospital and Georgetown University Hospital. The Company also enters into
contracts with other health care providers to participate in the Network.
PRACTICE MANAGEMENT SERVICES. Pursuant to the Company's PSO Agreements, the
Company's operations include the delivery of certain practice management
services to the PCPs who are members of the Core Medical Groups. Such services
include administrative, legal and accounting services, lease negotiations, and
financial, billing and collection services. The practice management services
provided by the Company also include maintaining the financial and business
books and records of the Core Medical Groups, providing legal support, providing
marketing and advertising, and paying for costs and expenses incurred in
connection with the operation and administration of the Core Medical Group's
practice of medicine.
The Company operates a billing and claims processing center in White Marsh,
Maryland which processes claims, generates and delivers bills to patients and
Payors, and collects amounts owed. As of June 30, 1997, the Company provided
billing services for 94 PCPs and one laboratory. The Company does not intend to
increase significantly the number of PCPs who receive these services.
GOVERNMENTAL REGULATION
Both the health care business generally and the activities of the Company,
and activities of PCPs and other health care providers in the Network are
subject to extensive and pervasive federal and state regulation. The Company
believes that its operations are in material compliance with applicable federal
and state laws and regulations, as currently interpreted and applied.
Nevertheless, federal and state laws and regulations, including the federal
"fraud and abuse" laws, "Stark" and state law restrictions on physician
self-referral, and the pervasive regulation of the activities of managed care
entities, tend to be broadly written and lack extensive judicial interpretation.
There can be no assurance that a review of the Company's operations and
structure by regulatory authorities or courts might not result in a
determination that could adversely affect the Company. Moreover, the regulatory
environment in which the Company operates has changed materially in recent
years, and future changes are likely, some of which could restrict the Company's
existing structure or business relationships, limit its growth, or inhibit its
financial operations or opportunities for success.
MEDICARE AND MEDICAID FRAUD AND ABUSE LIMITATIONS. Under the Social
Security Act, it is a felony, punishable by imprisonment or fines or both, to
make false statements of material fact in Medicare or Medicaid billing, or
knowingly and willfully to offer, pay, solicit or receive, directly or
indirectly, any form of remuneration in exchange for referring any patients or
arranging or furnishing any item or service reimbursable by the Medicare or
Medicaid programs (the "fraud and abuse" or "anti-kickback" rules). Criminal
prosecutions are controlled by the Justice Department. The Department of Health
and Human Services ("DHHS"), through the Office of the Inspector General (the
"OIG"), may bring civil actions for monetary penalties and to exclude
individuals from participating in the Medicare or Medicaid programs for
violations of the fraud and abuse rules. The fraud and abuse rules are broadly
drafted, and have been broadly interpreted by courts. Read literally, the fraud
and abuse rules may prohibit not only kick-backs but many legitimate business
arrangements and joint venture activities. Many states have adopted rules
similar to the fraud and abuse rules. While the Company believes that its
activities do not violate the fraud and abuse rules, there can be no assurance
that federal or state regulators might not challenge some of the Company's
activities.
Concerned that legitimate business arrangements were being stifled by the
fraud and abuse rules, Congress directed DHHS to promulgate regulations which
establish "safe harbor" exceptions to the fraud and abuse rules. Initial Safe
Harbors were adopted in July 1991, and others have been proposed and adopted
from time to time. Some of these Safe Harbors are applicable to the activities
of the Core Medical Groups, its employee physicians, and the Company, including
provisions related to space and equipment leases, personal service and
management contracts, the sale of practices, bona fide employment relationships,
group practices and managed care contracting activities. Basically, all lease
and services agreements must be in writing, describe all services to be
provided, be on commercially reasonable terms, and require payment consistent
with fair market value in arms length transactions which is not determined by
taking into account the volume or value of referrals of Medicare and Medicaid
business. The Company believes that its lease and management activities
generally fall within the safe harbors. However, no independent appraisal or
fairness opinion concerning the fair market value of such leases or services
agreements or the reasonableness of the consideration received by the Company
therefor has been secured, and there
8
<PAGE>
can be no assurance that federal or state regulators might not challenge some of
the transactions or practices of the Company. Failure to comply with a safe
harbor exception or the lack of a safe harbor with respect to a transaction does
not itself result in, or constitute a violation of, the fraud and abuse rules.
FEDERAL AND STATE LAW REGARDING RESTRICTIONS ON PHYSICIAN SELF-REFERRAL.
Federal law, generally referred to as the "Stark II" legislation, as well as the
fraud and abuse laws of Maryland and Virginia and some other states in which the
Company may operate in the future, prohibit "physician self-referrals," which
may be defined generally as referrals to another provider by a physician with a
financial interest in the provider. If a physician has a financial interest in
the provider, including a direct or indirect ownership or investment interest,
or a compensation arrangement with a provider (including the physician's own
Core Medical Group), and no exception is applicable, the physician may not refer
to the provider, and neither the physician nor the provider may bill for any
service rendered pursuant to a prohibited self-referral. The fundamental
difference between the fraud and abuse rules and Stark II is that the former
require some form of intent to induce referrals to support a finding of
violation, while Stark II makes intent irrelevant. Under Stark II, if a
physician refers a Medicare or Medicaid patient or test to an entity in which he
or she has a financial interest, and if no exception applies, a violation has
occurred.
Stark II extended a prior ban on physician self-referral on laboratory
services ("Stark I") to a broad list of designated health services payable under
Medicare and Medicaid, including radiology and other diagnostic services,
radiation therapy services, physical and occupational therapy, durable medical
equipment, enteral and parenteral supplies, equipment, orthotics, outpatient
prescription drugs, home health services, and inpatient and outpatient hospital
services. If a prohibited self-referral occurs, and is not within an exception,
(i) neither the patient nor the Payor may be billed; (ii) Payors can recover all
amounts previously billed and paid in respect of non-excepted self-referrals;
and (iii) the referring physician and the provider are jointly and severally
liable to repay any amounts paid in respect of non-excepted self-referrals. Both
state and federal law also impose substantial monetary (up to $15,000 for each
prohibited referral and up to $100,000 for participating in a "circumvention
scheme") and other penalties for violations, including possible exclusion from
the Medicare and Medicaid programs.
The Maryland statute and Stark II have been recently enacted and there is
considerable uncertainty concerning how they will be interpreted, including
specifically how broadly the exemptions and exceptions to their application will
be applied. Regulations have been promulgated which apply to Stark I and some,
but not all, of Stark II. Certain PCPs participating in the Company's Network
will have both an ownership interest in and a compensation arrangement with the
Company, and certain PCPs will have similar relationships with the Core Medical
Groups and with IPA entities. Certain PCPs will refer patients among themselves
within their practices and as part of the Network. The Company believes that it
is not an entity to which referrals can be made, and that the referrals of
patients by PCPs in the Network should fall within one or more of the exceptions
permitted by Stark II and the state self-referral laws. Future regulations or
statutes might require the Company to restructure its relationships with its
Network, and violation of Stark II by the Company or its Core Medical Groups
could result in significant fines and financial losses which could adversely
affect the Company.
The federal government is implementing regulations which provide a
physician incentive plan exception to the Stark II rules. These regulations
complement a safe harbor for arrangements between entities such as the Company
and Medicare HMOs which will be permitted although they might create incentives
for physicians to limit care to enrollees of Medicare or Medicaid HMOs. The
Company has entered into arrangements with physicians which it believes fall
within the safe harbor for physician incentive plans.
ANTITRUST. PCPs who participate in the Network are separate legal entities
and may be deemed to be competitors subject to a range of antitrust laws which
prohibit anti-competitive behavior, including price fixing, division of markets,
and group boycotts and refusals to deal. The Federal Trade Commission has
published guidelines for the formation and activities of managed care
contracting networks, and the Company intends to comply with those guidelines in
developing networks. Nevertheless there is no assurance that review of the
Company's business by courts or state or federal regulatory authorities, or
private antitrust challenges by competitors, will not result in a determination
that could adversely affect the operation of the Company and its Network.
INSURANCE. States heavily regulate the activities of insurance companies
and health maintenance organizations. The Company is not registered as an
insurance company or HMO with any state, and does not believe that its
activities constitute the business of insurance, but there can be no assurance
that state regulators might not challenge some of the Company's present or
future activities as falling within the business of insurance, or that the
Company might not be required to become a licensed insurer at some time in the
future. The Company can not, without an HMO or insurance license, offer or sell
to
9
<PAGE>
individuals or companies health insurance or the opportunity to purchase health
insurance from the Company or hold itself out or advertise as an insurer or HMO.
On August 10, 1995, the National Association of Insurance Commissioners
("NAIC") issued a report opining that risk-transferring arrangements may
constitute the business of insurance to which state licensing laws apply. The
NAIC opined that such licensing laws would not apply to the Company's Global
Capitation Contracts or Full Risk Contracts because the Company assumes
"downstream risk" from a duly licensed health insurer or HMO for health care
provided to that carrier's enrollees. The NAIC's conclusions are not binding on
the states.
In Maryland, licensed HMOs are permitted to enter into capitation
arrangements with entities like the Company which assume the obligation to pay
providers directly as long as the HMO has obtained approval for the form of the
"administrative service provider contract" with the entity. In particular, an
administrative service provider is not required to be licensed as an HMO if such
provider accepts the risk of providing and paying for the medical services
required by enrollees of an HMO. In connection with accepting such risk, the
Company organizes networks of physicians, provides administrative, care
management, utilization review, referral management and other services necessary
to profitably accept managed care risk. All of the Company's Global Capitation
Contracts are administrative service provider contracts with licensed HMOs.
The Attorney General of the State of Maryland has issued an advisory
opinion that calls into question the ability of an unlicensed entity to provide
health care services under global capitation contracts in situations where a
licensed HMO was not the entity contracting with the insured. The Company has no
such arrangements and no present intention to enter into any such arrangements.
The Company has no present plans to become an HMO or insurance company licensed
to offer health insurance in Maryland and intends to continue to offer services
under Global Capitation Contracts only under administrative service provider
contracts.
Some states impose requirements on entities which contract with HMOs and
insurers, and such requirements might impose significant costs on the business
of the Company, which might adversely affect the business or operations of the
Company. The Company is required under its Global Capitation Contracts to either
post a letter of credit or create a segregated fund for the benefit of health
care providers which provide services to enrollees under Global Capitation
Contracts to which the Company is a party. These added financial requirements
have not created any financial burden to date for the Company.
FUTURE REGULATION. The health care industry is subject to extensive
regulation and is in a state of change. A variety of legislative proposals to
substantially reform the payment for and delivery of health care services have
been presented at both the federal and state levels in the past several years.
Among issues addressed by such legislation have been means to control or reduce
public and private spending on health care, to reform the payment methodology
for health care goods and services by both the public (Medicare and Medicaid)
and private sectors, limitations on federal spending for health care benefits,
and universal access to health care. Reform proposals may continue to be
considered by the legislatures of both the federal and state level in the
future; however, it is uncertain what proposals may be made in the future or
whether any such proposals will be enacted as law. Elements of reform proposals,
if acted upon by federal, state or private Payors for health care goods and
services, may result in reduced or limited payment for health care services or
in controlled or limited access to certain health care services generally. There
can be no assurance what effect such reforms may have on the business of the
Company, and no assurance can be given that any such reforms would not have an
adverse effect on the Company's revenues and/or earnings. There can be no
assurance that future statutes or regulations, or future interpretations of
existing statutes or regulations, will not make it difficult or impossible for
the Company to conduct its business in the manner presently contemplated and
described herein. In any such event, the management of the Company will attempt
to restructure the business of the Company in order to comply with any such new
statutes, regulations or interpretations. There can be no assurance, however,
that the Company will be able to do so, or that such restructuring will not
adversely impact the business of the Company.
Future regulations, statutes or interpretations might require the Company
to restructure its relationships with the Network providers and the Core Medical
Groups, and a violation of Stark II by the Company or its Core Medical Groups
could result in significant fines and financial losses which could adversely
affect the Company.
RECENT DEVELOPMENTS
The Company has completed certain material business and financing
transactions since June 30, 1997. The material financing transactions are
described below in "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Subsequent Events." The material business
transactions completed since June 30, 1997 consist of (i) the execution of a
memorandum of understanding to manage a physician network in Maryland,
Washington, D.C. and Virginia which
10
<PAGE>
is responsible for approximately 11,000 Medicare enrollees; and (ii) the planned
re-incorporation of the Company as a Delaware corporation.
NETWORK MANAGEMENT. On September 10, 1997, the Company and NYLCare Health
Plans of the Mid-Atlantic, Inc. ("NYLCare") entered into a memorandum of
understanding which provides that NYLCare will designate the Company as its
"Network Manager" responsible for managing the health care needs of NYLCare's
Medicare managed care patients who reside in certain portions of Maryland,
Washington, D.C. and Virginia. The Company will perform medical management
services through its care management department, NYLCare's current network of
approximately 2,000 PCPs and 6,000 specialists and the Company's Network. The
Company expects to enter into a Global Capitation Contract with NYLCare with
respect to NYLCare's Medicare product, which is expected to generate Capitation
Revenue of approximately $4 million per month from this contract.
RE-INCORPORATION IN DELAWARE. On or before October 31, 1997, the Company
intends to create a new corporation in the State of Delaware ("Delaware Doctors
Health") and merge the Maryland corporation, Doctors Health, Inc., into Delaware
Doctors Health with Delaware Doctors Health surviving. The transaction has been
approved by the Company's Board of Directors and stockholders. There are no
material amendments to the rights and privileges of the Company's stockholders
as a result of the re-incorporation of the Company in Delaware.
COMPETITION
The Company's Network competes with other provider networks and medical
groups, including those established by hospitals, other individual physicians,
and IPAs in obtaining managed care contracts with Payors and for quality
physicians to participate in the Network. The Company believes that it can
successfully compete with other entities seeking managed care contracts with
Payors because of the Company's large number of PCPs and specialists, thereby
providing Payors and their enrollees with access to a large number of health
care providers under the Company's medical management program. The Company also
has an increasing geographic coverage of PCPs and specialists with extensive
coverage in the Baltimore metropolitan area and surrounding regions. However,
there are a large number of physicians who could join other provider networks
which compete for managed care contracts.
The Company competes with certain HMOs, other Payors, other provider
networks, medical groups, and hospitals, some of which have greater resources,
to obtain PCPs to participate in the Company's Network. Further, large
established traditional indemnity insurance companies also are entering the
managed care field and may compete with the Company in acquiring certain assets
of physician practices and developing physician networks. Certain of the
Company's competitors (i) employ physicians, (ii) own such physicians' medical
practices, clinics or medical groups and (iii) exercise broad control over
clinical decisions of such physicians and their medical practices. Competitive
methods include the type and amount of compensation offered to PCPs, the level
of clinical autonomy afforded the physician and the level and extent of care
management services provided to the physician. The Company believes it can
effectively compete with other groups in acquiring certain assets of physician
practices because the Company is driven by primary care physicians and primary
care strategies. Further, the Company believes that it provides its affiliated
PCPs with greater clinical autonomy than may be offered by hospitals, HMOs or
insurance companies.
EMPLOYEES
As of June 30, 1997, the Company had approximately 500 employees, of which
approximately 150 were full-time employees in its corporate headquarters in
Owings Mills, Maryland and operations center in White Marsh, Maryland, and
approximately 350 were assigned by the Company to work in physician offices. An
additional 100 physicians, medical staff and laboratory personnel were employed
by the Core Medical Groups.
ITEM 2. PROPERTIES
The Company leases approximately 25,800 square feet in Owings Mills,
Maryland for its corporate headquarters. The term of the lease continues until
2001. The Company also has entered into a sublease through 1999 and a lease
through 2002 for approximately 18,770 square feet in White Marsh, Maryland for
its billing and claims processing operation. The Company also leases physician
offices of varying sizes, generally ranging from approximately 900 square feet
to more than 5,000 square feet. The Company anticipates that as it continues to
grow, expanded facilities will be required. The Company does not anticipate
significant difficulties in obtaining additional or new facilities. On July 1,
1997, the Company leased approximately 2,500 square feet of office space in
McLean, Virginia for use as the headquarters of the Company's operations in
Northern Virginia.
11
<PAGE>
The Company has filed service mark applications to register its logo and
corporate names "Doctors Health System, Managing Quality Health Care", "Doctors
Health", and "Doctors Health, It's the Sure Sign of Caring."
ITEM 3. LEGAL PROCEEDINGS
The Company is not currently subject to any material legal proceedings.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the annual meeting of the Company's stockholders held on June 17, 1997,
three matters were voted upon by the Company's stockholders. The Company's
stockholders elected directors of the Company The vote to elect such directors
was as follows:
(1) Class A Directors: Stewart B. Gold, Scott Rifkin, Alan Kimmel, John R.
Dwyer, Jr. and Paul A. Serini.
FOR 800,000
AGAINST 0
ABSTENTIONS 0
(2) Class B Directors: Richard Diamond, Peter LoPresti, Robert Ancona, J.
David Nagel, Alexander Rocha, Robert Graw, William Lamm and Mark Eig.
FOR 2,593,000
AGAINST 0
ABSTENTIONS 0
(3) Series A Preferred Directors: John Ellis and John Prout.
FOR 1,000,000
AGAINST 0
ABSTENTIONS 0
(4) Series B Preferred Director: Robert Zetzer.
FOR 355,556
AGAINST 0
ABSTENTIONS 0
(5) Series C Preferred Director: Richard Howard.
FOR 571,428
AGAINST 0
ABSTENTIONS 0
The second matter voted upon at the annual meeting was the approval of an
Amended and Restated Omnibus Stock Plan. The Board of Directors recommended
stockholder approval of an Amended and Restated Omnibus Stock Plan (the "Omnibus
Stock Plan") to (i) expand the classes of stock available for grant under the
Omnibus Plan to include Class A, Class B and Class C Common Stock; (ii) limit
the number of shares issuable to management under the Omnibus Plan to 15% of the
number of shares outstanding during the period that a registration statement is
in effect in the Commonwealth of Virginia in order to comply with that state's
securities laws; (iii) provide the committee that administers the Omnibus Plan
with additional flexibility by deleting the 10-year limitation on exercise
periods for options, permitting issuance of free-standing stock appreciation
rights and other awards not in connection with an option grant, and allowing the
committee to make appropriate option adjustments due to reclassification, stock
split, stock dividend and any other unusual, non-recurring events affecting the
Company, and (iv) clarify eligibility to permit issuance of options to
physicians whose practices are affiliated with the Company. The vote to adopt
such amendments was as follows:
FOR 5,319,984
AGAINST 0
ABSTENTIONS 0
The third matter voted upon at the annual meeting was the approval of
certain amendments to the Amended and Restated Articles of Incorporation of
Doctors Health System, Inc. to (a) authorize 5,750,000 shares of Series D
Preferred
12
<PAGE>
Stock, par value $10.00 per share and provide certain rights and preferences
with respect to such Series D Preferred Stock; (b) amend the terms of the Series
A Preferred Stock and Series C Preferred Stock including elimination of certain
veto and redemption rights prior to the fifth anniversary of the date of the
sale of the Series D Preferred Stock to Beacon and to provide that the Series A
Preferred Stock and Series C Preferred Stock would be pari passu with respect to
payment of dividends, liquidation rights and redemption rights; (c) amend the
terms of the Series B Preferred Stock including elimination of all veto and
special redemption rights and subordination of the Series B Preferred Stock to
all other Preferred Stock with respect to dividends, liquidation and redemption;
and (d) to change the name of the Company to "Doctors Health, Inc." The vote to
approve such amendments was as follows:
FOR 5,319,984
AGAINST 0
ABSTENTIONS 0
At a special meeting of the Company's stockholders held on August 13, 1997,
one matter was voted upon by the Company's stockholders. The Company's
stockholders approved re-incorporation of the Company as a Delaware corporation
by (a) establishing a Delaware subsidiary ("Doctors Health Delaware") by filing
of a Certificate of Incorporation with the state of Delaware and (b) the merger
of the current Maryland corporation, Doctors Health, Inc., with Doctors Health
Delaware, with Doctors Health Delaware surviving. The vote to approve such
transactions was as follows:
FOR 7,412,496
AGAINST 0
ABSTENTIONS 0
13
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
There is no established public trading market for the Registrant's common
equity securities. As of September 22, 1997, there were four holders of Class A
Common Stock and 242 holders of the Class B Common Stock.
ITEM 6. SELECTED FINANCIAL DATA
The selected consolidated financial data presented below as of and for the
Company's period ended June 30, 1995 and year ended June 30, 1996 and 1997 have
been derived from the audited consolidated financial statements of the Company.
The data set forth below are qualified in their entirety by, and should be read
in conjunction with, "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and the Company's Consolidated Financial
Statements, the notes thereto and the other financial and statistical
information included elsewhere in this Form 10-K.
<TABLE>
<CAPTION>
PERIOD FROM
FEBRUARY 24, 1995 YEAR ENDED YEAR ENDED
(INCEPTION) TO JUNE 30, JUNE 30,
JUNE 30, 1995 1996 1997
----------------- ----------- ------------
<S> <C> <C> <C>
STATEMENT OF OPERATIONS:
Net revenue........................................................ $ 850,665 $ 5,428,561 $ 12,037,188
Capitation revenue................................................. -- 689,068 10,794,909
----------------- ----------- ------------
Total revenues..................................................... 850,665 6,117,629 22,832,097
Medical services expense........................................... -- 969,677 11,188,450
Care center costs.................................................. 776,865 5,287,348 11,635,163
General and administrative......................................... 1,877,735 6,082,902 12,760,687
Depreciation and amortization...................................... 27,508 435,573 1,512,772
Interest and other income.......................................... (99,673) (272,666) (246,889)
Interest expense................................................... 23,915 226,908 781,964
----------------- ----------- ------------
Loss before taxes.................................................. (1,755,685) (6,612,113) (14,800,050)
----------------- ----------- ------------
Income tax expense................................................. -- -- --
----------------- ----------- ------------
Net loss........................................................... $ (1,755,685) $(6,612,113) $(14,800,050)
----------------- ----------- ------------
----------------- ----------- ------------
LOSS APPLICABLE TO COMMON STOCK:
Net loss........................................................... $ (1,755,685) $(6,612,113) $(14,800,050)
Less: preferred stock dividends and issuance costs accreted........ 113,300 552,531 1,382,083
----------------- ----------- ------------
Loss applicable to common stock.................................... $ (1,868,985) $(7,164,644) $(16,182,133)
----------------- ----------- ------------
----------------- ----------- ------------
Net loss per share................................................. $ (.62) $ (2.34) $ (4.84)
----------------- ----------- ------------
----------------- ----------- ------------
Dividends declared per common share................................ -- -- --
Weighted average number of shares outstanding...................... 3,000,000 3,063,205 3,345,397
----------------- ----------- ------------
----------------- ----------- ------------
BALANCE SHEET DATA:
Cash and cash equivalents.......................................... $ 131,885 $ 1,419,295 $ 4,737,828
Working capital (deficit).......................................... 73,314 882,132 (5,072,878)
Total assets....................................................... 1,510,171 11,154,138 24,478,642
Long term obligations.............................................. 587,339 5,798,037 8,122,077
Redeemable convertible preferred stock............................. 1,948,300 7,910,831 19,282,113
Redeemable Class A Common Stock.................................... 8,000 2,400,000 --
Class A Common Stock............................................... -- -- 8,100
Total stockholders' deficit........................................ $ (1,845,467) $(9,077,851) $(19,542,179)
</TABLE>
14
<PAGE>
The following is a condensed pro forma balance sheet of the Company as if
the July 15, 1997 sale of the Series D Redeemable Convertible Preferred Stock
transaction had taken place as of June 30, 1997:
<TABLE>
<CAPTION>
PRO FORMA
JUNE 30, PRO FORMA JUNE 30,
1997 ADJUSTMENTS 1997
------------ ----------- ------------
<S> <C> <C> <C>
Cash and Cash Equivalents............................................ $ 4,737,828 $18,913,000 $ 23,650,828
Other Current Assets................................................. 6,805,925 -- 6,805,925
Long-term Assets..................................................... 12,934,889 (552,500) 12,382,389
------------ ----------- ------------
Total Assets....................................................... $ 24,478,642 $18,360,500 $ 42,839,142
------------ ----------- ------------
------------ ----------- ------------
Current Liabilities.................................................. $ 16,616,631 $ -- $ 16,616,631
Long-term Liabilities................................................ 8,122,077 -- 8,122,077
Redeemable Convertible Preferred Stock............................... 19,282,113 18,195,500 37,477,613
Total Stockholders' Equity (Deficit)................................. (19,542,179) 165,000 (19,377,179)
------------ ----------- ------------
Total Liabilities and Stockholders 'Deficit........................ $ 24,478,642 $18,360,500 $ 42,839,142
------------ ----------- ------------
------------ ----------- ------------
</TABLE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
GENERAL
OVERVIEW. The Company derives substantially all of its revenue from (i)
payments made by Payors to the Company pursuant to Global Capitation Contracts
and Gatekeeper Capitation Contracts ("Capitation Revenue") and (ii) the
contractual management and similar fees earned under its long-term PSO
Agreements with Core Medical Groups ("Net Revenues"). The Company's Net Revenues
include the reimbursement of all medical practice operating costs and the
contractual management fees pursuant to the PSO Agreements and other agreements.
Net Revenue is recognized when services are performed and collection of the
related revenues is probable.
The Company expects that the greatest contributor to operating income will
be Capitation Revenue. The Company's level of profitability associated with
Capitation Revenue will depend on (i) increasing the number of PCPs, in the
Company's Networks and increasing the number of networks the Company manages;
(ii) attracting patients to enroll in benefit plans that enter into Global
Capitation Contracts with the Company (principally Medicare beneficiaries);
(iii) securing additional, Global Capitation Contracts and maintaining existing
Global Capitation Contracts with adequate reimbursement rates; and (iv)
assisting PCPs in managing the delivery of high quality care at a cost less than
the payments received under the Global Capitation Contracts.
SOURCE OF REVENUES. Under Global Capitation Contracts, the Company receives
Capitation Revenue in the form of a fixed fee from a Payor in exchange for
undertaking the obligation to provide or arrange for the provision of
substantially all of the health care services required by the enrollees (the
majority of expenses associated with such activities are reported as "Medical
Services Expense"). These services are provided by PCPs, specialists, hospitals
and other health care providers which are part of the Company's Network.
Due to the Company's focus on Global Capitation Contracts, the Company is
exposed to certain financial risks. The Company may influence, but does not
control the clinical decisions made by health care providers. To the extent that
enrollees require more care than may be anticipated or require care that is not
reimbursed by the Payor, aggregate capitation payments received by the Company
may not be sufficient to cover the costs of treating the enrollees. If the
Capitation Revenue is not sufficient to cover the costs, the Company's operating
income would be adversely affected.
Capitation Revenue is prepaid monthly based on the number of enrollees and
is recognized as Capitation Revenue during the month services are provided to
the enrollees. During the year ended June 30, 1997, approximately $9,253,000 and
$1,542,000, were recorded as Capitation Revenue from Global Capitation Contracts
and Gatekeeper Capitation Contracts, respectively, in the Company's financial
statements. During the year ended June 30, 1996, approximately $382,000 and
$307,000, were recorded as Capitation Revenue from Global Capitation Contracts
and Gatekeeper Capitation Contracts, respectively, in the Company's financial
statements. During the period ended June 30, 1995, the Company had no Global
Capitation Contracts or Gatekeeper Capitation Contracts.
The Company's commercial Global Capitation Contract provides that the
Company may earn incentive revenue or incur Medical Services Expense based upon
the enrollees' utilization of hospital services. Under this contract, the Payor
allocates a monthly capitation amount to an account as an estimate of hospital
expenses that will be incurred. Actual hospital costs are
15
<PAGE>
charged against such account. The Company and the Payor share equally any profit
or loss arising from such account caused by hospital and other institutional
expenses that are less than, or exceed the estimated amount allocated to the
account pursuant to a settlement following the applicable contract year.
Included in Accrued Medical Services as of June 30, 1997 and 1996 is
approximately $180,000 and $68,000, respectively, of estimated amounts due to
the HMO under this arrangement. Also, as of June 30, 1997 and June 30, 1996, the
Company has included in Medical Services Expense a provision of approximately
$146,000 and $77,000, respectively, which represents an estimate of the loss to
be incurred over the remaining term of the commercial Global Capitation
Contract.
Under the Company's two Medicare Global Capitation Contracts, the Company
has assumed responsibility for managing and paying for substantially all of the
medical care for the respective Payors' enrollees. Consequently, the Company
does not perform a settlement with the HMO's under the two Medicare contracts.
The Company is responsible for some or all of the medical services provided
by its PCPs, specialists and other providers to which it refers enrollees under
Global Capitation Contracts. The cost of medical services is recognized in the
period in which it is provided and includes an estimate of the cost of services
which have been incurred but not yet reported. Estimates are continually
monitored and reviewed and, as settlements are made estimates are adjusted, and
differences are reflected in current operating results. As of June 30, 1997 and
1996, approximately $4,975,000 and $405,000, respectively, was recorded in
Accrued Medical Services for incurred but not reported services.
The inability of the Company to renew its current Payor contracts, to
maintain favorable terms of such contracts, to attract patients who enroll in
such benefit plans, to expand such contracts to other geographical areas in the
Baltimore and Washington metropolitan area and surrounding regions or to manage
the cost of care efficiently would materially and adversely affect the Company's
Capitation Revenues and its ability to achieve profitability.
As of June 30, 1997, the Company believes there were not a sufficient
number of enrollees under the Company's Global Capitation Contracts to realize
operating income in excess of the Company's operating costs. To the extent
enrollees do not enroll in such benefit plans in adequate numbers, it will have
a material adverse effect on the operating results and financial condition of
the Company. The Company's ability to manage successfully the cost of care under
such contracts depends on the overall health of the enrollees, its ability to
manage appropriate and timely utilization of medical resources in coordination
with the clinical decision-making authority of individual physicians and its
ability to maintain favorable agreements with other health care providers
(hospital and ancillary services). To the extent the Company is unable to
provide or arrange for the provision of substantially all of the health care
services required by its enrollees at a cost less than the Capitation Revenue
received, it will have a material adverse effect on the operating results and
financial condition of the Company.
The Company currently derives a portion of its total revenues from
contractual management and similar fees earned pursuant to the PSO Agreements
with Core Medical Groups which employ physicians who have transferred medical
practice assets to the Company. The Company intends to increase the number of
PCPs who are employees of the Core Medical Groups at a rate substantially lower
than in the past, and the Company expects Capitation Revenue to grow at a faster
rate than Net Revenue. Thus, Net Revenue as a percentage of total revenues is
expected to decrease over time. The Company provides the Core Medical Groups
with traditional practice management services (such as marketing, advertising,
budgeting, physician acquisition, information systems and accounting services);
billing and collection of patient care fees; office personnel; equipment and
office space; maintenance of patient records and other medical practice
management services. Under the PSO Agreements, the Core Medical Groups agree to
comply with the terms of various managed care contracts, including the delivery
of health care services, 24-hour coverage, coordination with the Company's care
managers, utilization review, quality assurance and peer review programs and
credentialing matters.
As consideration for the services, assets, and facilities provided by the
Company, most of the Core Medical Groups agree to pay the Company the cost of
services, assets and facilities provided by the Company to the Core Medical
Groups. Such amounts paid to the Company are reflected in the Company's
financial statements as Net Revenues.
In addition, pursuant to the PSO Agreements with most of the Core Medical
Groups, the Company is entitled to compensation from the Core Medical Groups
calculated by subtracting the costs of operating the Core Medical Groups'
medical practices (including physician salaries) from the Core Medical Groups'
income. For the fiscal year ended June 30, 1997, the Company recognized
approximately $402,000 in operating income pursuant to these provisions of the
PSO Agreements.
PHYSICIAN AFFILIATION TRANSACTIONS. The Company expects to continue
expanding the Network through additional managed care contracting arrangements
primarily with PCPs in individual and group physician practices and IPAs, and,
to a lesser extent than in the past, with PCPs who sell their assets to the
Company and become employed by a Core Medical Group. In these affiliation
transactions, PCPs, medical groups and IPAs designate the Company as their
exclusive agent for
16
<PAGE>
managed care contracting and they agree to provide health care services to
enrollees under the Company's Global Capitation Contracts. As of June 30, 1997,
109 PCPs participated in the Network individually through independent medical
groups or IPAs and 88 PCPs participated in the Network through the Core Medical
Groups.
RESULTS OF OPERATIONS
The Company's operating results are significantly affected by the number of
PCPs, the number of PCPs participating in Global Capitation Contracts, the
number of Global Capitation Contracts in which the Company participates, and the
number of patients enrolled in benefit plans under Global Capitation Contracts
with the Company. The following table summarizes the Company's history with
respect to PCPs, executed Global Capitation Contracts and patients enrolled in
benefit plans under Global Capitation Contracts with the Company:
<TABLE>
<CAPTION>
JUNE 30, 1995 JUNE 30, 1996 JUNE 30, 1997
------------- ------------- -------------
<S> <C> <C> <C>
Number of PCPs in the Network as of..................................... 24 59 197
Number of PCPs participating in Global Capitation Contracts as of....... 0 45* 110*
Number of regional networks as of....................................... 1 5 7
Number of Global Capitation Contracts as of............................. 0 3 3
Number of Global Capitation Contract Patients:
Commercial............................................................ 0 2,039 4,943
Medicare.............................................................. 0 491 3,256
</TABLE>
- - - ---------------
*There is a lag between when physicians join the Network and when they become
eligible to participate in Global Capitation Contracts as a result of the
credentialing process and other internal Company controls.
The following table sets forth for the period ended June 30, 1995 and for
the years ended June 30, 1996 and 1997 selected financial data expressed as a
percentage of total revenues. Because of the Company's limited operating
history, the limited period in which it has been assisting and managing PCPs,
its limited experience with full and shared-risk capitated arrangements and the
effects of the acquisitions, the Company does not believe that the period to
period comparisons, percentage relationships within periods and apparent trends
set forth below are necessarily indicative of future operations.
<TABLE>
<CAPTION>
PERIOD FROM
FEBRUARY 24, 1995
(INCEPTION) TO YEAR ENDED YEAR ENDED
JUNE 30, JUNE 30, JUNE 30,
1995 1996 1997
----------------- ---------- ----------
<S> <C> <C> <C>
Net revenue............................................................. 100.0% 88.7% 52.7%
Capitation revenue...................................................... 0.0% 11.3% 47.3%
------- ---------- ----------
Total revenues.......................................................... 100.0% 100.0% 100.0%
Medical services expense................................................ 0.0% 15.8% 49.0%
Care center costs....................................................... 91.3% 86.5% 51.0%
General and administrative.............................................. 220.7% 99.4% 55.9%
Depreciation and amortization........................................... 3.3% 7.1% 6.6%
Interest and other income............................................... (11.7%) (4.5%) (1.1%)
Interest expense........................................................ 2.8% 3.7% 3.4%
Income tax expense...................................................... N/A N/A N/A
------- ---------- ----------
Net loss................................................................ (206.4%) (108.0%) (64.8%)
------- ---------- ----------
------- ---------- ----------
</TABLE>
COMPARISON OF THE YEARS ENDED JUNE 30, 1997, 1996 AND THE PERIOD ENDED JUNE
30, 1995.
The period ended June 30, 1995 is not comparable to the fiscal years ended
June 30, 1996 and 1997, as the period ended June 30, 1995 represents only
approximately four months of operations. Therefore, a comparison of increases
from June 30, 1995 to other periods is generally not meaningful.
TOTAL REVENUES. The Company's total revenues increased to $22,832,097 for
the year ended June 30, 1997 from $6,117,629 in 1996 and $850,665 in 1995.
Capitation Revenue increased to $10,794,909 ($9,252,877 due to Global Capitation
contracts and $1,542,032 due to Gatekeeper Capitation Contracts) or 47.3% of
total revenues for the year ended June 30, 1997, compared to $689,068 ($382,068
due to Global Capitation Contracts and $307,000 due to Gatekeeper Capitation
Contracts) or 11.3% of total revenues in 1996. During the period ended June 30,
1995, the Company had no Global Capitation Contracts. This increase in
Capitation Revenue from 1996 to 1997 is primarily attributable to an increase in
the number of
17
<PAGE>
PCPs affiliated with the Company from 88 to 197, the increase in the number of
PCPs participating in Global Capitation Contracts from 45 to 110 and the
increase in the number of enrollees participating in the Company's Global
Capitation Contracts from 2,530 to 8,199. The Company expects the Capitation
Revenue to increase in total and as a percentage of total revenues due to the
increase in the number of enrollees participating in the Company's Global
Capitation Contracts.
MEDICAL SERVICES EXPENSE. Medical services expense for the year ended June
30, 1997 was $11,188,450 or 49.0% of the total revenues compared to $969,677 or
15.8% in 1996. During the period ended June 30, 1995, the Company had no medical
services expense. This increase resulted from the increase in the number of PCPs
participating in Global Capitation Contracts from 45 to 104, and the increase in
the number of enrollees under Global Capitation Contracts from 2,530 to 8,199.
The Company expects these expenses to increase as the number of PCPs
participating in and the number of enrollees under Global Capitation Contracts
with the Company grows.
CARE CENTER COSTS. Care center costs increased to $11,635,163 or 51.0% of
total revenues for the year ended June 30, 1997 from $5,287,348 or 86.5% of
total revenues in 1996 and $776,865 or 91.3% of total revenues in 1995. This
increase in care center costs resulted from the increases in the number of
physicians from 88 to 97. While these expenses are expected to increase as the
Company continues adding physicians employed in CMGs, the Company expects that
these expenses will continue to decline as a percentage of total revenues.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative expenses
increased to $12,760,687 or 55.9% of total revenues for the year ended June 30,
1997 from $6,082,902 or 99.4% of total revenues in 1996, and $1,877,735 or
220.7% of total revenues in 1995. This increase in dollar amount resulted
primarily from increased compensation expenses from expansion of the Company's
corporate management team, as well as its marketing, acquisitions, network
development and care management departments and additional costs incurred in
adding physicians to the Company's Network and attracting patients who enroll in
benefit plans under Global Capitation Contracts. While these expenses are
expected to increase as the Company adds PCPs, the Company expects that these
expenses will continue to decline as a percentage of total revenues.
DEPRECIATION AND AMORTIZATION EXPENSES. Depreciation and amortization
expenses increased to $1,512,772 or 6.6% of total revenues for the year ended
June 30, 1997 from $435,573 or 7.1% of total revenues in 1996 and $27,508 or
3.3% of total revenue in 1995. These increases resulted primarily from
intangibles acquired in connection with the purchase of certain medical practice
assets from PCPs, as well as purchasing certain fixed asset additions.
INTEREST AND OTHER INCOME. Interest and other income was $246,889 or 1.1%
of the total revenues for the year ended June 30, 1997 compared to $272,666 or
4.5% of total revenues in 1996, and $99,673 or 11.7% of total revenues in 1995.
INTEREST EXPENSE. Interest expense increased to $781,964 or 3.4% of total
revenues for the year ended June 30, 1997, compared to $226,908 or 3.7% of total
revenues in 1996, and $23,915 or 2.8% of total revenues in 1995. These dollar
increases resulted primarily from the increase in the level of the Company's
borrowings.
INCOME TAX EXPENSE. In light of the Company's loss and its valuation
allowance for deferred tax assets, for the years ended June 30, 1997 and 1996,
and the period ended June 30, 1995, the Company did not require a provision for
income taxes.
NET LOSS. The Company had a net loss of $14,800,050 for the year ended June
30, 1997 compared to $6,612,113 in 1996 and $1,755,685 in 1995.
LOSS APPLICABLE TO COMMON STOCK. In arriving at loss applicable to common
stock, the Company's net loss is increased by dividends payable to the
Redeemable Convertible Preferred Stockholders and the amortization of Redeemable
Convertible Preferred Stock issuance costs. The net loss applicable to common
stock was $16,182,133 for the year ended June 30, 1997 compared to $7,164,644 in
1996 and $1,868,985 in 1995.
LIQUIDITY, CASH FLOW AND CAPITAL RESOURCES
LIQUIDITY. As of June 30, 1997 and 1996, the Company had working capital
(deficit) and available credit facilities of $(5,072,878) and $1,482,132,
respectively. Subsequent to June 30, 1997, the Company received proceeds of
approximately $19,000,000 from the issuance of Series D Redeemable Convertible
Preferred stock which increased the Company's working capital. Also, it is the
intent of the Company to refinance approximately $6,000,000 in notes payable
which are presented as a current liability at June 30, 1997.
CASH FLOW. Net cash used in operating activities was $9,914,501 for the
year ended June 30, 1997, compared to $5,057,464 in 1996 and $1,292,824 in 1995.
The use of cash for operating activities for the year ended June 30, 1997
resulted
18
<PAGE>
primarily from (i) $14,800,050 in net losses, (ii) a $1,501,138 increase in
prepaid expenses and other receivables offset by (iii) a $5,665,582 increase in
accrued and other liabilities and (iv) depreciation and amortization of
$1,512,772.
Net cash used in investing activities was $4,396,624 for the year ended
June 30, 1997, compared to $2,044,842 in 1996 and $410,489 in 1995. The Company
used $2,501,963, $2,129,464 and $238,926 of cash for the acquisition of certain
assets of medical practices and other fixed assets during the year ended June
30, 1997 and 1996 and the period ended June 30, 1995, respectively.
Net cash provided by financing activities was $17,629,658 for the year
ended June 30, 1997, compared to $8,389,716 in 1996 and $1,835,198 in 1995. (See
"Capital Resources".)
CAPITAL RESOURCES. On December 1, 1995, the Company issued 355,556 shares
of Series B Preferred Stock to Med-Lantic Management Services, Inc. ("the Series
B Preferred Stockholder") in exchange for $4,000,000 in cash and entered into an
agreement ("the NationsBank Credit Facility Agreement") with NationsBank of
Maryland, N.A. ("NationsBank") as agent, which provides a revolving bank credit
facility ("the NationsBank Credit Facility") with a maximum availability of
$4,000,000. Advances under the NationsBank Credit Facility bear interest at the
Company's option at either NationsBank prime rate or the Eurodollar rate plus
0.75%. The NationsBank Credit Facility expires on December 31, 1997, and will
not be renewed by NationsBank. The Company is currently negotiating with Chase
Manhattan Bank, N.A. on refinancing the NationsBank Credit Facility. (See
"Credit Facility Negotiations").
Loans made pursuant to the NationsBank Credit Facility are guaranteed by
the Company's Series B Preferred Stockholder. In exchange for the guarantee of
the NationsBank Credit Facility, the Company issued 88,889 warrants to the
Series B Preferred Stockholder. The guarantee is collateralized by a security
interest in certain contract rights, including rights to the Company's patient
and global capitation receivables, under the PSO Agreements between the Company
and Core Medical Groups. Upon redemption of the Series B Preferred Stock in the
event of the issuance of junior preferred stock to a holder whose interest are
deemed adverse to the guarantor, the Company is required to obtain a release of
the guarantee.
The proceeds from the issuance of the Series B Preferred Stock were used
for the acquisition of certain medical practices from PCPs, the incurrence of
corporate expenses and the development of the Company's infrastructure in
conjunction with the Company's business strategy. The proceeds from the
NationsBank Credit Facility were used for the acquisition of certain medical
practices from PCPs, the funding of operating expenses and the funding of
capital expenditures. At June 30, 1997, approximately $4,000,000 was outstanding
under the NationsBank Credit Facility.
On June 25, 1996, the Company received $1,000,000 in additional cash
payments on the Series A Note from the Series A Preferred Stockholder. These
proceeds were used to fund the incurrence of corporate expenses and the
continuing development of infrastructure in conjunction with the business
strategy.
(For a discussion of the terms of conversion of the Preferred Stock into
Class C Common Stock, see "Description of Capital Stock".)
On August 15, 1996, the Company established a $1,500,000 bridge loan
facility (the "Bridge Loan Facility") with First National Bank of Maryland, N.A.
("First National"). The Bridge Loan Facility was repaid on January 13, 1997.
On September 4, 1996, the Company issued 428,571 shares of Series C
Preferred Stock to Genesis Health Ventures, Inc. (the "Series C Preferred
Stockholder"), in exchange for $7,500,000 in cash. On January 2, 1997, the
Company issued 142,857 additional shares of the Series C Preferred Stock to the
Series C Preferred Stockholder in exchange for $2,500,000 in cash. The proceeds
from these issuances (the "Initial Genesis Funding") have been used to fund
corporate expenses in conjunction with the business strategy and the acquisition
of medical practices or managed care contracting rights.
On January 31, 1997, the Company and the Series C Preferred Stockholder
entered into a Note Purchase Agreement pursuant to which the Series C Preferred
Stockholder established a $5,000,000 credit facility for the Company. The
Company issued its Convertible Subordinated 11% Promissory Note ("Subordinated
Debt Facility") to the Series C Preferred Stockholder. On January 31, 1997, the
Series C Preferred Stockholder advanced the sum of $2,800,000 pursuant to the
Subordinated Debt Facility. On April 23, 1997 and June 30, 1997 the Company
received additional advances of $525,000 and $1,675,000. As of June 30, 1997 the
entire $5,000,000 is outstanding. Interest is payable at maturity in shares of
Series C Preferred Stock at the rate of $14.00 per share. The Subordinated Debt
Facility matures on January 31, 1999 or upon the earlier of a change in control
or an initial public offering of the Company's common stock. The Subordinated
Debt Facility is now convertible into shares of Series C Preferred Stock.
19
<PAGE>
On May 14, 1997, the Company borrowed $2,000,000 from HBO & Company
("HBOC"), the Company's current information system vendor, and issued its
subordinated promissory note to HBOC in the principal amount of $2,000,000 (the
"Note"). The Note is payable in full on May 14, 1998.
Until the Company attracts an adequate number of Capitated Lives in Global
Capitation Contracts, the Company expects to incur operating losses and
experience negative operating cash flows. The Company believes that its cash and
cash equivalents as of July 15, 1997 and internally-generated cash will be
sufficient to fund the Company's operations through June 30, 1998.
The Company also intends to expend capital on improving information
systems, expanding corporate infrastructure, and increasing the size and
geographic scope of the Network.
SUBSEQUENT EVENTS.
The Company has completed certain material financing transactions since
June 30, 1997 involving (i) the consummation of a redeemable convertible
preferred stock financing with Beacon Group III--Focus Value Fund, L.P.
("Beacon") and the related restructuring of the Company's equity capital and
issuance of redeemable convertible preferred stock to University Care, LLC, an
affiliate of the University of Maryland Medical System ("UMMS"); and (ii)
negotiations to refinance the NationsBank Credit Facility prior to December,
1997. Certain material business transactions which have been completed since
June 30, 1997 are discussed above under "Business--Recent Developments."
EQUITY FINANCING. On July 7, 1997, the Company entered into a Preferred
Stock Purchase Agreement, as amended on July 15, 1997 (the "Series D Purchase
Agreement") with Beacon pursuant to which the Company agreed to sell to Beacon
3 million shares of the Company's Series D Redeemable Convertible Preferred
Stock (the "Series D Preferred Stock") for a purchase price of $30,000,000. The
parties completed an initial purchase of two million shares for $20,000,000 on
July 15, 1997. Under the Series D Purchase Agreement, the Company expects to
complete a subsequent purchase of one million shares for $10,000,000 on or
before June 30, 1998, subject to certain conditions set forth in the Series D
Purchase Agreements.
Upon the issuance of the full 3,000,000 shares of Series D Preferred Stock
to Beacon, Beacon will own 100% of the Company's issued and outstanding Series D
Preferred Stock and approximately 30% of the issued and outstanding capital
stock of the Company, on a fully diluted basis.
In connection with the issuance of its Series D Preferred Stock, the
Company amended its Amended and Restated Articles of Incorporation (the
"Restated Articles") to, among other things, (a) authorize 5,750,000 shares
Series D Convertible Preferred Stock, (b) amend or revise certain of the terms
and conditions of its currently authorized and issued Series A Convertible
Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible
Preferred Stock, (c) increase the size of its Board of Directors from nineteen
to twenty members, (d) elect two of Beacon's designees to the Company's Board of
Directors and Executive Committee, (e) modify the composition and authority of
the Company's Executive Committee, and (f) change the name of the Company to
"Doctors Health, Inc.".
The Series D Preferred Stock issued to Beacon is senior to all other
classes of the Company's capital stock with respect to payment of dividends and
distributions and liquidation rights. The Series D Preferred Stock also is
subject to redemption by the Company at the election of the holder of the Series
D Preferred Stock at $10.00 per share, plus accrued but unpaid dividends, after
five years from the issuance date of the Series D Preferred Stock and is
convertible at an adjustable rate into the Company's Class C Common Stock at the
option of the holder of the Series D Preferred Stock and automatically upon a
qualifying initial public offering of the Company.
The number of shares of Class C Common Stock issuable upon conversion of
the Series D Preferred Stock is subject to adjustment pursuant to two stock
adjustment agreements between the Company and Beacon. The first stock adjustment
agreement provides for an upward or downward adjustment in the number of shares
issuable to Beacon based upon the Company's Medicare Medical Loss Ratio and the
number of Medicare enrollees in the Company's Medicare Global Capitation
Contracts with Payors. Pursuant to the first agreement, the number of shares
issuable to Beacon could be reduced to 2,727,272 shares of Class C Common Stock
or increased to 5,454,545 shares of Class C Common Stock. The second stock
adjustment agreement provides that the adjustment set forth in the second
agreement would supersede the first stock adjustment agreement if the 105th U.S.
Congress adopted certain changes in the Medicare program to reduce payments to
health maintenance organizations and medical management companies such as the
Company. Pursuant to the second stock adjustment agreement, the number of shares
issuable to Beacon could be reduced to 2,727,272 shares of Class C Common Stock
or
20
<PAGE>
increased to 7,500,000 shares of Class C Common Stock. Management of the Company
has determined that the second stock adjustment agreement is not applicable in
light of the Medicare legislation adopted by the 105th Congress.
In connection with the Series D Purchase Agreement, the Company modified
the composition and authority of the Executive Committee of its Board of
Directors. The Executive Committee is comprised of seven members (two Beacon
directors, one Series C Preferred Director, three physician directors, and the
Company's Chief Executive Officer). To the extent permitted by law, the
authority of the Board to act on all matters is now vested in and exercised by
the Executive Committee. In the event of certain default situations related to
the Company's not meeting certain targets with respect to its net income and its
medical loss ratio, Beacon has the right to take control of the Executive
Committee and the Board of Directors.
In connection with Beacon's investment in the Company, the Company also
entered into, among other agreements, (a) a Shareholders' and Voting Agreement,
which supersedes the Company's Stockholders Agreement and provides, among other
things, for certain restrictions on the sale and transfer of all classes of the
Company's capital stock, and (b) a Registration Rights Agreement with Beacon
which provides Beacon with certain rights to require the Company to register
with the Securities and Exchange Commission Beacon's shares of Series D
Preferred Stock for resale.
CREDIT FACILITY NEGOTIATIONS. The Company is currently in negotiations with
Chase Manhattan Bank, N.A. ("Chase") for the purpose of refinancing the
NationsBank Credit Facility of $4,000,000 with a maturity of December 31, 1997
and the HBOC note payable of $2,000,000 with a maturity of May 14, 1998.
Although there can be no assurance that such a refinancing will be successfully
concluded, the Company has received a proposal from Chase and is completing
negotiations. Under the terms of the Beacon transaction, any or all of the notes
not refinanced may be retired with a portion of the remaining $10 million to be
invested by Beacon on or before June 30, 1998.
21
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
TO THE BOARD OF DIRECTORS OF
DOCTORS HEALTH, INC. AND SUBSIDIARIES:
We have audited the accompanying consolidated balance sheet of Doctors
Health, Inc. (formerly Doctors Health System, Inc.) and Subsidiaries as of June
30, 1997, and the related consolidated statements of operations, stockholders'
equity (deficit) and cash flows for the year then ended. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Doctors Health, Inc. and
Subsidiaries as of June 30, 1997 and the results of its operations and its cash
flows for the year then ended in conformity with generally accepted accounting
principles.
Our audit was made for the purpose of forming an opinion on the basic
financial statements taken as a whole. Schedule II-Valuation and Qualifying
Accounts is presented for the purposes of complying with the Securities and
Exchange Commission's reporting requirements and is not part of the basic
financial statements. This schedule has been subjected to the auditing
procedures applied in the audit of the basic financial statements and, in our
opinion, fairly states in all material respects the financial data required to
be set forth therein in relation to the basic financial statements taken as a
whole.
ARTHUR ANDERSEN, LLP
Baltimore, Maryland
August 18, 1997
(except with respect to the matter
discussed in Note 20, as to which
the date is September 10, 1997)
22
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
BOARD OF DIRECTORS AND STOCKHOLDERS
DOCTORS HEALTH, INC. AND SUBSIDIARIES:
We have audited the accompanying consolidated balance sheets of Doctors
Health, Inc. (formerly Doctors Health System, Inc.) and Subsidiaries, as of June
30, 1996 and the related consolidated statements of operations, stockholders'
equity (deficit), and cash flows for the year ended June 30, 1996 and for the
period February 24, 1995 (date of inception) to June 30, 1995. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above, present fairly,
in all material respects, the consolidated financial position of Doctors Health,
Inc. and Subsidiaries as of June 30, 1996 and the consolidated results of its
operations and its cash flows for the year ended June 30, 1996 and for the
period February 24, 1995 (date of inception) to June 30, 1995, in conformity
with generally accepted accounting principles.
We have also audited Schedule II--Valuation and Qualifying Accounts for the
year ended June 30, 1996. In our opinion, this schedule presents fairly, in all
material respects, the information required to be set forth therein.
GRANT THORNTON LLP
Baltimore, Maryland
October 3, 1996
(except for Note 20,
which is now incorporated
into the second paragraph
of Note 11, the date of
which is January 13, 1997)
23
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 1996 AND 1997
<TABLE>
<CAPTION>
JUNE 30, JUNE 30,
1996 1997
------------ ------------
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents (Notes 1 and 9)........................................................... $ 1,419,295 $ 4,737,828
Restricted cash (Note 1)............................................................................ -- 680,000
Accounts receivable (net of allowance for doubtful accounts of
$324,521 and $270,521 at June 30, 1996 and 1997, respectively) (Notes 1 and 2).................... 1,303,941 2,722,891
Accounts receivable-affiliates (Note 1)............................................................. 1,208,685 1,115,885
Other receivables (Note 4).......................................................................... 64,251 1,170,504
Prepaid expenses.................................................................................... 117,096 190,987
Due from affiliates (Note 18)....................................................................... 891,985 925,658
------------ ------------
Total Current Assets.............................................................................. 5,005,253 11,543,753
------------ ------------
PROPERTY AND EQUIPMENT, net (Notes 1,2 and 7)......................................................... 2,485,547 4,205,532
OTHER ASSETS
Intangibles (net of accumulated amortization of $65,170 and $445,148 at June 30, 1996 and 1997,
respectively)
(Notes 1 and 2)................................................................................... 2,448,030 6,475,925
Deferred charges (net of accumulated amortization of $147,475 and $515,056 at June 30, 1996 and
1997, respectively) (Note 1)...................................................................... 636,772 1,595,396
Note receivable (Note 6)............................................................................ 300,000 --
Accrued interest receivable......................................................................... 253,976 374,970
Other receivable.................................................................................... -- 200,000
Deposits............................................................................................ 24,560 83,066
------------ ------------
Total Other Assets................................................................................ 3,663,338 8,729,357
------------ ------------
TOTAL ASSETS...................................................................................... $ 11,154,138 $ 24,478,642
------------ ------------
------------ ------------
LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Current maturities of notes payable (Note 8)........................................................ $ 303,915 $ 6,007,589
Current maturities of capital lease obligations (Note 8)............................................ 101,985 --
Accounts payable.................................................................................... 330,647 1,108,499
Accrued medical services (Note 1)................................................................... 550,520 5,301,384
Other accrued expenses (Note 5)..................................................................... 2,069,579 3,233,955
Due to affiliates (Note 18)......................................................................... 766,475 965,204
------------ ------------
Total Current Liabilities......................................................................... 4,123,121 16,616,631
------------ ------------
LONG-TERM OBLIGATIONS
Note payable (Note 8)............................................................................... 3,400,000 5,462,621
Notes payable and purchase obligations-related parties (Notes 8 and 14)............................. 2,077,364 2,659,456
Capital lease obligations, less current maturities (Note 8)......................................... 320,673 --
------------ ------------
Total Long-term Obligations....................................................................... 5,798,037 8,122,077
------------ ------------
COMMITMENTS AND CONTINGENCIES (Note 9)
REDEEMABLE CONVERTIBLE PREFERRED STOCK (Notes 8,10,13 and 14)
6.5% cumulative, Series A, $5 par value, authorized and issued 1,000,000 shares
(Liquidation value $3,500,000 plus unpaid dividends).............................................. 5,273,305 5,651,472
Less subscription receivable........................................................................ (1,500,000) (1,500,000)
------------ ------------
3,773,305 4,151,472
9.75% cumulative, Series B, $11.25 par value, authorized and issued 355,556 shares
(Liquidation value $4,000,000 plus unpaid dividends)............................................ 4,137,526 4,548,945
8% cumulative, Series C, $17.50 par value, authorized 1,071,428 shares; issued and
outstanding 571,428 shares (Liquidation value $10,000,000 plus unpaid dividends).................. -- 10,581,696
REDEEMABLE CLASS A COMMON STOCK (Note 11)
$.01 par value, authorized, issued and outstanding 800,000 shares at June 30, 1996.................. 2,400,000 --
STOCKHOLDERS' EQUITY (DEFICIT) (Notes 11,12,13 and 19)
Preferred Stock, $.01 par value; authorized 1,000,000 shares, no shares issued...................... -- --
Common Stock
Class A, $.01 par value; authorized 20,700,000 shares, issued and outstanding
810,000 shares at June 30, 1997................................................................. -- 8,100
Class B, $.01 par value; authorized 10,000,000 shares; issued and outstanding 2,398,000
and 2,645,167 shares at June 30, 1996 and 1997, respectively.................................... 23,980 26,452
Class C, $.01 par value; authorized 29,050,000 shares; no shares issued........................... -- --
Additional paid-in capital.......................................................................... 2,323,600 6,551,539
Deferred compensation............................................................................... -- (912,508)
Accumulated deficit................................................................................. (11,425,431) (25,215,762)
------------ ------------
Total Stockholders' Equity (Deficit)............................................................ (9,077,851) (19,542,179)
------------ ------------
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)............................................ $ 11,154,138 $ 24,478,642
------------ ------------
------------ ------------
</TABLE>
The accompanying notes are an integral part of these consolidated balance
sheets.
24
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE PERIOD FROM FEBRUARY 24, 1995 (INCEPTION)
TO JUNE 30, 1995 AND THE YEARS ENDED
JUNE 30, 1996 AND 1997
<TABLE>
<CAPTION>
FOR THE PERIOD
FROM FEBRUARY 24,
1995 (INCEPTION) YEAR ENDED YEAR ENDED
TO JUNE 30, JUNE 30, JUNE 30,
1995 1996 1997
----------------- ----------- ------------
<S> <C> <C> <C>
REVENUES
Net revenue (Notes 1 and 3).............................................. $ 850,665 $ 5,428,561 $ 12,037,188
Capitation revenue (Note 1).............................................. -- 689,068 10,794,909
----------------- ----------- ------------
850,665 6,117,629 22,832,097
----------------- ----------- ------------
EXPENSES
Medical services expense................................................. -- 969,677 11,188,450
Care center costs........................................................ 776,865 5,287,348 11,635,163
General and administrative............................................... 1,877,735 6,082,902 12,760,687
Depreciation and amortization............................................ 27,508 435,573 1,512,772
----------------- ----------- ------------
2,682,108 12,775,500 37,097,072
----------------- ----------- ------------
Loss from operations.................................................. (1,831,443) (6,657,871) (14,264,975)
OTHER INCOME (EXPENSE)
Interest and other income................................................ 99,673 272,666 246,889
Interest expense......................................................... (23,915) (226,908) (781,964)
----------------- ----------- ------------
75,758 45,758 (535,075)
----------------- ----------- ------------
Loss before income taxes.............................................. (1,755,685) (6,612,113) (14,800,050)
Income taxes (Note 15)................................................... -- -- --
----------------- ----------- ------------
NET LOSS............................................................ $(1,755,685) $(6,612,113) $(14,800,050)
----------------- ----------- ------------
----------------- ----------- ------------
Loss applicable to common stock
Net loss.............................................................. $(1,755,685) $(6,612,113) $(14,800,050)
Preferred stock dividends and issuance
costs accreted...................................................... 113,300 552,531 1,382,083
----------------- ----------- ------------
Loss applicable to common stock....................................... $(1,868,985) $(7,164,644) $(16,182,133)
----------------- ----------- ------------
----------------- ----------- ------------
Net loss per share (Note 16)............................................... $(0.62) $(2.34) $(4.84)
------- ----------- ------------
------- ----------- ------------
Weighted average number of common shares outstanding (Note 16)............. 3,000,000 3,063,205 3,345,397
----------------- ----------- ------------
----------------- ----------- ------------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
25
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE PERIOD FROM FEBRUARY 24, 1995 (INCEPTION)
TO JUNE 30, 1995 AND THE YEARS ENDED
JUNE 30, 1996 AND 1997
<TABLE>
<CAPTION>
FOR THE PERIOD
FROM FEBRUARY 24,
1995 (INCEPTION) YEAR ENDED YEAR ENDED
TO JUNE 30, JUNE 30, JUNE 30,
1995 1996 1997
----------------- ----------- ------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss.................................................................. $(1,755,685) $(6,612,113) $(14,800,050)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation and amortization.......................................... 27,508 435,573 1,512,772
Deferred compensation.................................................. -- -- 128,125
Changes in operating assets and liabilities, net of effects of
medical practice receivables acquired
Restricted cash...................................................... -- -- (680,000)
Accounts receivable.................................................. 83,984 (245,801) (544,974)
Accounts receivable--affiliates...................................... (31,931) (327,386) 138,462
Prepaid expenses and other receivables............................... (219,436) (178,583) (1,501,138)
Due from/to affiliates............................................... 307,843 (433,353) 165,056
Accounts payable..................................................... 76,420 231,649 777,852
Accrued and other liabilities........................................ 364,473 2,340,798 5,665,582
Organizational costs and deferred charges............................ (146,000) (268,248) (776,188)
----------------- ----------- ------------
Net cash used in operating activities............................. (1,292,824) (5,057,464) (9,914,501)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment........................................ (238,926) (2,129,464) (2,501,963)
Payments for acquisitions................................................. (22,000) (42,773) (1,836,155)
Deposits.................................................................. (149,563) 127,395 (58,506)
----------------- ----------- ------------
Net cash used in investing activities............................. (410,489) (2,044,842) (4,396,624)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of redeemable convertible
preferred stock........................................................ 1,835,000 5,410,000 9,989,199
Net proceeds from issuance of common stock................................ 198 -- --
Borrowings under notes payable............................................ -- 3,400,000 8,911,566
Principal payments on capital lease obligations........................... -- (79,157) (245,836)
Issuance of note receivable............................................... -- (300,000) --
Payments on notes payable................................................. -- (41,127) (1,025,271)
----------------- ----------- ------------
Net cash provided by financing activities......................... 1,835,198 8,389,716 17,629,658
Net increase in cash and cash equivalents......................... 131,885 1,287,410 3,318,533
Cash and cash equivalents, at beginning of period........................... -- 131,885 1,419,295
----------------- ----------- ------------
Cash and cash equivalents, at end of period................................. $ 131,885 $ 1,419,295 $ 4,737,828
----------------- ----------- ------------
----------------- ----------- ------------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
26
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE PERIOD FROM FEBRUARY 24, 1995 (INCEPTION)
TO JUNE 30, 1995 AND THE YEARS ENDED
JUNE 30, 1996 AND 1997
<TABLE>
<CAPTION>
COMMON STOCK-- COMMON STOCK-- RETAINED
CLASS A(2) CLASS B ADDITIONAL EARNINGS/
----------------- -------------------- PAID-IN DEFERRED (ACCUMULATED
SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION DEFICIT)
-------- ------ ---------- ------- ----------- ------------ ------------
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE AT FEBRUARY 24, 1995(1).... -- $ -- -- $ -- $ 198 $ -- $ --
Net loss......................... -- -- -- -- -- -- (1,755,685)
Issuance of Class B Common
Stock.......................... -- -- 2,200,000 22,000 -- -- --
Series A Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (113,300)
Capital related to MHLP
transactions................... -- -- -- -- 1,320 -- --
-------- ------ ---------- ------- ----------- ------------ ------------
BALANCE AT JUNE 30, 1995........... -- -- 2,200,000 22,000 1,518 -- (1,868,985)
Net loss......................... -- -- -- -- -- -- (6,612,113)
Issuance of common stock purchase
warrants for services (Note
13)............................ -- -- -- -- 370,000 -- --
Issuance of Class B Common
Stock.......................... -- -- 198,000 1,980 592,020 -- --
Series A Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (325,005)
Series B Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (227,526)
Capital related to MHLP
transactions................... -- -- -- -- 1,360,260 -- --
Increase in value of Redeemable
Class A Common Stock (Note
11)............................ -- -- -- -- (198) -- (2,391,802)
-------- ------ ---------- ------- ----------- ------------ ------------
BALANCE AT JUNE 30, 1996........... -- -- 2,398,000 23,980 2,323,600 -- (11,425,431)
Net loss......................... -- -- -- -- -- -- (14,800,050)
Series A Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (325,000)
Series B Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (390,044)
Series C Preferred Stock dividend
accretion...................... -- -- -- -- -- -- (590,976)
Amortization of Preferred Stock
issuance costs................. -- -- -- -- -- -- (76,063)
Issuance of Class A Common
Stock.......................... 10,000 100 -- -- 69,900 -- --
Issuance of Class B Common
Stock.......................... -- -- 247,167 2,472 1,727,698 -- --
Capital related to MHLP
transactions................... -- -- -- -- 717,010 -- --
Effect of obtaining insurance for
the Redeemable Class A Common
Stock.......................... 800,000 8,000 -- -- 198 -- 2,391,802
Issuance of common stock purchase
warrants for services (Note
13)............................ -- -- -- -- 672,500 -- --
Issuance of common stock options
(Note 12)...................... -- -- -- -- 1,040,633 (1,040,633) --
Amortization of deferred
compensation (Note 12)......... -- -- -- -- -- 128,125 --
-------- ------ ---------- ------- ----------- ------------ ------------
BALANCE AT JUNE 30, 1997........... 810,000 $8,100 2,645,167 $26,452 $ 6,551,539 $ (912,508) $(25,215,762)
-------- ------ ---------- ------- ----------- ------------ ------------
-------- ------ ---------- ------- ----------- ------------ ------------
<CAPTION>
TOTAL
------------
<S> <C>
BALANCE AT FEBRUARY 24, 1995(1).... $ 198
Net loss......................... (1,755,685)
Issuance of Class B Common
Stock.......................... 22,000
Series A Preferred Stock dividend
accretion...................... (113,300)
Capital related to MHLP
transactions................... 1,320
------------
BALANCE AT JUNE 30, 1995........... (1,845,467)
Net loss......................... (6,612,113)
Issuance of common stock purchase
warrants for services (Note
13)............................ 370,000
Issuance of Class B Common
Stock.......................... 594,000
Series A Preferred Stock dividend
accretion...................... (325,005)
Series B Preferred Stock dividend
accretion...................... (227,526)
Capital related to MHLP
transactions................... 1,360,260
Increase in value of Redeemable
Class A Common Stock (Note
11)............................ (2,392,000)
------------
BALANCE AT JUNE 30, 1996........... (9,077,851)
Net loss......................... (14,800,050)
Series A Preferred Stock dividend
accretion...................... (325,000)
Series B Preferred Stock dividend
accretion...................... (390,044)
Series C Preferred Stock dividend
accretion...................... (590,976)
Amortization of Preferred Stock
issuance costs................. (76,063)
Issuance of Class A Common
Stock.......................... 70,000
Issuance of Class B Common
Stock.......................... 1,730,170
Capital related to MHLP
transactions................... 717,010
Effect of obtaining insurance for
the Redeemable Class A Common
Stock.......................... 2,400,000
Issuance of common stock purchase
warrants for services (Note
13)............................ 672,500
Issuance of common stock options
(Note 12)...................... --
Amortization of deferred
compensation (Note 12)......... 128,125
------------
BALANCE AT JUNE 30, 1997........... $(19,542,179)
------------
------------
</TABLE>
- - - ---------------
(1) All share amounts have been restated to give effect to a two-for-one stock
split.
(2) Classified as Redeemable Class A Common Stock as of June 30, 1995 and
1996--See Note 11.
The accompanying notes are an integral part of these consolidated financial
statements.
27
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1995, 1996 AND 1997
NOTE 1--SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Doctors Health, Inc., a Maryland corporation, and its subsidiaries
(collectively "the Company") is a managed care and medical management company
which conducts its business through a network consisting of primary care
physicians ("PCPs"), specialist physicians, hospitals and other providers of
medical care (the "Network"). The Company was incorporated in June 1994 and
commenced operations on February 24, 1995. Effective July 15, 1997 the Company
changed its name from Doctors Health System, Inc. to Doctors Health, Inc. (See
Note 19). As a managed care company, the Company negotiates and enters into
global capitation contracts, pursuant to which (i) payors pay the Company a
fixed amount per month based on the number of enrollees who have selected a PCP
in the Network and (ii) the Company pays the health care providers within the
Network, or those having other contractual arrangements with the Company for
providing the required medical care. In addition, the Company, directly and
through wholly-owned subsidiaries, acquires certain assets of and operates
physician practices under long-term physician service agreements ("PSO
Agreements") with affiliated core medical groups ("CMGs") that practice
exclusively through such physician practices.
The Company provides administrative and technical support for professional
services rendered by the CMGs under service agreements. Under the PSO
Agreements, the Company is reimbursed for all care center expenses, as defined
in the agreement, and participates at varying levels in the excess of net
physician revenue over care center expenses.
The Company conducts its operations through the following wholly-owned and
majority owned subsidiaries and CMGs under long-term PSO Agreements:
<TABLE>
<CAPTION>
SUBSIDIARIES PERCENTAGE OWNED
- - - ----------------------------------------------------------------------------------- ----------------
<S> <C>
Doctors Health Primary Care IPA, Inc. 100.0%
(inactive during 1995 and 1996)..................................................
Doctors Health--Medalie Equipment 100.0%
Corporation (incorporated in 1996)...............................................
Mishner Newco, Inc. (incorporated in January 1996)................................. 100.0%
Williams Newco, Inc. (incorporated in May 1996).................................... 100.0%
WomanCare IPA, Inc. (incorporated in March 1997)................................... 99.0%
PCPA Newco, Inc. (incorporated in February 1996)................................... 100.0%
Doctors Health of Virginia, Inc. (incorporated November 1996 in Va.)............... 100.0%
Montgomery Newco, Inc. (incorporated September 1996)............................... 100.0%
Medicap, Inc. (incorporated January 1997).......................................... 100.0%
<CAPTION>
AFFILIATES
- - - -----------------------------------------------------------------------------------
<S> <C>
Anne Arundel Medical Group, LLC (Anne Arundel Medical, formed in December 1996)
Baltimore Medical Group, LLC (Baltimore Medical, formed in February 1995)
Carroll Medical Group, LLC (Carroll Medical, formed in November 1995)
Cumberland Valley Medical Group, LLC (Cumberland Valley Medical, formed in May 1996)
Doctors Health Montgomery, LLC (Doctors Health Montgomery, formed January 1996)
</TABLE>
A summary of the significant accounting policies consistently applied in
the preparation of the accompanying consolidated financial statements follows.
Basis of Presentation/Principles of Consolidation
The consolidated financial statements have been prepared on the accrual
basis of accounting and include the accounts of the Company and its
subsidiaries. All significant intercompany accounts and transactions have been
eliminated in the consolidation.
28
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 1--SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--CONTINUED
Net Revenue Recognition
The Company's net revenues represent contractual management and similar
fees earned under its long-term PSO Agreements with CMGs. Under the PSO
Agreements, the Company is contractually responsible and at risk for the
operating costs of the CMGs, with the exception of amounts retained by
physicians. The Company's net revenues include the reimbursement of all medical
practice operating costs and the contractual management fees due as defined and
stipulated in the PSO Agreements. Contractual fees are recognized when
collection is probable (see Note 3). During the period ended June 30, 1995 and
the years ended June 30, 1996 and 1997, the Company recorded contractual
management fees of $73,800, $141,213 and $402,025, respectively.
Capitation Revenue and Medical Services Expense Recognition
As of June 30, 1997, the Company has three global capitated contracts and
five gatekeeper capitation contracts with seven health maintenance organizations
(HMOs). Under the contracts, the Company receives monthly capitation fees based
on the number of enrollees electing any one of the Company's affiliated PCPs.
The capitation revenue under these contracts is prepaid monthly based on the
number of enrollees and is recognized as capitation revenue during the month
services are provided to the enrollees. During the year ended June 30, 1996,
approximately $382,000 and $307,000, were recorded as global capitation and
gatekeeper capitation revenue, respectively, in the Company's consolidated
financial statements. During the year ended June 30, 1997, approximately
$9,253,000 and $1,542,000, were recorded as global capitation and gatekeeper
capitation revenue, respectively, in the Company's consolidated financial
statements. During the period ended June 30, 1995, the Company had no global or
gatekeeper capitation contracts. The gatekeeper capitation contracts represent
PCP capitation and the Company records no profit margin on these contracts.
The Company's commercial capitation contract also includes a provision
whereby the Company can earn incentive revenue or incur medical services
expenses based upon the enrollees' utilization of hospital services. Estimated
amounts receivable or payable from the HMO are recorded based upon actual
hospital and other institutional utilization and associated costs incurred by
assigned HMO enrollees, compared to the portion of the commercial capitation
fees allocated for institutional care. Differences between actual contract
settlements and estimated receivables or payables relating to the arrangement
are recorded in the year of settlement. Included in accrued medical services as
of June 30, 1996 and 1997 is approximately $68,000 and $180,000, respectively,
of estimated amounts due to the HMO under this arrangement. Also, as of June 30,
1996 and 1997, the Company has included in accrued medical services a provision
of approximately $77,000 and $146,000 which represents an estimate of the loss
to be incurred over the remaining term of the commercial capitation contract.
Under the Company's two Medicare global capitation contracts, the Company
has assumed responsibility for managing and paying for substantially all of the
medical care for the respective payors' enrollees. Consequently, the Company
does not perform an institutional incentive settlement with the HMO's under the
two Medicare contracts.
The Company is responsible for some or all of the medical services provided
by its affiliated physicians and other providers to which it refers patients who
are covered under global capitated contracts. The cost of medical services is
recognized in the period in which the care is provided and includes an estimate
of the cost of services which have been incurred but not yet reported. The
estimate for accrued medical services is calculated by pricing the open
authorizations for medical services from the Company's medical management system
as well as projecting the associated costs using historical studies of claims
paid and actuarial assistance. Estimates are continually monitored and reviewed
and, as settlements are made or estimates are adjusted, differences are
reflected in current operations. As of June 30, 1996 and 1997, approximately
$405,000 and $4,975,000, respectively, was recorded as accrued medical services
for incurred but not reported services.
The Company purchases reinsurance from independent insurance companies
which limits the amount of risk it ultimately bears by providing reimbursement
payments once medical services provided to an individual enrollee exceed an
agreed-upon amount. Under the commercial capitation contract, the Company is
insured for 90% of all medical services expense over $5,000 per enrollee per
year. Under the Medicare global capitation contracts, the Company is insured for
90% of all physician and hospital medical services expense over $5,000 and
$75,000, respectively, per enrollee per year. During
29
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 1--SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--CONTINUED
the years ended June 30, 1996 and 1997, the Company recorded approximately
$23,000 and $173,000, respectively, as reinsurance recoveries. Estimates of
reinsurance receivables as of June 30, 1996 and 1997 under these arrangements
were approximately $23,000 and $102,000, respectively.
Significant Sources of Capitation Revenue
During the year ended June 30, 1997, the Company obtained 52.0% and 48.0%
of the $9,253,000 of global capitation revenue from two private insurers under
the three global capitated contracts ($7,653,000 related to Medicare enrollees
and $1,600,000 related to commercial enrollees). During the year ended June 30,
1996, the Company obtained 100% of the $382,000 of global capitation revenue
from one private insurer.
Cash and Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with original
maturities of three months or less when purchased to be cash equivalents. As of
June 30, 1997, $680,000 of cash and cash equivalents were restricted for the
payment of medical claims under contractual obligations included in the
Company's managed care contracts. As of June 30, 1996, there were no restricted
cash and cash equivalents.
Accounts Receivable
Accounts receivable principally represent receivables from third party
payors and patients for patient medical services provided by affiliated CMGs.
The accounts receivable have been assigned to the Company under the terms of the
PSO agreements. Such amounts are recorded net of contractual allowances and
estimated bad debts.
Accounts Receivable--Affiliates
Accounts receivable--affiliates include amounts due from the CMGs for
Medicare and Medicaid services provided in respect of which the Company has
legal rights to the proceeds.
Medical Supplies
The Company expenses the cost of routine medical and laboratory supplies
when purchased.
Property and Equipment
Property and equipment are stated at cost. Depreciation and amortization
are provided for in amounts sufficient to relate the cost of depreciable assets
to operations over their estimated service lives, ranging from three to ten
years. Leasehold improvements are amortized over the lives of the respective
leases or the service lives of the improvements, whichever is shorter. The
straight-line method of depreciation is followed for substantially all assets
for financial reporting purposes and accelerated methods are used for tax
purposes.
Deferred Charges and Intangible Assets
Deferred charges include deferred loan acquisition costs and organization
costs. These costs are being amortized to operations using the straight-line
basis over the term of the loan (25 months) and five years, respectively.
As a result of the Company's acquisitions of certain practice assets and
affiliations with CMGs, the Company acquires and reports intangible assets.
These assets consist principally of long-term management agreements between the
Company and the CMGs. The Company evaluates on an ongoing basis the period of
amortization of the intangibles and determines if the value of the underlying
assets has been impaired (see Note 14). Since events and circumstances
surrounding the acquisition will change over time, there can be no assurance
that the value of the intangibles will be realized by the Company. At June 30,
1996 and 1997, the recorded intangibles acquired were not considered to be
impaired. The Company's policy is to amortize the intangibles over a 10 to 40
year period. These agreements are being amortized over 20 years. Amortization
expense for the period ended June 30, 1995 and the years ended June 30, 1996 and
1997 was $9,949, $202,697 and $745,604, respectively.
30
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 1--SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--CONTINUED
Income Taxes
The Company is a corporation subject to federal and state income taxes. The
Company's year-end for tax reporting purposes is December 31. Deferred income
taxes result from the future tax consequences associated with temporary
differences between the amount of assets and liabilities recorded for financial
accounting and income tax purposes. Currently, these temporary differences
relate primarily to net operating loss carryforwards, the accrued medical
services liability, and depreciation differences. Future use of the net
operating loss carryforwards by the Company may be limited due to certain
changes in control as provided for in the Internal Revenue Code.
Use of Estimates
In preparing financial statements in accordance with generally accepted
accounting principles, management makes estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosures of contingent
assets and liabilities at the date of the financial statements, as well as the
reported amounts of revenues and expenses during the reporting period. Actual
results could differ from these estimates.
Operating Losses and Liquidity
The business description in Note 1 discusses the current nature of the
Company's operations. Until there are an adequate number of capitated patients
in the Company's global capitated contracts, the Company expects to incur
operating losses and experience negative operating cash flows. The Company
believes that its cash on hand at June 30, 1997, and the $18,913,000 received on
July 15, 1997 as outlined in Note 19, will be sufficient to meet the Company's
working capital needs through June 30, 1998. However, in the event that the
Company has not attracted an adequate number of capitated patients in global
capitated contracts in order to offset operating expenses or maintain favorable
terms under such contracts, the Company's operations and liquidity would be
adversely affected.
Stock Options and Warrants
The Company uses the Black-Scholes model to value all warrants and options
issued (see Note 12).
Newly Issued Accounting Standards
In February 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("FASB") No. 128, "Earnings Per
Share" ("SFAS 128"), which requires that entities with complex capital
structures, such as the Company, disclose both basic and diluted earnings per
share. The Company is required to adopt this standard during the quarter ended
December 31, 1997. Due to the Company's operating losses, implementation of the
standard will not have a material impact on the Company's earnings per share
disclosed in the accompanying consolidated financial statements.
In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive
Income" ("SFAS 130"), which is effective for fiscal years beginning after
December 15, 1997. The statement establishes standards for reporting and display
of comprehensive income and its components. The Company plans to adopt SFAS 130
in the fiscal year beginning July 1, 1998 and has not determined the impact of
adoption.
In June 1997, the FASB issued SFAS No. 131, "Disclosures about Segments of
an Enterprise and Related Information" ("SFAS 131"), which is effective for
fiscal years beginning after December 15, 1997. The statement establishes
revised standards under which an entity must report business segment information
in its financial statements. The Company plans to adopt SFAS 131 in the fiscal
year beginning July 1, 1998 and has not determined the impact of adoption.
The Emerging Issues Task Force of the FASB is currently evaluating certain
matters relating to the physician practice management industry, which the
Company expects will include a review of the consolidation of professional
corporation revenues and the accounting for business combinations. The Company
is unable to predict the impact, if any, that this review may have on the
Company's accounting methods.
31
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 2--ACQUISITIONS OF CERTAIN ASSETS OF PHYSICIAN GROUPS
During the years ended June 30, 1996 and 1997, the Company acquired certain
operating assets and assumed certain operating liabilities of physician groups
located in Maryland and Virginia. The purchase price has been allocated to the
assets acquired based on the estimated fair values at the dates of acquisition
and the consideration related to long-term management agreements.
The estimated fair value of assets acquired, liabilities assumed and
consideration paid are summarized as follows:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED
JUNE 30, JUNE 30,
ASSETS ACQUIRED, NET: 1996 1997
- - - -------------------------------------------------------------- ---------- ----------
<S> <C> <C>
Accounts receivable, net...................................... $1,384,200 $ 919,638
Property and equipment, net................................... 138,188 167,442
Management service agreements................................. 2,447,107 4,398,005
Other assets.................................................. 6,892 --
---------- ----------
$3,976,387 $5,485,085
---------- ----------
---------- ----------
<CAPTION>
CONSIDERATION:
- - - --------------------------------------------------------------
<S> <C> <C>
Cash.......................................................... $ 289,581 $1,836,155
Notes payable and liabilities assumed......................... 1,732,546 1,131,750
Fair value of common stock interests issued................... 1,954,260 2,517,180
---------- ----------
$3,976,387 $5,485,085
---------- ----------
---------- ----------
</TABLE>
On February 24, 1995 the Company issued 2,200,000 shares of Class B Common
Stock to MHLP (Medical Holdings Limited Partnership--a Maryland limited
partnership formed to hold the stock). These shares were in consideration of
current and future affiliations of physicians to the CMGs and an expansion of
the physician base encompassed by the PSO Agreements. The affiliation of
physicians and the purchase of their accounts receivable and fixed assets occur
when the practice assets are sold to MHLP in exchange for a limited partnership
interest and the assets are then conveyed to the Company. Simultaneously, the
physicians enter into an employment agreement with one of the affiliated CMGs.
Management believes that the underlying fair value of the PSO Agreement acquired
is equal to the value of the underlying stock held by MHLP at the time of the
acquisition. The percentage of limited partnership interests in MHLP that are
issued are adjusted to reflect the estimated fair value of the Company's stock
at the time the transaction occurs.
Generally the contracts with individual physicians provide for a nine to
twelve month period during which the parties may cancel the contract. If this
option is exercised, the Company and the physician would be restored to their
respective positions before the acquisition. Expenses and fees incurred for
professional services in connection with acquisitions are considered part of the
acquisition cost and are capitalized in the financial statements as intangibles.
During 1996 and 1997, the Company capitalized costs of approximately $43,000 and
$148,000 respectively, as part of the acquisitions. In the event that a
physician exercises his option to leave or retire, the Company charges any
unamortized intangibles associated with the acquisition to operations in the
period when notice of withdrawal is received. Subsequent to June 30, 1997, all
reaquisition rights had expired, except that one medical practice consisting of
three physicians exercised its reaquisition rights during August 1997. The
August reaquisition was deemed to have an immaterial impact on the Company.
NOTE 3--NET REVENUE
Revenue for all CMGs is recorded at established rates reduced by allowances
for doubtful accounts and contractual adjustments and amounts retained by
physician groups.
The following represent amounts included in the determination of net
revenue:
32
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 3--NET REVENUE--CONTINUED
<TABLE>
<CAPTION>
PERIOD FROM
FEBRUARY 24
THROUGH YEAR ENDED YEAR ENDED
JUNE 30, JUNE 30, JUNE 30,
1995 1996 1997
----------- ----------- ------------
<S> <C> <C> <C>
Gross physician revenue......................................................... $ 1,760,503 $13,613,426 $ 31,354,983
Less: Provision for contractual and other adjustments......................... (562,024) (5,206,105) (12,170,819)
Gatekeeper capitated income..................................................... 146,983 1,345,207 3,384,331
----------- ----------- ------------
Net physician revenue........................................................... 1,345,462 9,752,528 22,568,495
Amounts retained by affiliated core medical groups:
Physicians.................................................................... 374,761 4,016,712 9,941,388
Ancillary employees and expenses.............................................. 120,036 307,255 589,919
----------- ----------- ------------
Net revenue..................................................................... $ 850,665 $ 5,428,561 $ 12,037,188
----------- ----------- ------------
----------- ----------- ------------
</TABLE>
The Company derives its net revenue from five affiliated CMGs with which it
has PSO agreements. For the years ended June 30, 1996 and 1997, one of these
CMGs comprised approximately 93% and 50% respectively, of the Company's net
revenue.
NOTE 4--OTHER RECEIVABLES
As of June 30, 1996 and 1997, other receivables consist of the following:
<TABLE>
<CAPTION>
1996 1997
---------- ----------
<S> <C> <C>
Due from HMO's under global capitation contracts.............. $ -- $ 950,218
Reinsurance receivables....................................... 23,040 101,602
Other......................................................... 41,211 118,684
---------- ----------
$64,251 $1,170,504
---------- ----------
---------- ----------
</TABLE>
NOTE 5--OTHER ACCRUED EXPENSES
As of June 30, 1996 and 1997, other accrued expenses consist of the
following:
<TABLE>
<CAPTION>
1996 1997
---------- ----------
<S> <C> <C>
Payroll and benefits.......................................... $ 765,637 $1,179,534
Professional services......................................... 645,235 570,669
Other......................................................... 658,707 1,483,752
---------- ----------
$2,069,579 $3,233,955
---------- ----------
---------- ----------
</TABLE>
NOTE 6--NOTE RECEIVABLE
As of June 30, 1996, the Company had a note receivable that resulted from
an advance to a medical practice from which the Company had a binding letter of
intent to acquire certain assets for the approximate value of a portion of the
practice's net realizable accounts receivable. The note was issued by the
medical practice to the Company to secure the Company's right to repayment of
such advance in the event that the Company did not complete the acquisition of
certain assets of the medical practice. Interest on the note was calculated
based on the prime rate (8.25% as of June 30, 1996). The transaction was
consummated on December 4, 1996, the note receivable was canceled and the
advance plus accrued interest was treated as part of the consideration paid.
33
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 7--PROPERTY AND EQUIPMENT
Property and equipment, at cost, as of June 30, 1996 and 1997 is summarized
as follows:
<TABLE>
<CAPTION>
1996 1997
---------- ----------
<S> <C> <C>
Furniture and fixtures........................................ $ 976,430 $1,662,412
Computer equipment............................................ 1,156,829 1,680,674
Computer software............................................. 265,259 1,080,754
Medical equipment............................................. 57,507 195,888
Leasehold improvements........................................ 279,957 601,355
---------- ----------
2,735,982 5,221,083
Less accumulated depreciation and amortization................ 250,435 1,015,551
---------- ----------
Property and equipment, net................................... $2,485,547 $4,205,532
---------- ----------
---------- ----------
</TABLE>
Depreciation expense for the period ended June 30, 1995, and the years
ended June 30, 1996 and 1997 was $17,559, $232,876 and $767,168, respectively.
NOTE 8--NOTES PAYABLE AND LONG-TERM OBLIGATIONS
Notes payable at June 30, 1996 and 1997 are as follows:
<TABLE>
<CAPTION>
1996 1997
---------- -----------
<S> <C> <C>
Notes payable................................................ $3,703,915 $11,470,210
Notes payable and purchase obligations--related parties...... 2,077,364 2,659,456
Capital lease obligations.................................... 422,658 --
---------- -----------
6,203,937 14,129,666
Less: Current maturities of notes payable.................... 303,915 6,007,589
Current maturities of capital lease obligations......... 101,985 --
---------- -----------
$5,798,037 $ 8,122,077
---------- -----------
---------- -----------
</TABLE>
As of June 30, 1997, future principal payments of notes payable and
long-term obligations are as follows:
<TABLE>
<S> <C>
1998....................................................................... $ 6,007,589
1999....................................................................... 5,436,193
2000....................................................................... 53,163
2001....................................................................... 14,066
2002....................................................................... 706,611
2003 and thereafter........................................................ 1,912,044
------------
$ 14,129,666
------------
------------
</TABLE>
In December 1995, the Company entered into a loan agreement with
NationsBank, N.A. (the "NationsBank Credit Facility"), under which the Company
may request advances up to a maximum of $4 million. Interest on advances is
payable monthly and is calculated based on the bank's prime rate, unless the
Company designates a portion of the advances to be subject to the Eurodollar
rate plus .75% (effective rate of 6.20% and 6.56% at June 30, 1996 and 1997).
All advances are due at December 31, 1997. The Company has outstanding advances
under this agreement of $3,400,000 and $4,000,000 at June 30, 1996 and 1997,
respectively. The bank has the right to offset the Company's demand deposit
accounts with the bank against any past due amounts, which expires on December
31, 1997. While it is the Company's intent to refinance this note payable on or
before December 31, 1997, as of June 30, 1997 the $4,000,000 has been presented
as a current liability.
The NationsBank Credit Facility is guaranteed by the holder of the
Company's Series B Preferred Stock (see Note 19). The guarantee, which expires
on December 31, 1997, is collateralized by a security interest in all
receivables and the PSO Agreements between the Company and all the CMG's. The
guarantee agreement also provides for certain restrictions on the Company,
including limitations on incurring additional debt and reduction of amounts due
from the Series A Preferred
34
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 8--NOTES PAYABLE AND LONG-TERM OBLIGATIONS--CONTINUED
Stockholder. As consideration for the guarantee, the Company issued warrants
valued at $370,000 for the purchase of its common stock (see Note 13). As of
June 30, 1997, the Company was in compliance with the guarantee agreement.
On August 15, 1996, the Company borrowed approximately $983,000 under a
bridge loan facility (the "Bridge Loan Facility") with First National Bank of
Maryland, N.A. The Bridge Loan Facility was repaid on January 13, 1997.
On May 14, 1997, the Company borrowed $2,000,000 from HBO & Company
("HBOC"), the Company's current information system vendor, and issued a
subordinated promissory note to HBOC in the principal amount of $2,000,000 (the
"Note"). The Note is payable in full on May 14, 1998 and is included in current
portion of notes payable. In connection with this transaction, the Company
issued warrants to purchase 60,000 shares of the Company's common stock at
$15.00 per share. Utilizing a fair market value of the Company's common stock of
$7.00 per share the value of the warrants was recorded as a $120,000 discount on
the note payable which will approximate an interest rate of 6% over the 1 year
term of the loan.
On January 31, 1997, the Company and the Series C Preferred Stockholder
entered into a Note Purchase Agreement pursuant to which the Series C Preferred
Stockholder established a $5,000,000 credit facility for the Company. The
Company issued a Convertible Subordinated 11% Promissory Note ("Subordinated
Debt Facility") to the Series C Preferred Stockholder. On January 31, 1997, the
Series C Preferred Stockholder advanced the sum of $2,800,000 pursuant to the
Subordinated Debt Facility. On April 23, 1997 and June 30, 1997, the Company
received additional advances of $525,000 and $1,675,000, respectively. As of
June 30, 1997, the entire $5,000,000 is outstanding in long-term notes payable.
Interest shall be payable at maturity in shares of Series C Preferred Stock at
the rate of $14.00 per share. The Subordinated Debt Facility matures on January
31, 1999 or upon the earlier of a change in control or initial public offering.
The Subordinated Debt Facility is now convertible into shares of Convertible
Series C Preferred Stock.
On January 31, 1997, the Company issued to the Series C Preferred
Stockholder warrants to purchase 250,000 shares of Class A Common stock at
$14.00 per share in consideration of the Series C Preferred Stockholder's
efforts to assist the Company in securing additional financing for the Company.
The value of the warrant was recorded as a $552,000 deferred cost at June 30,
1997. Subsequent to June 30, 1997, the Company reclassified this amount as a
reduction of the Series D Redeemable Convertible Preferred Stock (see Note 19).
In connection with the acquisitions of certain assets of medical practices
and other transactions, the Company is obligated on short-term notes payable to
physicians and others aggregating approximately $304,000 and $320,000 at June
30, 1996 and 1997, respectively.
The Company is also obligated on notes payable to various physicians, who
are members of either Baltimore Medical, Carroll Medical, Cumberland Valley
Medical, or Doctors Health Montgomery in connection with the original purchase
of the accounts receivable from the physicians' former practices. The notes bear
interest at rates ranging from 6.25% to 10.00% and the notes mature at the
earlier of seven years from the date of closing or any of the following events:
(i) termination of the respective Professional Services Employment Agreements,
(ii) a liquidating distribution to the stockholders of the Company, (iii)
combination, consolidation or merger where the Company is not the survivor, (iv)
disposal of substantially all of the Company' assets, or (v) a public offering
with a certain cash issuance amount to the Company. The notes may be reduced or
adjusted based on receivable collections and may be prepaid without penalty. The
Company does not expect to conclude any of the events (i) through (v) above
before June 30, 1998. Accordingly, these notes have been classified as long-term
obligations.
NOTE 9--COMMITMENTS AND CONTINGENCIES
Legal
The Company is party to certain legal actions arising in the ordinary
course of business. In the opinion of the Company's management, liability, if
any, under these claims will not have a material effect on the Company's
financial position or results of operations.
35
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 9--COMMITMENTS AND CONTINGENCIES--CONTINUED
Malpractice Coverage
The Company and its affiliated CMGs have purchased a claims-made policy
with coverage limits of $1 million per medical professional per incident and $3
million annual aggregate per medical professional. This policy expires on
January 1, 1998 and it is management's intention to obtain renewal coverage. The
Company has obtained retroactive coverage for affiliated physicians that were
not previously covered by the current carrier (prior to the physician's
affiliation with the Company). Management believes that losses and costs related
to unknown incidents not provided for, if any, would not be material to the
financial position, liquidity or results of operations of the Company.
Pursuant to an agreement dated December 1, 1995, the prior written approval
of the Series B Preferred Stockholder is required in connection with decisions
regarding medical malpractice coverage for the Company, participating physicians
and affiliated entities. Such decisions include, but are not limited to, the
selection of the underwriter, the form of the insurance policy and the premium
payment provisions. The Company must make certain payments to the Series B
Preferred Stockholder if the required approval is not obtained: the Series B
Preferred Stockholder could require the Company to pay it $400,000 and to redeem
all or a portion of the Series B Preferred Stock at the price equal to the
greater of the fair market value per share or the sum of the issue price per
share and all accumulated and unpaid interest and dividends. The Series B
Preferred Stockholder agrees to provide medical malpractice coverage to the
Company for premiums consistent with its rates as approved by the Maryland
Insurance Administration. In addition, the Series B Preferred Stockholder will
consider alternative insurance programs to meet the Company's special needs and
will request the necessary approvals for such alternative programs from the
Maryland Insurance Administration. This agreement terminates upon the earlier of
a change in control of the Company or termination of the loan guarantee provided
by the Series B Preferred Stockholder.
Employee Benefit Plans
Effective January 1, 1996, the Company adopted a 401(k) Plan (the "Plan")
covering all its employees. Subject to certain limitations, participants may
elect to defer a portion of their compensation as contributions to the Plan. The
Company will make matching contributions of 50% of each participant's
contribution up to six percent of the participant's salary. Participants vest in
the Company's contributions at the rate of 20% per year beginning in fiscal
1997. Company matching contributions of approximately $110,000 and $244,000,
were expensed in fiscal 1996 and 1997, respectively.
Effective February 1, 1996, the Company adopted a Flexible Benefits Plan
covering all full-time employees. Subject to certain limitations, the Company
may make "non-elective contributions" on behalf of employees and employees may
elect to defer a portion of their compensation as "flexible pay contributions"
to pay for certain covered expenses.
Operating Leases
The Company conducts its operations at leased facilities and leases office
equipment under noncancelable operating leases. Certain of the leased facilities
are owned by physicians who have membership interests in affiliates. Amounts
paid to the related parties approximated $8,700, $14,500, and $317,000 in 1995,
1996 and 1997, respectively. The operating leases have initial terms that expire
at various times through 2008 and, generally, provide for renewal for various
periods at stipulated rates. Some of the operating leases provide that the
Company pay taxes, maintenance, insurance and other occupancy costs applicable
to leased premises. Total rent expense for all operating leases approximated
$74,000, $454,000 and $2,224,000 for 1995, 1996 and 1997, respectively. Minimum
rental commitments, excluding sublease income, under operating leases as of June
30, 1997, with existing or renewable terms greater than one year are as follows
(the Company has approximately $371,000 of minimum rental commitments due in
1998 to related parties):
<TABLE>
<S> <C>
1998........................................................................ $ 1,301,168
1999........................................................................ 1,288,620
2000........................................................................ 1,090,650
2001........................................................................ 940,930
2002........................................................................ 445,155
2003 and thereafter......................................................... 1,146,674
-----------
$ 6,213,197
-----------
-----------
</TABLE>
36
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 9--COMMITMENTS AND CONTINGENCIES--CONTINUED
Cash and Cash Equivalents
The Company maintains its cash balances in three financial institutions in
Maryland. At times the cash balances may exceed the federally insured limits.
The Company has not experienced any losses in such accounts and believes it is
not exposed to any significant credit risk on cash and cash equivalents.
Employment Agreements
The Company has entered into employment agreements with certain of its
management employees, which include, among other terms, noncompetition
provisions and salary and benefits continuation.
Commitments to Affiliated CMGs
Under the terms of certain of its PSO agreements, the Company is committed
to provide minimum guarantees of certain affiliated physician salaries based on
a defined formula.
Loan Guarantee
In connection with the purchase of certain assets of a physician's
practice, the Company has agreed to guarantee a loan, beginning in October 1997,
that has an outstanding balance of approximately $1,100,000 as of June 30, 1997.
The underlying loan matures during August 2001. Management does not believe it
is probable that the Company will have to fund the guarantee.
NOTE 10--REDEEMABLE CONVERTIBLE PREFERRED STOCK
The Company is authorized to issue 6.50% cumulative Series A shares, 9.75%
cumulative Series B shares and 8.00% cumulative Series C shares of redeemable
convertible preferred stock at June 30, 1997.
Preferred Stock Conversion and Redemption Rights
Series A and B Redeemable Convertible Preferred Stock ("Series A and Series
B Preferred Stock") are convertible to Class C Common on a share for share basis
at the holder's option, at any time before February 25, 2000. Series C
Redeemable Convertible Preferred Stock ("Series C Preferred Stock") is
convertible to Class C Common on a share for share basis at the holder's option,
at any time. In addition, the Preferred Stock is automatically converted to
Class C Common Stock on a share for share basis upon the occurrence of certain
events, including a public offering of the Company's stock. Only the fully-paid
shares are subject to conversion.
Between March 1 and June 1, 2000, the Series A and Series B Preferred
Stockholders have the right to require the Company to redeem all of their shares
at the greater of fair value (as determined by an independent appraiser selected
jointly by the parties) or the issuance price plus unpaid dividends and interest
thereon. Upon expiration of these rights, and if the shares are not otherwise
converted to Class C Common Stock, the Company has the right to redeem the
outstanding shares of Series A Preferred Stock at the issuance price plus unpaid
dividends and interest thereon. It may also redeem the Series B Preferred Stock
on the same terms that the holders could require the Company to pay on a
requested redemption by the holders.
In addition, upon the occurrence of certain events, the Series A, Series B
and Series C Preferred Stockholders have the right to require the Company, and
the Company has the right, to redeem all of the respective preferred shares then
held. In the event of any non-compliance (as defined), the Preferred Stock is
mandatorily redeemable. If the Company decides to take certain actions without
the approval of the Series A, Series B, and Series C Preferred Stockholders then
the Preferred Stockholders have the right to require the Company to redeem all
of their outstanding shares. In the foregoing instances, the redemption price is
the greater of fair value or the issuance price plus unpaid dividends and
interest thereon. If the Company elects to enforce certain non-competition
covenants with the Series B Preferred Stockholder, then the holder may require
the Company to redeem the shares held for the greater of $4.8 million or par
value plus unpaid dividends and interest thereon. If the Company issues Series A
Junior Stock or Series B Junior Stock to holders deemed to have interests
adverse to the respective Preferred Stockholder, then the holder may require the
Company to redeem their shares at the greater of: (i) the
37
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 10--REDEEMABLE CONVERTIBLE PREFERRED STOCK--CONTINUED
purchase price of the adverse junior stock on a fully diluted basis, (ii) fair
value, or (iii) one and one-half (1 1/2) times the liquidation preference.
Series A Preferred Stock Subscription Receivable
As partial consideration for the issuance of Series A Preferred Stock, the
Company received a note in the original amount of $3 million ($3 million balance
outstanding at June 30, 1995 and $1.5 million outstanding at June 30, 1996 and
1997). The note bears interest at 6.5% per annum, compounded quarterly, and
interest is payable only to the extent that the Company pays dividends on the
Series A Preferred Stock. The parties have the right to offset like amounts of
dividends and interest.
Scheduled note payments are subject to deferral at the option of the
Company until February 14, 1998, but interest continues to accrue on any unpaid
balance. As of June 30, 1997 the Company elected to defer payments of
$1,500,000. Upon redemption or conversion of Series A Preferred Stock, any
unpaid principal on the note is to be canceled in an amount equal to five
dollars times the number of shares converted or redeemed. The Company has the
option to require payment of any outstanding principal and interest on February
14, 1998, or the Company may elect to redeem the outstanding Series A Preferred
Stock and cancel the remaining principal and interest.
Preferred Stock Dividends
Series A Redeemable Convertible Preferred Stock accrues dividends quarterly
at the rate of thirty-two and one half cents ($0.325) per share per annum
beginning on February 24, 1995. Unpaid dividends accrue interest at the rate of
6.5% per annum, compounded quarterly, and may be offset by the Company against
any unpaid interest that is owed by the holders of the Series A Redeemable
Convertible Preferred Stock under the related note receivable.
Series B Redeemable Convertible Preferred Stock accrues dividends quarterly
at the rate of one dollar and nine and seven tenths cents ($1.097) per share per
annum beginning December 1, 1995. Unpaid dividends accrue interest at the rate
of 9.75% per annum, compounded quarterly.
Series C Redeemable Convertible Preferred Stock accrues dividends quarterly
at the rate of one dollar and forty cents ($1.40) per share per annum beginning
September 4, 1996 with respect to 428,751 shares and beginning January 2, 1997
with respect to 142,857 shares. Unpaid dividends accrue interest at the rate of
8% per annum, compounded quarterly.
Until April 1, 2000, payment of dividends on Series A Preferred Stock and
Series B Preferred Stock are only permitted in the event of redemption,
conversion or liquidation, and, in any event, dividends on Series B Preferred
Stock may only be paid after all dividends and interest on the Series A
Preferred Stock have been satisfied. Beginning April 1, 2000, dividends on
Series A Preferred Stock and Series B Preferred Stock will accrue at a rate
equal to the prime rate plus 100 basis points.
Payment of dividends on Series C Preferred Stock is permitted only in the
event of redemption, conversion or liquidation and, in any event, dividends on
Series C Preferred Stock may only be paid after dividends and interest on the
Series A and Series B Preferred Stock. If not paid when due, such dividends on
Series C Preferred Stock accrue interest at a rate equal to the prime rate plus
100 basis points.
Cumulative Series A, B and C Redeemable Convertible Preferred Stock accrued
and undeclared dividends at June 30, 1995, 1996 and 1997 are as follows:
<TABLE>
<CAPTION>
1995 1996 1997
-------- -------- ----------
<S> <C> <C> <C>
Series A........................................... $113,300 $438,305 $ 763,305
Series B........................................... -- 227,526 617,570
Series C........................................... -- -- 590,976
-------- -------- ----------
$113,300 $665,831 $1,971,851
-------- -------- ----------
-------- -------- ----------
</TABLE>
Accrued dividends are reflected as an accretion in the value of the
preferred stock with a corresponding reduction in stockholders' equity to
reflect redemption value.
38
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 10--REDEEMABLE CONVERTIBLE PREFERRED STOCK--CONTINUED
Preferred Stock Liquidation Preferences
Upon liquidation or dissolution of the Company, the Series A, Series B, and
Series C Preferred Stockholders are entitled to receive a liquidating
distribution in an amount equal to the greater of: (i) the fair value (as
defined) per share of the respective series of preferred stock or (ii) the
original purchase price per share of the respective stock. The distribution will
be weighted taking into account all unpaid cumulative dividends and accrued
interest thereon; however, the total distributable amount due to each preferred
stockholder is limited to the amount of cash paid to the Company for the
purchase of the respective shares. No distribution will be paid to the Series B
Preferred Stockholder until all amounts due to the Series A Preferred
Stockholder have been fully paid. Also, no distribution will be paid to the
Series C Preferred Stockholder until all amounts due to the Series A and Series
B Preferred Stockholders have been fully paid. Subsequent to June 30, 1997 (see
Note 19), the liquidation preferences carried by the Series A, Series B and
Series C Preferred Stock were revised.
NOTE 11--STOCKHOLDERS' EQUITY
Substantially all of the Company stockholders are parties to an agreement
dated September 4, 1996 that restricts transfer of the Company's Common stock.
The agreement terminates upon occurrence of certain specified events, including
a public offering of the Company's Common stock. Under the terms of the
Stockholders' Agreement, the Company may be required to purchase shares of the
Company's capital stock in certain circumstances, such as: (i) Class A Common
Stock owned by management stockholders, in the event of their death or
disability if other management stockholders do not exercise their rights to
acquire the shares offered, in which case the Company is required to purchase
all of the offered shares at fair value (as agreed to by the parties or as
determined by an independent appraisal); (ii) Class A Common Stock purchased by
certain stockholders after December 1, 1995, if their employment is terminated,
in which case the Company is required to purchase these shares at fair value (as
agreed to by the parties or as determined by an independent appraisal); (iii)
Class A Common Stock owned by other management stockholders if their employment
is terminated and the remaining management stockholders do not exercise their
rights to acquire the shares offered. In this case if termination is without
cause, the purchase price is based on fair value (as agreed to by the parties or
as determined by an independent appraisal). If termination is with cause, then
the purchase price is the lesser of $1.00 per share or the original issuance
cost of the shares. At June 30, 1996 and 1997, 800,000 shares of Class A Common
Stock were subject to such repurchase requirement. Based on the current fair
value of the Company's stock, the repurchase obligation for 800,000 shares in
the event of death or disability to all three Class A Common Stockholders would
be approximately $5,600,000 at June 30, 1997. If the Company is required to
purchase shares of the management stockholder under the foregoing circumstances,
then all accrued dividends due to Series A, B and C Preferred Stockholders must
first be paid; (iv) All classes of capital stock--upon the occurrence of an
involuntary transfer involving any of its outstanding capital stock, the Company
has the right of first refusal to purchase the offered shares at fair value (as
agreed to by the parties or as determined by an independent appraisal).
As noted above, under the terms of the Stockholders' Agreement with three
founding stockholders (who are also officers and directors of the Company), the
Company may be required to purchase shares of the Company's Class A Common Stock
in certain circumstances including death or disability. As of June 30, 1996, the
Company had obtained insurance to cover the purchase of the capital stock in the
event of death. On December 20, 1996, the Company obtained insurance to cover
the purchase of the capital stock in the event of a disability. By agreement
dated February 1, 1997, one of the founding shareholders agreed to waive the
repurchase requirement with respect to any disability not covered by insurance.
As of February 17, 1997, the disability portion of the insurance lapsed with
respect to the founding shareholder who had waived the repurchase requirement.
Under each of the above policies, the Company has obtained insurance that is in
excess of the estimated fair value of its Class A Common Stock. The Company has
presented the common stock that is redeemable based on events outside the
Company's control (i.e. a disability) as Redeemable Class A Common Stock in the
accompanying Balance Sheet as of June 30, 1996. As a result of the coverage
provided by the life and disability policies described above and the waiver of
certain stock repurchase rights described above, as of June 30, 1997 there are
no circumstances in which a redemption event would result in a decrease in the
Company's stockholders' equity. Accordingly, the Company has presented the Class
A Common Stock as stockholders' equity as of June 30, 1997. The Company intends
to maintain insurance at levels sufficient to finance its redemption
obligations. The terms of the stock purchase agreement terminate in the event of
an initial public offering or a change in control of the Company as defined in
the Stockholders' Agreement.
39
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 11--STOCKHOLDERS' EQUITY--CONTINUED
During the year ended June 30, 1997, the Company issued 10,000 shares of
Class A common stock to Noah Investments in connection with the acquisition of a
long-term care management company, which had no operations during the year ended
June 30, 1997.
All classes of Common Stock have the same preferences, rights and voting
powers. A portion of the Class A Common Stock is reserved for issuance upon
exercise of warrants, and a portion of the Class C Common Stock is reserved for
issuance to the holders of Series A, B and C Preferred Stock upon conversion of
those shares of stock.
NOTE 12--STOCK OPTIONS
The Company has an Omnibus Stock Plan which is accounted for under
Accounting Principles Board Opinion No. 25 ("APB No. 25") and related
Interpretations (as allowed by SFAS No. 123) with respect to employee
transactions. Transactions with non-employees are accounted for at fair value at
the date of grant. The Omnibus Stock Plan permits the Company to grant incentive
and non-qualified stock options, stock appreciation rights ("SARs") and
restricted or unrestricted share awards to directors, officers, employees and
other key contributors to the Company. SARs entitle the optionee to surrender
unexercised stock options for cash or stock equal to the excess of the fair
value of the surrendered shares over the option value of such shares. The
Omnibus Stock Plan is administered by a committee (the "Committee") appointed by
the Company's Board of Directors. Subject to adjustment as provided in the
Omnibus Stock Plan, the aggregate number of shares of the Company Common Stock
which may be awarded is limited to 6,175,000. Shares under any grants that
expire unexercised are available for future grant.
The exercise price and exercise period for stock options is determined by
the Committee, provided that the exercise period may not exceed ten years from
the grant date and the exercise price for incentive stock options may not be
less than 100% of the fair value of the shares on the date the option is
granted. Incentive stock options are granted only to employees of the Company.
During the year ended June 30, 1996, the Company granted incentive stock
options, to purchase Class A Common Stock, to eleven employees for a total of
218,380 shares at the exercise price of $0.01 per share, the estimated fair
value of the shares at the date of grant based on the financial position and
liquidity of the Company and the limited marketability of the shares. The
options become exercisable on various dates ranging from April 1, 1996 through
April 1, 2000. Upon exercise, 68,832 shares will be fully vested and
nonforfeitable; the remainder vest ratably over four years. Options may expire
or become exercisable, and shares issued may be fully vested, at earlier dates
upon occurrence of certain specified events, including a change in control of
the Company or the employee's death, disability, retirement, or termination
without cause. Also, in May 1996, the Company granted incentive stock options to
purchase Class A Common Stock for 70,000 shares with an exercise price of $11.00
per share to an employee.
During the year ended June 30, 1997, the Company granted incentive stock
options to purchase Class A Common Stock to employees for a total of 155,250
shares at the exercise price of $15.00 per share, which was deemed to be in
excess of management's estimate of the fair value of the Company's Common Stock
at the date of grant. The options become exercisable on various dates ranging
from October 1, 1997 through November 7, 2001. The options vest over a five-year
period from the date of issuance. During 1996 and 1997, employees forfeited
20,050 and 10,000 Class A Common Stock options, respectively.
During the year ended June 30, 1996, the Company granted non-qualified
stock options to purchase Class A Common Stock to three employees for a total of
12,500 shares at the exercise price of $0.01 per share. The options became
exercisable on December 21, 1996. Upon exercise, 5,000 shares issued will be
fully vested and nonforfeitable; the remainder vest ratably over four years.
Options may expire or become exercisable, and shares issued may be fully vested,
at earlier dates upon occurrence of certain specified events, including a change
in control of the Company or the employee's death, disability, retirement, or
termination without cause. The Company is recognizing compensation expense as
the shares vest based upon the option price and the fair value of the Company's
Common Stock at the date of grant. The fair value of the common stock at the
time of grant in December 1995, $3.00 per share, was based in part on a
discounted value of the per share price of the Company's Series B Redeemable
Convertible Preferred Stock.
40
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 12--STOCK OPTIONS--CONTINUED
During the year ended June 30, 1997, the Company granted non-qualified
stock options to purchase Class A Common Stock to employees for a total of
118,250 shares at the exercise price of $.01 per share. The options become
exercisable on various dates ranging from October 1, 1997 through November 7,
2001. The options vest on the fifth anniversary of the issuance date or over a
five-year period from the date of issuance. The Company is recognizing
compensation expense as the options vest based upon the option price and the
fair value of the Company's Common Stock at the date of grant. The fair value of
the common stock at the time of the grants was $3.00 and $7.00 per share. The
fair value was based in part on a discounted value of the per share price of the
Company's Series B and C Redeemable Convertible Preferred Stock. The Company
also granted stock options to a non-employee for a total of 10,000 shares at the
exercise price of $18.75 per share. The fair value of the options was deemed
immaterial by management at the date of grant.
During the year ended June 30, 1996, the Company granted a non-qualified
stock option to purchase 5,000 shares of Class B Common Stock to a physician at
an exercise price of $0.01 per share, the estimated fair value of the stock at
the date of grant.
During the year ended June 30, 1997, the Company granted non-qualified
stock options to purchase Class B Common Stock to physicians in connection with
acquisitions for a total of 22,000 shares at the exercise price of $15.00 per
share. The options are fully vested. The options are exercisable on various
dates ranging from June 12, 1997 through April 1, 2000. In addition, the Company
granted non-qualified options to purchase Class B Common Stock to a physician in
connection with his employment for a total of 33,000 shares at the exercise
price of $.01 per share. The options vest fully on March 25, 2002. The Company
is recognizing compensation expense as the shares vest based upon the option
price and the fair value of the Company's Common Stock at the date of grant
which was $7.00 per share. Also, during the year ended June 30, 1997, the
Company granted a non-qualified stock option to purchase 3,000 shares of Class B
Common Stock to a physician at an exercise price of $0.01 per share.
During the year ended June 30, 1997, the Company recorded $1,040,633 as
additional paid-in capital related to the issuance of common stock options at a
price less than the fair value of the common stock at the date of grant. A
corresponding amount was recorded as a reduction to stockholders equity. The
deferred compensation will be amortized as expense over the five year vesting
period of the options. During the year ended June 30, 1997, the company
recognized $128,125 as deferred compensation expense in the consolidated
statement of operations. The Company recognized no compensation expense related
to the issuance of stock options during the year ended June 30, 1996.
Stock option activity during the periods indicated is as follows:
<TABLE>
<CAPTION>
CLASS A CLASS B EXERCISE PRICE
OPTIONS OPTIONS PER SHARE
------- ------- --------------
<S> <C> <C> <C>
Balance at February 24, 1995......................................... -- -- --
Granted............................................................ -- -- --
Exercised.......................................................... -- -- --
Forfeited.......................................................... -- -- --
------- -------
Balance at June 30, 1995............................................. -- -- --
Granted............................................................ 300,880 5,000 $.01-$11.00
Exercised.......................................................... -- -- --
Forfeited.......................................................... (20,050) -- .01
------- -------
Balance at June 30, 1996............................................. 280,830 5,000 .01-11.00
Granted............................................................ 283,500 58,000 .01-18.75
Exercised.......................................................... -- -- --
Forfeited.......................................................... (10,000) -- .01-15.00
------- -------
Balance at June 30, 1997............................................. 554,330 63,000 $.01-$18.75
------- -------
------- -------
</TABLE>
At June 30, 1997, the weighted-average remaining contractual life of
outstanding options was 8.8 years. The per share weighted-average fair value of
stock options granted during the years ended June 30, 1996 and 1997 was $.26 and
$4.09.
41
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 12--STOCK OPTIONS--CONTINUED
During 1995, the FASB issued SFAS No. 123, "Accounting for Stock Based
Compensation" ("SFAS 123"). which defines a fair value based method of
accounting for an employee stock option or similar equity instrument. This
statement allows an entity to continue to measure compensation cost for those
plans using the method of accounting prescribed by the APB No. 25, "Accounting
for Stock Issued to Employees." Entities electing to remain with the accounting
in APB No. 25 must make pro forma footnote disclosures of net income and
earnings per share, as if the fair value based method of accounting defined in
this Statement had been applied.
The Company has elected to account for its stock-based compensation plans
in accordance with APB No. 25, under which $128,125 of compensation expense has
been recognized during 1997. The Company has computed for pro forma disclosure
purposes the value of all compensatory options granted during 1996 and 1997,
using the Black-Scholes option pricing model as prescribed by SFAS No. 123. The
following assumptions were used for grants:
<TABLE>
<CAPTION>
1996 1997
----------- -----------
<S> <C> <C>
Risk-free interest rate (range)........................ 5.48%-6.38% 5.91%-6.66%
Expected dividend yield................................ 0.0% 0.0%
Expected lives......................................... 5 years 5 years
Expected volatility.................................... 50.0% 50.0%
</TABLE>
Options were assumed to be exercised upon vesting for the purposes of this
calculation. Adjustments are made for options forfeited prior to vesting. Had
compensation costs for compensatory options been determined consistent with SFAS
No. 123, the Company's net loss applicable to common stock and net loss per
share information reflected on the accompanying consolidated statements of
operations would have been increased to the following proforma amounts:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED
JUNE 30, JUNE 30,
1996 1997
----------- ------------
<S> <C> <C>
Loss Applicable to Common Stock:
As reported in financial statements.......................................................... $(7,164,644) $(16,182,133)
Proforma..................................................................................... $(7,166,464) $(16,219,681)
Net Loss per Share:
As reported in financial statements.......................................................... $ (2.34) $ (4.84)
Proforma..................................................................................... $ (2.34) $ (4.85)
</TABLE>
The Company's stock did not actively trade during 1996 and 1997.
Under SFAS No. 123, proforma net loss applicable to common stock reflects
only options granted during the years ended June 30, 1996 and 1997. The Company
granted no options prior to July 1, 1995.
NOTE 13--COMMON STOCK PURCHASE WARRANTS
In consideration for the guarantee of a loan agreement, the Company issued
on December 1, 1995 warrants to its Series B Preferred Stockholder for the
purchase of 88,889 shares of the Company Class A Common Stock at $5.625 per
share. The warrants expire on December 1, 2005 and are exercisable (i) if the
holder does not receive notice of a change in control within thirty days after
the change is effective or (ii) ninety days prior to the filing of a
registration statement for a public offering that includes shares held by
management stockholders. The warrants were valued at the present value of the
difference between the estimated fair value of the common stock subject to the
warrants and the aggregate strike price, discounted at the interest savings rate
(the difference between the rate obtained on the loan agreement and the rate of
interest that management believes would have been available without the
guarantee). At June 30, 1996, this amount ($370,000) is reflected as additional
paid-in capital and a deferred charge, which is being amortized on the interest
method over 25 months (the length of the guarantee).
On December 1, 1995, in consideration for certain consulting services, the
Company issued warrants for the purchase of 24,000 shares of the Company's
common stock at $11.25 per share (a price greater than management's estimate of
fair value
42
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 13--COMMON STOCK PURCHASE WARRANTS--CONTINUED
at the date of grant). A value was not attributed to these warrants at the time
of issue. These warrants expire December 1, 2005, and are exercisable if there
is a change in control of the Company.
On January 31, 1997, the Company issued warrants for the purchase of
250,000 shares of the Company's common stock at $14.00 per share to the Series C
Preferred Stockholder in consideration for its efforts to assist in securing up
to $30,000,000 in financing for the Company. Utilizing a fair market value of
the Company's common stock of $7.00 per share, the Company valued the warrants
at $552,000.
As stated in Note 8, on May 14, 1997, the Company issued warrants for the
purchase of 60,000 shares of the Company's common stock at $15.00 per share to
HBOC in lieu of interest on a $2,000,000 note payable.
NOTE 14--FAIR VALUE OF FINANCIAL INSTRUMENTS
Fair Value of Financial Instruments
The carrying amounts of financial instruments included in current assets
and current liabilities approximate fair values because of the short maturity of
those instruments. The following methods and assumptions were used to estimate
the fair value of each class of financial instruments for which it is
practicable to estimate that value:
Redeemable Convertible Preferred Stock and Series A Preferred Stock
Subscription Receivable
The Series A, B and C Preferred Stock are carried at issue price plus
accrued dividends, and have features unique to these securities including, but
not limited to, the right to appoint directors and the right to approve certain
significant activities of the Company. There is no quoted market price for the
Series A, B and C Preferred Stock, however, management believes that the initial
recorded amounts approximate fair value.
The carrying value of the Series A Preferred Stock subscription receivable
is based on the issue price of the related Series A Preferred Stock. In
December, 1995, the Company issued Series B Preferred Stock with the same rights
and privileges as the Series A Preferred Stock, other than the dividend rate and
related interest rate, for consideration greater than the per share value
received for the Series A Preferred Stock. Since both classes of Preferred Stock
are convertible to Class C Common Stock, it is not practical to determine if the
related stock subscription will be realized in cash, included in the conversion
to Common Stock or offset against the issued Series A Preferred Stock, thereby
reducing the number of shares outstanding. Furthermore, the Company has the
right to defer or cancel payment of the stock subscription receivable.
Long-Term Obligations
Long-term obligations-related parties were incurred by the Company when
individual physicians joined the affiliated CMGs. These notes are payable upon
an initial public offering of the Company's stock or a change in control as
defined in the stockholders' agreement. In addition, the Company incurred a
long-term obligation to the Series C Preferred Stockholder during 1997 to fund
the working capital needs of the Company. The fair value of these obligations is
assumed to approximate recorded value because there have not been any
significant changes in circumstances since the obligations were recorded.
NOTE 15--INCOME TAXES
The Company has accumulated net operating losses (NOL's) of approximately
$18,205,000. Significant temporary differences between the determination of this
loss for financial reporting and income tax purposes include depreciation, the
allowance for uncollectible receivables, and certain accrued liabilities. These
losses may be carried forward for 15 years and expire at various dates through
2011. Under federal tax law, certain changes in ownership of the Company, which
may not be within the Company's control, may operate to limit future utilization
of these carryforwards. As of June 30, 1997, based on the available information,
management does not believe that it is more likely than not that the net
deferred tax assets will be realized. As a result, the net deferred tax assets
have been fully reserved at June 30, 1996 and 1997. Deferred tax assets
(liabilities) at June 30, 1996 and 1997, consist of the following:
43
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 15--INCOME TAXES--CONTINUED
<TABLE>
<CAPTION>
1996 1997
----------- -----------
<S> <C> <C>
Tax benefit of NOL carryforward............................. $ 2,876,000 $ 7,282,000
Depreciation and amortization............................... (360,000) (700,000)
Allowance for uncollectable receivables..................... 130,000 108,000
Accrued medical services.................................... 236,000 1,268,000
Other accrued liabilities................................... 40,000 168,000
----------- -----------
2,922,000 8,126,000
Less: valuation allowance................................... (2,922,000) (8,126,000)
----------- -----------
Net deferred tax asset.................................... $ -- $ --
----------- -----------
----------- -----------
</TABLE>
NOTE 16--EARNINGS PER SHARE
The weighted average common shares outstanding presented for the period
ended June 30, 1995, and the years ended June 30, 1996 and 1997 were 3,000,000,
3,063,205 and 3,345,397, respectively. Stock options and warrants have been
excluded in fiscal 1995, 1996 and 1997 since their exercise would be
anti-dilutive. The weighted average common shares in fiscal 1995 have been
restated to reflect the two-for-one stock split in fiscal 1995. The net loss for
purposes of the calculation of loss per share has been adjusted for the
accretion of redeemable preferred stock dividends and issuance costs.
NOTE 17--SUPPLEMENTARY CASH FLOW INFORMATION
<TABLE>
<CAPTION>
PERIOD FROM
FEBRUARY 24
(INCEPTION)
THROUGH YEAR ENDED YEAR ENDED
JUNE 30, JUNE 30, JUNE 30,
1995 1996 1997
----------- ----------- -----------
<S> <C> <C> <C>
Cash paid for interest.............................................................. $ 11,825 $ 176,169 $ 345,759
Cash paid for income taxes.......................................................... -- -- --
Significant supplementary noncash investing and financing information:
Liabilities assumed in connection with the purchase of medical practice assets...... 184,322 1,732,546 1,131,750
Accounts receivable and other assets assumed in connection with the purchase of
medical practice assets........................................................... 167,153 1,391,092 919,638
Cancellation of note receivable..................................................... -- -- 300,000
Assets acquired under capital leases................................................ -- 600,290 --
Issuance of common stock purchase warrants for services............................. -- 370,000 672,500
Issuance of common stock options.................................................... -- -- 1,040,633
Common stock issued in connection with purchase of medical practice assets.......... -- 1,954,260 2,517,180
Renegotiation of capital lease...................................................... -- -- 176,822
</TABLE>
NOTE 18--RELATED PARTIES
Amounts due under the terms of the PSO agreements between the Company and
the affiliated medical groups are reflected in the Due to/from Affiliates on the
consolidated balance sheet. The amounts due from the affiliates represents
working capital advances, amounts due for management fees from BMG LLC related
to the management of the laboratory and management fees due under the PSO
agreement. The amounts due to the affiliates represent amounts due to the
physicians related to the collection of accounts receivable.
Because of the nature of the Company's arrangements with Affiliated CMGs,
substantially all transactions included in Net Revenues, Medical Services
Expense and Care Center Costs in the accompanying financial statements are
viewed as related party transactions.
44
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 18--RELATED PARTIES--CONTINUED
MHLP (See Note 2) was formed on February 24, 1995 to hold the Class B
Common Stock that was issued by the Company and intended to be used for the
acquisition of PSO agreements by the Company. MHLP has no assets other than the
Class B Common Stock of the Company and has no liabilities or operations.
Two of the Company's executive management members and nine directors are
practicing physicians with CMGs affiliated with the Company.
During the years ended June 30, 1996 and 1997, the Company paid
approximately $98,000 and $296,000 to the Series B Redeemable Convertible
Preferred Stockholder for professional liability insurance on behalf of the
affiliated CMGs in connection with the PSO agreement.
The Company has entered into acquisition transactions with certain of its
directors who are physicians. These transactions were entered into on
commercially reasonable terms, substantially similar to the terms of its
acquisition transactions with other affiliated physicians, and the consideration
paid in connection with such acquisitions was based on the fair market value of
the medical practice assets or services acquired:
(a) During the year ended June 30, 1996, the Company purchased certain
assets of a director of the Company, and four physician partners of the
physician. The physician and his four partners received a limited partnership
interest in MHLP equivalent to 167,000 shares of Class B Common Stock, valued at
$3.00 per share, and a promissory note with a face value of approximately
$158,000 as consideration for the acquisition. As of June 30, 1997, the
physician has outstanding advances from the Company of approximately $53,000.
(b) During the year ended June 30, 1996, the Company purchased certain
assets of a director of the Company. In addition, the physician received a
limited partnership interest in MHLP equivalent to 33,000 shares of Class B
Common Stock, valued at $3.00 per share, approximately $34,000 in cash and a
promissory note with a face value of approximately $45,000 as consideration for
the acquisition. As of June 30, 1997, the physician has outstanding advances
from the Company of approximately $146,000.
(c) During the year ended June 30, 1997, the Company purchased certain
assets of a director of the Company. The physician received 16,000 shares of
Class B Common Stock and 1,000 options to acquire Class B Common Stock, valued
at $7.00 per share, cash in the amount of $5,000 and a promissory note with a
face value of approximately $38,000 as consideration for the acquisition.
(d) During the year ended June 30, 1997, the Company purchased certain
assets of a director of the Company. In connection with the acquisition, the
physician's limited liability partnership, which he owns with five other
physicians, received a limited partnership interest in MHLP equivalent to 63,430
shares of Class B Common Stock, an option to acquire a limited partnership
interest equivalent to 20,000 shares of Class B Common Stock, exercisable at
$15.00 per share, and cash for the practice's collectable accounts receivable,
which will not exceed $625,000. As of June 30, 1997, the Company has recorded
approximately $200,000 as a non-current receivable from the physician in
connection with the purchase transaction. This amount is payable at the rate of
$5,000 per month beginning in July 1998. During the year ended June 30, 1996,
the Company advanced $300,000 to the physician and the practice for the purchase
of the practice's accounts receivable and received a promissory note from the
physician evidencing such advance. The promissory note was canceled at the
closing of the acquisition. See Note 9 regarding the loan guarantee related to
this practice acquisition. The Company has delegated to the physician's
practice, and the practice will perform, certain practice management business
functions, which the Company ordinarily performs for its physicians at its
headquarters. The Company reimburses the physician's practice up to
$50,000/month for the expenses it incurs in performing the business management
services. The amount reimbursed for the year ended June 30, 1996 and 1997 was
$100,000 and $486,000, respectively.
As of June 30, 1997, the Company has also advanced to a physician director
a total of approximately $223,000.
During the year ended June 30, 1997, the Company acquired a long-term care
management company from an entity which is partially owned by the brother of a
director of the Company in exchange for 10,000 shares of Class A common stock
valued at $7.00 per share.
45
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 19--SUBSEQUENT EVENTS
Series D Preferred Stock Issue and Amended Articles of Incorporation
The Company amended and restated its charter on July 15, 1997. The amended
and restated articles authorize the Company to issue 68,438,068 shares of
capital stock as follows:
<TABLE>
<CAPTION>
SHARES PAR
AUTHORIZED VALUE
---------- ------
<S> <C> <C>
Redeemable Convertible Preferred Series A......................................... 1,000,000 $ 5.00
Redeemable Convertible Preferred Series B......................................... 438,068 11.25
Redeemable Convertible Preferred Series C......................................... 1,500,000 17.50
Redeemable Convertible Preferred Series D......................................... 5,750,000 10.00
Class A Common.................................................................... 20,700,000 0.01
Class B Common.................................................................... 10,000,000 0.01
Class C Common.................................................................... 29,050,000 0.01
----------
68,438,068
----------
----------
</TABLE>
On July 7, 1997, the Company entered into a Preferred Stock Purchase
Agreement, as amended on July 15, 1997 (the "Preferred Stock Purchase
Agreement") with the Series D Preferred Stockholder pursuant to which the
Company agreed to sell and the Series D Preferred Stockholder agreed to purchase
three million (3,000,000) shares of the Company's Series D Redeemable
Convertible Preferred Stock ("Series D Preferred Stock") for a purchase price of
$30 million, subject to the terms and conditions thereof. The Company closed the
transaction on July 15, 1997, with an initial sale of two million (2,000,000)
shares for $20 million. The Company incurred issuance costs of approximately
$1,087,000 in connection with the Series D financing including financing and due
diligence fees. The $18,913,000 in net proceeds will be used to fund the
expansion of the Company and operating losses. A subsequent sale is expected to
take place on or before June 30, 1998 of an additional one million (1,000,000)
shares for $10 million subject to the satisfaction of certain contingencies or
conditions precedent by such date as provided in the Preferred Stock Purchase
Agreement, some of which are outside of the control of the Company.
Upon the issuance of the full 3,000,000 shares of Series D Preferred Stock
to the Series D Preferred Stockholder, the Series D Preferred Stockholder will
own 100% of the Company's issued and outstanding Series D Preferred Stock and
approximately 30.0% of the issued and outstanding capital stock of the Company,
on a fully diluted basis.
In connection with the issuance of its Series D Preferred Stock to the
Series D Preferred Stockholder pursuant to the Preferred Stock Purchase
Agreement, the Company amended its Amended and Restated Articles of
Incorporation (the "Restated Articles") to, among other things, (a) authorize
5,750,000 shares of a new class of stock designated as Series D Convertible
Preferred Stock, (b) amend or revise certain of the terms and conditions of its
currently authorized and issued Series A Convertible Preferred Stock, Series B
Convertible Preferred Stock, and Series C Convertible Preferred Stock, (c)
increase the size of its Board of Directors from nineteen to twenty members, (d)
elect two of the Series D Preferred Stockholder's designees to the Company's
Board of Directors and Executive Committee, (e) modify the composition and
authority of the Company's Executive Committee, and (f) change the name of the
Company from "Doctors Health System, Inc." to "Doctors Health, Inc." The Company
also agreed to use its best efforts to change its state of incorporation from
Maryland to Delaware within sixty days of the closing of the initial purchase
transaction, subject to the approval of the Company's Board of Directors and
stockholders.
The Series D Preferred Stock issued to the Series D Preferred Stockholder
is senior to all other classes of the Company's capital stock with respect to
payment of dividends and distributions and liquidation rights. The Series D
Preferred Stock also is subject to redemption by the Company at the election of
the holder of the Series D Preferred Stock at $10.00 per share, plus accrued but
unpaid dividends, after five years from the issuance date of the Series D
Preferred Stock and is convertible at an adjustable rate into the Company's
Class C Common Stock at the option of the holder of the Series D Preferred Stock
and automatically upon a qualifying initial public offering of the Company. The
Series D Redeemable Convertible Preferred Stock accrues dividends quarterly at
the rate of eighty cents ($0.80) per share per annum beginning on July 15, 1997.
46
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 19--SUBSEQUENT EVENTS--CONTINUED
The number of shares of Class C Common Stock issuable upon conversion of
the Series D Preferred Stock is subject to adjustment pursuant to two stock
adjustment agreements between the Company and the Series D Preferred
Stockholder. The first stock adjustment agreement provides for an upward or
downward adjustment in the number of shares issuable to the Series D Preferred
Stockholder based upon the Medicare Medical Loss Ratio and the number of
Medicare enrollees in the Company's Medicare global risk service agreements with
health maintenance organizations and other payors. Pursuant to the first
agreement, the number of shares issuable to the Series D Preferred Stockholder
could be reduced to 2,727,272 shares of Class C Common Stock or increased to
5,454,545 shares of Class C Common Stock. The second stock adjustment agreement
provides that it will supersede the first stock adjustment agreement if the
105th U.S. Congress makes certain changes in the Medicare program to reduce
payments to health maintenance organizations and medical management companies
such as the Company. Pursuant to the second stock adjustment agreement, the
number of shares issuable to the Series D Preferred Stockholder could be reduced
to 2,727,272 shares of Class C Common Stock or increased to 7,500,000 shares of
Class C Common Stock.
On July 9, 1997, the Company entered into a Stock Purchase Agreement, as
amended on July 15, 1997 (the "Stock Purchase Agreement") by and among
UniversityCare, L.L.C. ("UniversityCare"), Genesis Health Ventures, Inc.
("Genesis"), and Med-Lantic Management Services, Inc. ("Med-Lantic"), and on
July 15, 1997 closed the transactions contemplated by the Stock Purchase
Agreement. Pursuant to the Stock Purchase Agreement and related transactions,
(i) Genesis, the holder of the Company's Series C Preferred Stock, assigned and
delegated to UniversityCare all of Genesis' rights and obligations under that
certain Purchase Agreement dated May 2, 1997, which provided for the purchase by
Genesis from Med-Lantic of all 355,556 shares of the Company's Series B
Preferred Stock held by Med-Lantic (the "Med-Lantic Shares"); (ii)
UniversityCare purchased from Med-Lantic the Med-Lantic Shares at a purchase
price of $11.25 per share; (iii) the Company issued and delivered to Med-Lantic
60,290 shares of the Company's Series B Preferred Stock, which constituted the
accrued and unpaid dividends, and interest, on the Med-Lantic Shares (the
"Dividend Shares") and the Company issued and delivered 22,222 shares of the
Company's Series B Preferred Stock to a private investment banker as
reimbursement for certain investment advisory services and related expenses (the
"Expense Shares"); and (iv) the Dividend Shares and the Expense Shares were
transferred to UniversityCare for a purchase price of $11.25 per share. As a
result of these transactions, UniversityCare is the holder of 438,068 shares of
the Company's Series B Preferred Stock, which constitute all of the issued and
outstanding shares of Series B Preferred Stock of the Company.
Also, in connection with the above agreement the conversion price on the
250,000 warrants issued to the Series C Preferred Stockholder on January 31,
1997 was changed from $14.00 per share to $10.00 per share. The Company recorded
an additional $165,000 related to the valuation of the warrants at $10.00 per
share. In addition, the conversion rate of the Series C Preferred Stock into
Class C Common Stock at the time of an initial public offering was adjusted from
an equal conversion to 1.25 shares of Class C Common for each share of Series C
Preferred Stock.
The following is a condensed pro forma balance sheet of the Company as if
all of the above transactions had taken place on June 30, 1997:
47
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--CONTINUED
NOTE 19--SUBSEQUENT EVENTS--CONTINUED
<TABLE>
<CAPTION>
PRO FORMA
JUNE 30, PRO FORMA JUNE 30,
1997 ADJUSTMENTS 1997
------------ ----------- ------------
<S> <C> <C> <C>
Cash and Cash Equivalents................................. $ 4,737,828 $18,913,000 $ 23,650,828
Other Current Assets...................................... 6,805,925 -- 6,805,925
Long-term Assets.......................................... 12,934,889 (552,500) 12,382,389
------------ ----------- ------------
Total Assets............................................ $ 24,478,642 $18,360,500 $ 42,839,142
------------ ----------- ------------
------------ ----------- ------------
Current Liabilities....................................... $ 16,616,631 $ -- $ 16,616,631
Long-term Liabilities..................................... 8,122,077 -- 8,122,077
Redeemable Convertible Preferred Stock.................... 19,282,113 18,195,500 37,477,613
Total Stockholders' Equity (Deficit)...................... (19,542,179) 165,000 (19,377,179)
------------ ----------- ------------
Total Liabilities and Stockholders' Deficit............. $ 24,478,642 $18,360,500 $ 42,839,142
------------ ----------- ------------
------------ ----------- ------------
</TABLE>
NOTE 20--NEW GLOBAL CAPITATION AGREEMENT
On September 10, 1997, the Company entered into a letter of agreement with
an HMO on a new global capitation contract for Medicare enrollees. Under the
agreement, to be effective October 1, 1997, the Company will assume
responsibility for managing all physician and institutional care, subject to
certain exclusions, delivered to approximately 11,000 enrollees in exchange for
a capitation fee. The term of the agreement is for three years with annual
renewals after the initial term has expired. The Company expects to realize
capitation revenue of approximately $4 million per month from this new
agreement.
48
<PAGE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
Effective on May 28, 1997, The Company dismissed its principal accountant,
Grant Thornton, LLP ("Grant Thornton"), and authorized the engagement of Arthur
Andersen, LLP as Doctors Health, Inc.'s principal accountant. Grant Thornton
acted as the Company's principal accountant on the financial statements as of
and for the period ended June 30, 1995 and the year ended June 30, 1996
(collectively, the "Financial Statements"). Such Financial Statements did not
contain an adverse opinion or a disclaimer of opinion and they were not
qualified or modified as to uncertainty, audit scope or accounting principles.
The decision to change accountants was recommended by the Finance and Audit
Committee of the Board of Directors on May 16, 1997 and approved by the Board of
Directors of Doctors Health, Inc. on May 28, 1997. During the two most recent
fiscal periods and all subsequent interim periods prior to the change in
principal accountant, there were no disagreements with Grant Thornton on any
matter of accounting principles or practices, financial statement disclosure or
auditing scope or procedure.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
The directors and executive officers of the Company are as follows:
<TABLE>
<CAPTION>
NAME AGE POSITION WITH THE COMPANY
- - - --------------------------------------- --- ------------------------------------------------------------------------------
<S> <C> <C>
Scott M. Rifkin, M.D................... 38 Chairman, Director, Executive Vice President of Corporate Development
Stewart B. Gold........................ 55 President and Chief Executive Officer and Director
John R. Dwyer, Jr...................... 41 Executive Vice President, Chief Financial Officer, Treasurer and Director
Alan L. Kimmel, M.D.................... 44 Executive Vice President for Medical Policy and Practice; Medical Director,
Director
Paul A. Serini......................... 38 Executive Vice President of Strategic Operations and Director of Legal
Affairs, Secretary and Director
Elizabeth A. Beale..................... 42 Vice President of Marketing and Physician Recruiting
James A. Gast.......................... 34 Vice President of Administration and Assistant Secretary
Tracey Goessel, M.D.................... 40 Vice President and Associate Medical Director
Elizabeth A. Hennessey................. 46 Vice President of Information Technology
Thomas F. Mapp......................... 40 Vice President and Corporate Counsel
Kyle R. Miller......................... 35 Vice President of Finance and Assistant Treasurer
John Mulholland, M.D................... 65 Vice President and Associate Medical Director
Theresa A. Spoleti..................... 38 Vice President of Managed Care Products and Services
Robert A. Barish, M.D.................. 44 Director
Richard L. Diamond, M.D................ 46 Director
Mark H. Eig, M.D....................... 46 Assistant Medical Director and Director
Albert Herrera, M.D.................... 38 Director
Robert G. Graw, Jr., M.D............... 56 Vice President of Physician Practice Operations and Director
Richard R. Howard...................... 47 Director
William D. Lamm, M.D................... 44 Assistant Medical Director and Director
Peter J. LoPresti, D.O................. 34 Director
Thomas G. Mendell...................... 50 Director
J. David Nagel, M.D.................... 56 Director
John S. Prout.......................... 47 Director
D. Alexander Rocha, M.D................ 41 Director
Eric R. Wilkinson...................... 41 Director
</TABLE>
The Directors hold office until the next annual meeting of stockholders.
Scott M. Rifkin, M.D. is the Chairman, Executive Vice President of
Corporate Development and a Director of the Company designated by the Class A
stockholders. Dr. Rifkin has been a Director of the Company since 1995. Dr.
Rifkin is a co-founder of Baltimore Medical Group, LLC and currently is the
President and a Management Committee member of Baltimore Medical Group, LLC.
Baltimore Medical Group, LLC was founded in February 1995. Dr. Rifkin has also
served as Medical Director of Fairfield Nursing Center since 1989 and as
Director of Pre-Admission Consultation Service at Union
49
<PAGE>
Memorial Hospital since 1990. Dr. Rifkin has been engaged in the private
practice of medicine since 1988. Dr. Rifkin is also an expert in long-term care
issues and has advised the State of Maryland on this subject.
Stewart B. Gold is the Chief Executive Officer, President and a Director of
the Company designated by the Class A stockholders. He has been a Director of
the Company since 1995. Prior to joining the Company in 1994, Mr. Gold was CEO
and President of Veritus Services Inc., an arm of Blue Cross of Western
Pennsylvania from 1992 to 1993, where he was responsible for the for-profit
ventures in managed care, utilization and information systems. From 1991 to
1992, Mr. Gold served as President and Chief Executive Officer of Health Care
Affiliated Services, Inc.
John R. Dwyer, Jr., is the Executive Vice President, Chief Financial
Officer, and Treasurer of the Company, and has been a Director of the Company
designated by the Class A stockholders since May 1996. Prior to joining the
Company in May 1996, he was a principal in the Washington based private
investment bank of Graham, Hamilton & Dwyer, Inc. Before joining Graham,
Hamilton & Dwyer, Inc. in October 1990, Mr. Dwyer was the President of
Dimetrics, Inc., a wholly-owned subsidiary of Talley Industries in California, a
position he held since August 1987. Before joining Dimetrics, Inc., Mr. Dwyer
was the President of Merrick East, Inc. from April 1985 to July 1987, an entity
subsequently acquired by Dimetrics. Before joining Merrick East, Inc., Mr. Dwyer
practiced law with Arent, Fox, Kinter, Plotkin and Kahn in Washington, D.C. from
September 1981 to March 1985.
Alan L. Kimmel, M.D. serves as the Executive Vice President for Medical
Policy and Practice, Medical Director, and has been a Director of the Company
designated by the Class A stockholders since 1995. Dr. Kimmel is a co-founder of
Baltimore Medical Group and the Company, is the Chairman of Baltimore Medical
Group and has had an active clinical practice of Internal Medicine in Baltimore
since 1982. Dr. Kimmel's professional memberships include American College of
Physicians, American Society of Internal Medicine, Baltimore City Medical
Society and the Southern Medical Association.
Paul A. Serini is the Company's Executive Vice President of Strategic
Operations and Director of Legal Affairs, a position he has held since February
1995, and has been a Director of the Company designated by the Class A
stockholders since May 1996. From 1990 to 1995, Mr. Serini was a partner in the
Baltimore and Washington offices of the law firm of Venable, Baetjer and Howard,
LLP, where he headed the business transaction group's Health Care Strategic
Business Unit.
Elizabeth A. Beale has been the Company's Vice President of Marketing and
Physician Recruiting since January of 1996. Prior to joining the Company in
1995, from 1991 to 1995 Ms. Beale was employed as the Vice President/Management
Director of HRS Maine, Inc., a joint venture company owned by Blue Cross of
Western Pennsylvania and Blue Cross/Blue Shield of Maine. HRS Maine provides
health care and workers' compensation cost management services for 200,000
employees.
James A. Gast serves as Vice President of Administration. Prior to joining
the Company in February 1996, Mr. Gast served as Corporate Counsel at The Bank
of Baltimore from September 1991 until the bank was acquired by First Fidelity
Bancorporation. From 1988 to 1991, Mr. Gast served as Corporate Counsel at Hale
Intermodal Transport Co., an international shipping company.
Tracey Goessel, M.D. serves as the Company's Vice President and Associate
Medical Director, a position she has held since March 1997. Prior to joining the
Company, Dr. Goessel was Medical Director and Vice President, Medical Affairs
for Health Cost Consultants from 1994 to 1997 and Vice President, Medical
Affairs for PHP HealthCare from 1996 to 1997. In 1993, Dr. Goessel served as
Acting Medical Director of Pacific Review Services. Prior to that, she was an
Assistant Professor in the Department of Surgery at the Johns Hopkins Hospital.
Elizabeth A. Hennessey is the Company's Vice President of Information
Technology, a position she has held since August 1996. Ms. Hennessey joined the
Company in July 1995 as Director, Information Systems. Prior to joining the
Company, Ms. Hennessey served as Director, Information Systems for University of
Maryland's faculty practice, University Physicians, Inc. since 1989.
Thomas F. Mapp serves as Vice President and Corporate Counsel of the
Company. Prior to joining the Company in 1995, he was in the private practice of
law. From 1986 to 1994, Mr. Mapp practiced with the law firm of Venable, Baetjer
and Howard, LLP.
Kyle R. Miller, the Company's Vice President of Finance, joined the Company
in August 1996. From 1984 until he joined the Company, Mr. Miller was employed
by Arthur Andersen, LLP, CPAs where he was a senior manager in the firm's health
care audit and business consulting division. Mr. Miller is a member of the
American Institute of Certified Public Accountants (AICPA).
50
<PAGE>
Theresa A. Spoleti is the Company's Vice President of Managed Care Products
and Services, a position she has held since January of 1996. Prior to joining
the Company in 1995, Ms. Spoleti was Director of Management Services
Organization, then Director of Physician Alliances, at Greater Baltimore Medical
Center, from 1992 to June of 1995. From 1987 to 1992, she was a principal in
Management Consulting at Health Care Systems Associates (HSA), Inc. in Potomac,
Maryland.
Robert A. Barish, M.D. has served as a Director of the Company since July
1997. Dr. Barish is currently the Chief Executive Officer of UniversityCare,
LLC, the Company's Series B Preferred stockholder. Dr. Barish previously served
as the Director of Emergency Medical Services at the University of Maryland
Medical Center and as a Professor of Surgery and Medicine at the University of
Maryland School of Medicine.
Richard L. Diamond, M.D. is a Director of the Company designated by the
Class B stockholders, a position he has held since June 1997. Dr. Diamond has
been a physician in the private practice of adult medicine since 1981. Dr.
Diamond also is a director and the treasurer of BMGGP, Inc., the general partner
of Medical Holdings Limited Partnership and has served on the Management
Committee and as Treasurer of Baltimore Medical Group, LLC.
Mark H. Eig, M.D. has served as Director of the Company designated by the
Class B stockholders and Assistant Medical Director since May 1996. Dr. Eig has
practiced internal medicine and critical care medicine in Silver Spring,
Maryland since 1980. Dr. Eig currently serves on the Board of Directors for the
Jewish Social Service Home Health Agency and as the Chairman for their
Utilization Review Committee and Professional Advisory Committee. Dr. Eig also
serves as the Chairman for Holy Cross Hospital Pharmacy and Therapeutics
Committee and Montgomery County Medical Society Emergency Medical Service
Committee.
Albert Herrera, M.D. has been a Director of the Company designated by the
Class B stockholders since August 1997. Dr. Herrera has been in the private
practice of medicine in Alexandria, Virginia since 1989. Dr. Herrera also serves
on the Board of Directors and on the Medical Advisory Committee of Doctors
Health of Virginia, Inc.
Robert G. Graw, Jr., M.D. is a Director of the Company designated by the
Class B stockholders, a position he has held since May 1996. He has been in the
private practice of General Pediatrics and Pediatric Hematology and Oncology
since 1975 in Davidsonville, Maryland. From 1965 through 1975, Dr. Graw held
several positions with the National Institute of Health, where he performed
clinical medical research with the National Cancer Institute in childhood
malignancy and bone marrow transplantation. Since April 1996, Dr. Graw has
served as the Company's Vice President of Medical Practice Operations. Dr. Graw
is currently President and Managing Partner of the Pediatric Group, President of
Nighttime Pediatrics, Inc. and Nighttime Pediatrics North, and past Chief of
Pediatrics at Anne Arundel Medical Center in Annapolis, Maryland.
Richard R. Howard has served as a Director designated by the Series C
Preferred stockholder of the Company since September 1996. He has served as a
director of Genesis Health Ventures, Inc. since May 1985 and as Chief Operating
Officer of Genesis Health Ventures, Inc. since June 1986. He joined Genesis
Health Ventures, Inc. in September 1985 as Vice President of Development. Mr.
Howard's background in health care includes two years as the Chief Financial
Officer of HGCC. Mr. Howard's experience also includes over ten years with
Fidelity Bank, Philadelphia, Pennsylvania and one year with Equibank,
Pittsburgh, Pennsylvania.
William D. Lamm, M.D. has served as a Director of the Company designated by
the Class B stockholders since May 1996 and has been in the private practice of
medicine since 1983. Dr. Lamm's professional memberships include The American
Medical Association, the American Academy of Family Practice and the Medical and
Chirurgical Faculty of Maryland. Dr. Lamm is President of the Medical Staff at
Memorial Hospital and is on the Board of Trustees with both Memorial Hospital
and Western Maryland Health System. Dr. Lamm has served as the Chairman of
Cumberland Valley Medical Group, LLC and Assistant Medical Director of the
Company since May 1996.
Peter J. LoPresti, D.O. has been a Director of the Company designated by
the Class B Stockholders since February 1995. Dr. LoPresti has been a physician
in private practice since 1992.
Thomas G. Mendell has been a Director of the Company designated by the
Series D Preferred Stockholders since July 1997. Mr. Mendell has been a Partner
of The Beacon Group, L.L.C. and serves as director of Catalina Marketing
Corporation (NYSE) and several private companies. From November 1986 to December
1993, Mr. Mendell was a Partner of Goldman Sachs & Co.
John Mulholland, M.D. has served as Vice President and Associate Medical
Director of the Company since July 1995. Prior to joining Doctors Health, Dr.
Mulholland served as President of the Union Memorial Hospital Foundation in
Baltimore from 1992 to 1994, and as Associate Medical Director of Blue Cross --
Blue Shield of Maryland from 1994 to 1995. From 1972 to 1992, Dr. Mulholland was
Chief of Medicine at Union Memorial Hospital.
51
<PAGE>
J. David Nagel, M.D. has served as a Director of the Company and as
Director of Legislative Affairs since February 1995. Dr. Nagel has been in the
private practice of medicine since 1968 and is a past president of the Medical
and Chirurgical Faculty of Maryland.
John S. Prout is a Director of the Company, a position he has held since
February 1995. Mr. Prout currently serves as President and Chief Executive
Officer of St. Joseph Medical Center, Inc., where he has served since July 1994.
From 1988 to 1993, Mr. Prout was Executive Vice President, Little Company of
Mary Hospital and Health Care Centers in Evergreen Park, Illinois.
D. Alexander Rocha, M.D. has served as a Director of the Company since May
1996 and is currently the President of North Carroll Family Physicians, where he
has served since November 1989. Dr. Rocha has been Chairman of Carroll Medical
Group, LLC since December 1995.
Eric R. Wilkinson has been a Director of the Company designated by the
Series D Preferred Stockholders since July 1997. In addition, since December
1995, Mr. Wilkinson has been a Partner of The Beacon Group, L.L.C. From March
1994 to December 1995, Mr. Wilkinson served as a Principal of The Beacon Group,
L.L.C. From March 1989 to March 1994, Mr. Wilkinson served as a Partner and a
director of Apax Partners, a $300 million private equity fund.
All of the Company's directors serve until the next annual meeting of the
company.
COMMITTEES OF THE BOARD OF DIRECTORS
The Finance and Audit Committee has responsibility for reviewing and
supervising the financial controls of the Company. The Finance and Audit
Committee makes recommendations to the Board of Directors of the Company with
respect to the Company's financial statements and the appointment of independent
auditors, review significant audit and accounting policies and practices, meets
with the Company's independent public accountants concerning the scope of audits
and reports and reviews the performance of overall accounting and financial
controls of the Company. The Finance and Audit Committee consists of John Ellis,
Chairman, Stewart B. Gold, Scott Rifkin, John R. Dwyer, Jr., Paul A. Serini, and
Robert Graw. During fiscal year 1997, there were six meetings of the Finance and
Audit Committee.
The Employee Compensation Committee has the responsibility for reviewing
the performance of the executive officers of the Company and recommending to the
Board of Directors of the Company annual salary and bonus amounts for all
officers of the Company. The Employee Compensation Committee also administers
the Company's Omnibus Stock Plan. The Employee Compensation Committee consists
of Stewart B. Gold, Scott Rifkin, Alan Kimmel, Mark Eig, and John Ellis. During
fiscal year 1997, there were five meetings of the Employee Compensation
Committee.
To the extent permitted by law, the authority of the Board to act on all
matters is vested in and exercised by the Executive Committee. The Executive
Committee consists of Stewart B. Gold, Scott Rifkin, Alan Kimmel, Richard
Howard, Thomas Mendell and Eric R. Wilkinson. During fiscal year 1997, there
were four meetings of the Executive Committee and one written consent of the
committee in lieu of meeting.
52
<PAGE>
ITEM 11. EXECUTIVE COMPENSATION
COMPENSATION SUMMARY.
The following table sets forth certain information regarding the
compensation of the Company's Chief Executive Officer and each of the other four
most highly compensated executive officers during the three fiscal years ended
June 30, 1997 (the "Named Executive Officers"):
SUMMARY COMPENSATION TABLE (1)(2)
<TABLE>
<CAPTION>
SECURITIES
UNDERLYING ALL OTHER
NAME YEAR SALARY($)(3) OPTIONS # COMPENSATION(4)
- - - --------------------------------------------------------------------------- ---- ------------ ---------- ---------------
<S> <C> <C> <C> <C>
Stewart B. Gold, Chief Executive Officer................................... 1996 253,848 0 9,442
1997 300,777 0 12,407
Scott M. Rifkin, M.D., Chairman and
Executive Vice President................................................. 1996 126,923 100,000 9,211
1997 225,577 30,000 12,407
John R. Dwyer, Jr., Chief Financial Officer and
Executive Vice President................................................. 1996 32,250 70,000 772
1997 195,750 30,000 12,407
Paul A. Serini, Executive Vice President................................... 1996 203,010 50,080 41,529(5)
1997 175,673 30,000 11,907
Alan Kimmel, M.D., Medical Director and
Executive Vice President................................................. 1996 75,962 0 5,399
1997 160,385 30,000 6,887
</TABLE>
- - - ---------------
(1) In accordance with SEC rules, perquisites constituting less than the lesser
of $50,000 or 10% of the total salary and bonuses are not reported.
(2) See "Option Grants," "Option Exercises and Year-End Values" and "Omnibus
Stock Option Plan" for disclosure regarding outstanding stock options.
(3) Includes payments made in fiscal year 1998 with respect to services
performed by Mr. Gold and Drs. Rifkin and Kimmel through June 30, 1997 in the
amounts of $75,000, $75,000 and $60,000, respectively.
(4) Includes matching contributions under the Company's 401(k) Plan and
reimbursement for health, life and long-term disability insurance.
(5) Includes $37,500 paid in lieu of salary.
OPTION GRANTS.
Options granted to the Named Executive Officers during the fiscal year
ended June 30, 1997 are set forth in the following table. For disclosure
regarding the terms of stock options, see "Stock Option Plans." No stock
appreciation rights ("SARs") were granted during the fiscal year ended June 30,
1997.
<TABLE>
<CAPTION>
POTENTIAL
REALIZABLE
VALUE AT
ASSUMED
ANNUAL
RATES OF
STOCK
PRICE
APPRECIATION
FOR
OPTION
% OF TOTAL TERM
# SECURITIES OPTIONS GRANTED EXERCISE OR BASE (2)(3)
UNDERLYING TO ALL EMPLOYEES PRICE PER SHARE --------
NAME OPTIONS GRANTED(1) IN FISCAL YEAR ($/SH) EXPIRATION DATE 5%
- - - ----------------------------- ------------------ ------------------- ---------------- --------------- --------
<S> <C> <C> <C> <C> <C>
Stewart B. Gold.............. -- 10.6% $.01 11/6/06 $341,768
Scott M. Rifkin, M. D........ 30,000 10.6% $.01 11/6/06 $341,768
John R. Dwyer, Jr............ 30,000 10.6% $.01 11/6/06 $341,768
Paul A. Serini............... 30,000 10.6% $.01 11/6/06 $341,768
Alan Kimmel, M. D............ 30,000 10.6% $.01 11/6/06 $341,768
<CAPTION>
NAME 10%
- - - ----------------------------- --------
<S> <C>
Stewart B. Gold.............. $544,386
Scott M. Rifkin, M. D........ $544,386
John R. Dwyer, Jr............ $544,386
Paul A. Serini............... $544,386
Alan Kimmel, M. D............ $544,386
</TABLE>
- - - ---------------
(1) These options vest at a rate of 20% per year over a five year period.
(2) Unless otherwise noted, these options vest on the fifth anniversary of the
grant date, but the vesting may be accelerated at the rate of 20% per year in
the event the Named Executive Officer satisfies certain performance criteria
during the Company's fiscal year.
(3) The potential realizable value is calculated based on the term of the option
at its time of grant (10 years). It is calculated by assuming that the stock
price on the date of grant appreciates at the indicated annual rate compounded
annually for the entire term of the option and that the option is exercised and
sold on the last day of the term for the appreciated stock price.
53
<PAGE>
OPTION EXERCISES AND FISCAL YEAR-END VALUES.
No stock options were exercised by the Named Executive Officers during the
fiscal year ended June 30, 1997. There were no stock appreciation rights
outstanding during the fiscal year ended June 30, 1997. The following table sets
forth certain information regarding unexercised options held by each of the
Named Executive Officers as of June 30, 1997:
<TABLE>
<CAPTION>
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-
OPTIONS AT FY-END MONEY OPTIONS AT JUNE 30,
(JUNE 30, 1997) 1997 ($)(1)
NAME EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE
- - - -------------------------------------------------------------------- ------------------------- -------------------------
<S> <C> <C> <C> <C>
Stewart B. Gold..................................................... 0 0 N/A N/A
Scott M. Rifkin, M.D................................................ 0 130,000 0 $699,975
John R. Dwyer, Jr................................................... 22,000 86,000 0 $209,000
Paul A. Serini, Executive Vice President............................ 50,080 30,000 $350,059 $209,700
Alan Kimmel, M.D.................................................... 0 30,000 N/A N/A
</TABLE>
- - - ---------------
(1) The value is calculated on the basis of the difference between (i) the
option exercise price and (ii) the estimated value of the common stock at June
30, 1997 as determined by the Board of Directors of the Company, multiplied by
the numbers of shares of common stock underlying the option.
EMPLOYMENT AGREEMENTS
The Company has entered into employment agreements with Mr. Gold, Mr.
Dwyer, Dr. Rifkin, Mr. Serini and Dr. Kimmel.
Pursuant to the employment agreement with Mr. Gold, Mr. Gold's base salary
is $280,000 per annum and he is eligible to receive an annual bonus based on
performance as determined by the Employee Compensation Committee of the Board of
Directors. During fiscal year 1997, Mr. Gold earned $100,000 in deferred
compensation for services performed for the Company from November 1994 to June
30, 1997 and in consideration of his agreement to remove certain bonus pool
provisions from his employment agreement. Mr. Gold received 600,000 shares of
Class A Common Stock, in which Mr. Gold is fully vested. The employment
agreement with Mr. Gold terminates in April of 2000, and unless notice of
termination is given will be automatically extended for succeeding 12-month
periods. In the event that Mr. Gold is terminated by the Company other than for
"cause," he will be entitled to 50% of his base salary which would have been due
through the remainder of the term at the time such payments would otherwise be
made in accordance with the terms of his employment agreement.
Pursuant to the employment agreement with Dr. Rifkin, Dr. Rifkin receives a
base salary of $187,500 per year representing 75% of his working time. Pursuant
to the employment agreement, Dr. Rifkin was granted an option to purchase an
additional 100,000 shares of the Company's Class A Common Stock that will be
exercisable upon the earlier to occur of (i) a change in control of the Company,
(ii) termination of his employment without cause or under circumstances
constituting "constructive termination", or (iii) December 9, 1997. The options
became vested and nonforfeitable on December 9, 1996. The employment agreement
with Dr. Rifkin terminates in April 2000 and, unless notice of termination is
given, it will be automatically extended for succeeding 12-month periods on the
same terms as previously in effect. In the event that Dr. Rifkin's employment is
terminated by the Company other than "for cause," he will be entitled to all or
a portion of his base salary and bonus in accordance with the terms of his
employment agreement. In the event Dr. Rifkin is unable to perform in his duties
under the employment agreement for three consecutive months or periods
aggregating three months in a 12-month period, the Company is required to pay
Dr. Rifkin his base salary until one year after the end of the term of the
Employment Agreement. The Company may either terminate the Employment Agreement
or continue his employment following a disability, but is nevertheless required
to continue the payment of his base salary.
Pursuant to the employment agreement with Mr. Dwyer, Mr. Dwyer receives a
base salary of $195,000 per annum. Pursuant to a stock option agreement issued
in connection with his employment, Mr. Dwyer received an option to purchase
70,000 shares of Class A Common Stock. The employment agreement with Mr. Dwyer
terminates in April 2000 and, unless notice of termination is given by either
party it will be automatically extended for succeeding 12-month periods. In the
event that Mr. Dwyer is terminated by the Company other than for "cause" he will
be entitled to all or a portion of his base salary and bonus in accordance with
the terms of his employment agreement.
Pursuant to the employment agreement with Mr. Serini, Mr. Serini receives a
base salary of $175,000 per annum. Mr. Serini will be entitled to participate in
the Bonus Pool to the extent determined by the Chief Executive Officer, and the
standards by which such bonus will be determined for each applicable year will
be established upon agreement between Mr. Serini and the Chief Executive
Officer. Pursuant to the employment agreement, Mr. Serini received options to
purchase 50,080 shares of Class A Common Stock which are currently exercisable.
Certain of the shares issuable upon the exercise of
54
<PAGE>
the options are restricted. The employment agreement with Mr. Serini terminates
in April of 2000 and, unless notice of termination is given by either party it
will be automatically extended for succeeding 12-month periods. In the event
that Mr. Serini is terminated by the Company other than for "cause," he will be
entitled to all or a portion of his base salary and bonus in accordance with the
terms of his employment agreement.
Pursuant to the employment agreement with Dr. Kimmel, Dr. Kimmel receives a
base salary of $150,000 representing 50% of his working time. The employment
agreement with Dr. Kimmel terminates in April 2000 and, unless notice of
termination is given, it will be automatically extended for succeeding 12-month
periods on the same terms as previously in effect. In the event that Dr.
Kimmel's employment is terminated by the Company other than "for cause," he will
be entitled to 50% of his base salary which would have been due through the
remainder of the term at the time such payments would otherwise be made, in
accordance with the terms of his employment agreement.
EMPLOYEE COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION.
Mr. Gold, the Company's President and Chief Executive Officer, and Dr.
Rifkin, the Company's Chairman, and Dr. Kimmel are the only officers or
employees of the Company who serve on the Employee Compensation Committee.
During fiscal year 1997, the members of the Employee Compensation Committee were
Messrs. Gold and Ellis, Ms. Linda Dembiec and Drs. Rifkin and Eig. Ms. Dembiec
resigned from the Board of Directors and from the Employee Compensation
Committee in November 1996. No director was named as her replacement.
KEY MAN LIFE INSURANCE.
The Company maintains key man life insurance on Mr. Gold, and Drs. Rifkin
and Kimmel in the face amounts of $6,000,000, $3,000,000 and $3,000,000,
respectively. The Company maintains disability insurance on Messrs. Gold and
Kimmel in the face amounts of $6,000,000 and $1,000,000 respectively.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The following tables set forth as of September 22, 1997, certain
information with respect to the beneficial ownership of each class of voting
stock by: (i) each person known to the Company to beneficially own more than 5%
of each such class; (ii) each director of the Company of each such class; (iii)
each of the Named Executive Officers of each such class; and (iv) all directors
and executive officers of each such class as a group. The Company believes that
the beneficial owners of the classes of stock listed below, based on information
furnished by such owners, have sole voting and investment power with respect to
such shares, except as noted below. Beneficial ownership is determined in
accordance with the rules of the Securities and Exchange Commission and includes
voting or investment power with respect to the shares. Shares of stock subject
to options currently exercisable or exercisable within 60 days of September 22,
1997 ("Current Options") are deemed outstanding for computing the percentage of
the person holding such option, but are not deemed outstanding for computing the
percentage of any other person.
CLASS A COMMON STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - -------------------------------------------------------------------------------------------------- ------- ----------------
<S> <C> <C>
Stewart B. Gold................................................................................... 600,000 74.1
Scott M. Rifkin, M. D............................................................................. 100,000 12.3
John R. Dwyer, Jr................................................................................. 22,000(1) 2.6
Paul A. Serini.................................................................................... 50,080(1) 5.8
Alan L. Kimmel, M.D............................................................................... 100,000 12.3
Directors and Executive Officers as a group (25).................................................. 912,080(2) 100.0
</TABLE>
- - - ---------------
(1) Consists of shares in respect of Current Options.
(2) Includes 94,080 shares in respect of Current Options and warrants to
purchase 8,000 shares.
55
<PAGE>
CLASS B COMMON STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - ------------------------------------------------------------------------------------------------ --------- ----------------
<S> <C> <C>
Medical Holdings Limited Partnership............................................................ 2,200,000(1) 83.2%
Directors and executive officers as a group (25)................................................ 34,000(2) 1.3%
</TABLE>
- - - ---------------
(1) Drs. Rifkin, Kimmel, Nagel, LoPresti, Diamond, and Ancona are Directors of
the Company and are officers or directors of the managing general partner of
Medical Holdings Limited Partnership
(2) Represents 16,000 shares and 18,000 shares in respect of Current Options
held by Dr. Eig.
SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - ------------------------------------------------------------------------------------------------ --------- ----------------
<S> <C> <C>
St. Joseph Medical Center (1)................................................................... 1,000,000(2) 100%
Directors and Executive Officers as a Group (25)................................................ 0 0
</TABLE>
- - - ---------------
(1) St. Joseph's Medical Center, Inc. is entitled to designate one Director of
the Company.
(2) Convertible into 1,000,000 shares of Class C Common Stock, which, assuming
conversion of all currently outstanding Preferred Stock, will equal
approximately 25% of the maximum outstanding Class C Common Stock.
SERIES B REDEEMABLE CONVERTIBLE PREFERRED STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - -------------------------------------------------------------------------------------------------- ------- ----------------
<S> <C> <C>
University Care, LLC (1).......................................................................... 438,068(2) 100%
Directors and Executive Officers as a Group (25).................................................. 0 0
</TABLE>
- - - ---------------
(1) Mr. Barish, Director of the Company, is President of University Care, LLC.
(2) Convertible into 438,068 shares of Class C Common Stock, which, assuming
conversion of all currently outstanding Preferred Stock, will equal
approximately 11% of the maximum outstanding Class C Common Stock.
SERIES C REDEEMABLE CONVERTIBLE PREFERRED STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - -------------------------------------------------------------------------------------------------- ------- ----------------
<S> <C> <C>
Genesis Health Ventures, Inc. (1)................................................................. 571,428(2) 100%
Directors and Executive Officers as a group (25) 0 0
</TABLE>
- - - ---------------
(1) Mr. Richard Howard, a Director of the Company, is President and Chief
Executive Officer of Genesis Health Ventures, Inc.
(2) Convertible into 571,428 shares of Class C Common Stock, which assuming
conversion of all currently outstanding Preferred Stock, will equal
approximately 14.3% of the maximum outstanding Class C Common Stock.
SERIES D REDEEMABLE CONVERTIBLE PREFERRED STOCK
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - ------------------------------------------------------------------------------------------------ --------- ----------------
<S> <C> <C>
Beacon Group III Focus Value Fund, L.P. (1)..................................................... 2,000,000 100%
Directors and Officers as a Group (25).......................................................... 0 0
</TABLE>
- - - ---------------
(1) Messrs. Mendell and Wilkinson, Directors of the Company, are partners of The
Beacon Group and affiliates of the Beacon Group III--Focus Value Fund, L.P.
(2) Convertible into 2,000,000 shares of Class C Common Stock, subject to
adjustment as described in Management's Discussion and Analysis of Financial
Condition and Results of Operations--Subsequent Events, which, assuming
conversion of all currently outstanding Preferred Stock, will equal
approximately 50% of the maximum outstanding Class C Common Stock.
The following tables set forth certain information with respect to the
ownership of the Company by physician stockholders in relation to other
stockholders. The information presented assumes conversion of the Series A
Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C
Convertible Preferred Stock and Series D Convertible Preferred Stock to Class C
Common Stock.
56
<PAGE>
STOCKHOLDERS OF DOCTORS HEALTH, INC.
CLASS A STOCKHOLDERS
<TABLE>
<CAPTION>
PERCENTAGE OF
NAME SHARES OWNERSHIP
- - - --------------------------------------------------------------------------------------------------- --------- -------------
<S> <C> <C>
Stewart B. Gold.................................................................................... 600,000 8.1
Alan Kimmel, M.D................................................................................... 100,000 1.3
Scott Rifkin, M.D.................................................................................. 100,000 1.3
Noah Investments, LLC.............................................................................. 10,000 .1
Total.............................................................................................. 810,000 10.8
CLASS B STOCKHOLDERS
Medical Holdings Limited Partnership............................................................... 2,200,000 29.4
Other Primary Care Physicians...................................................................... 464,010 6.2
Total.............................................................................................. 2,664,010 35.6
CLASS C STOCKHOLDERS
St. Joseph Medical Center, Inc..................................................................... 1,000,000 13.4
University Care, LLC............................................................................... 438,068 5.9
Genesis Health Ventures, Inc....................................................................... 571,428 7.6
Beacon Group III Focus Value Fund, L.P............................................................. 2,000,000 26.7
Total.............................................................................................. 4,009,496 53.6
Total Class A, B and C Stockholders.............................................................. 7,483,506 100.0
</TABLE>
PHYSICIAN AND NON-PHYSICIAN OWNERSHIP OF
DOCTORS HEALTH SYSTEM, INC.
<TABLE>
<CAPTION>
NAME NUMBER PERCENT OF CLASS
- - - ------------------------------------------------------------------------------------------------ --------- ----------------
<S> <C> <C>
Physicians (Class A and Class B Stockholders)................................................... 2,864,010 38.2%
Other Class A Stockholders...................................................................... 610,000 8.2%
Investor Stockholders (St. Joseph Medical Center, Inc., University Care, LLC, Genesis Health
Ventures, Inc. The Beacon Group III--Focus Value Fund, L.P.).................................... 4,009,496 53.6%
Total........................................................................................... 7,483,506 100.0%
</TABLE>
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
Effective July 1, 1997, the Company entered into a Hospital Agreement with
University of Maryland Medical System, Inc. ("UMMS") which provides that the
Company and UMMS will engage in a variety of cooperative transactions to deliver
quality medical care to enrollees who require certain hospital services. In
addition, the Company has entered into managed care contracting agreements with
University Care, LLC and University Physicians, Inc., which are affiliates of
UMMS, pursuant to which these entities have agreed to exclusively participate in
the Company's Medicare managed care contracts. These agreements have a term of
10 years.
On July 15, 1997, the "Management Stockholders" (consisting of Mr. Gold and
Drs. Rifkin and Kimmel), Medical Holdings Limited Partnership ("MHLP"), St.
Joseph Medical Center ("SJMC"), University Care, LLC ("UCare"), Genesis Health
Ventures, Inc. ("Genesis") and The Beacon Group III-Focus Value Fund, L.P.
("Beacon") executed a Shareholders Agreement and Voting Trust (the "Shareholders
Agreement"). The Shareholders Agreement includes certain provisions regarding
corporate governance, restrictions on transfer of Common Stock or securities
convertible into Common Stock, and Beacon's right to require cooperation with
respect to certain transfers of the Company's securities. In general, the
Shareholder's Agreement terminates upon the completion of an underwritten public
offering with at least $35,000,000 of net proceeds with a Company value of
$150,000,000. See "Managements Discussion and Analysis of Financial Condition
and Results of Operations--Subsequent Events."
The Shareholders Agreement provides that the Executive Committee of the
Board shall be delegated all matters of corporate operations that may be
delegated under Maryland law, that Beacon shall have the right to designate two
members
57
<PAGE>
of the Board and that the Executive Committee shall have seven members, of which
two Executive Committee members shall be designated by Beacon.
The Shareholders Agreement also provides that no signatory may transfer any
Common Stock without first providing a right of first refusal to Management
Stockholders or holder of 5% or more of the Common Stock of the Company. In
addition, the Shareholders Agreement requires that Beacon may at any time after
July 15, 1999, require the other stockholders to participate in a transaction
involving the transfer of the shares of Series D Preferred Stock to an
unaffiliated third party.
The Company has agreed that it would consult with Medical Mutual Liability
Insurance Society of Maryland, an affiliate of the Company's former Series B
Preferred Stockholder ("Med Mutual") and follow Med Mutual's recommendation
regarding the provision of medical malpractice coverage to certain PCP's. Such
decisions include, but are not limited to, the selection of the underwriter, the
form of the insurance policy and the premium payment provisions. Med Mutual has
agreed to provide medical malpractice coverage to the Company for a premium
consistent with its rates as approved by the Maryland Insurance Administration.
In addition, Med Mutual will consider alternative insurance programs to meet the
Company's special needs and will request the necessary approvals for such
alternative programs from the Maryland Insurance Administration. This agreement
terminates upon the earlier of a change in control of the Company or termination
of the loan guarantee provided by Med Mutual. If the Company breaches this
agreement, the Company may be required to pay Med Mutual $400,000.
Pursuant to a Stock Purchase Agreement dated September 4, 1996 (the "Stock
Purchase Agreement"), the Company agreed that it would (i) advise Genesis, of
all substantive discussions and plans with respect to the delivery of long term
care, pharmacy services, durable medical equipment and home health care services
(the "Services") for the Company, (ii) provide Genesis with all information
needed by Genesis to submit a proposal to provide the Services and (iii) provide
Genesis with an opportunity to provide the Services on commercially reasonable
terms. In addition, the Company has agreed that it will not enter into exclusive
arrangements with third parties that would preclude Genesis from competing to
provide Services to the Company. Genesis and the Company have agreed that
commitments regarding the Services shall not prevent the Company from purchasing
the Services from third parties other than Genesis. The Company is engaged in
negotiations with Genesis pursuant to which the Company expects to manage a
network of PCPs which delivers care to approximately 7,000 capitated Medicare
lives in the State of Maryland.
The Company has entered into acquisition transactions with certain of its
directors who are physicians. These transactions were entered into on
commercially reasonable terms, substantially similar to the terms of its
acquisition transactions with other PCPs, and the consideration paid in
connection with such acquisitions was based on the fair market value of the
medical practice assets or services acquired.
In September, 1996, the Company purchased certain assets of the medical
practice of Dr. Eig, a director of the Company. Dr. Eig was elected to the Board
of Directors in May 1996 and as Chairman of Doctors Health Montgomery in
September 1996. Dr. Eig received 16,000 shares of Class B Common Stock and 1,000
options to acquire Class B Common Stock, valued at $7.00 per share, cash in the
amount of $5,000 and a promissory note with a face value of approximately
$38,000 as consideration for the acquisition.
In December 1996, the Company purchased certain assets of the medical
practice of Dr. Graw, a director of the Company since May 1996. In connection
with the acquisition, Dr. Graw's limited liability partnership, which he owns
with other physicians, received a limited partnership interest in MHLP
equivalent to up to 74,000 shares of Class B Common Stock, an option to acquire
a limited partnership interest equivalent to 20,000 shares of Class B Common
Stock, exercisable at $15.00 per share, and cash for the practice's collectable
accounts receivable, which will not exceed $625,000. The Company estimates that
the collected accounts receivable will be approximately $425,000 and that $
200,000 will constitute a loan payable to the Company upon repayment terms and
conditions to be determined. The Company has delegated to Dr. Graw's practice,
and the practice will perform, certain practice management business functions,
which the Company ordinarily performs for its physicians at its headquarters.
The Company reimburses Dr. Graw's practice for the expenses it incurs in
performing the business management services.
In January, 1997, the Company entered into an Agreement and Plan of Merger
with Medicap, Inc. ("Medicap"), Medicap Newco, Inc., ("Newco") and Noah
Investments, LLC ("Noah"), pursuant to which Medicap was merged with and into
Newco, a wholly-owned subsidiary of the Company. Medicap was engaged in the
business of seeking business opportunities to place Medicare patients in nursing
homes and similar long term care facilities in Global Capitation Contracts. Noah
was the sole stockholder of Medicap, and the owners of Noah are Alan Rifkin and
certain other persons. Alan Rifkin is the brother of Scott Rifkin, M.D., the
Chairman, an executive officer, and a stockholder of the Company. Pursuant to
the Merger
58
<PAGE>
Agreement, Noah received 10,000 shares of the Company's Class A Common Stock and
the separate existence of Medicap ceased. In connection with the merger, the
Company also entered into a Consulting Agreement with Alan Rifkin pursuant to
which Mr. Rifkin will advise the Company with respect to the development of
business opportunities for the management of global capitation of Medicare
patients in nursing homes or similar long term facilities and introduce the
Company to potential sources of equity financing and joint venture partners.
Pursuant to the Consulting Agreement, Alan Rifkin received an option to purchase
10,000 shares of the Company's Class A Common Stock under the Company's Omnibus
Plan. Alan Rifkin is a Vice President of Newco.
In the ordinary course of business during fiscal year 1997, the Company
advanced funds on behalf of certain Core Medical Groups to certain physician
medical practices. The Company and the Core Medical Groups anticipate that such
advances will be repaid in future periods, although such repayment schedules
have not been determined. As of June 30, 1997, the Company had advanced the
following amounts to the medical practices of certain directors of the Company:
Dr. LoPresti, $223,000, Dr. Lamm, $146,000, Dr. Rocha, $53,000 and Dr. Graw,
$200,000
59
<PAGE>
PART IV
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K.
(a) Documents filed as part of this Report:
(1) Financial Statements:
Report of Independent Public Accountants
Consolidated Balance Sheets, as of June 30, 1996 and 1997
Consolidated Statements of Operations for the Period From February
24, 1995 to June 30, 1995 and the Years Ending June 30, 1996 and
1997
Consolidated Statements of Stockholders' Equity (Deficit) for the
Period from February 24, 1995 to June 30, 1995 and Years Ending
June 30, 1996 and 1997
Consolidated Statements of Cash Flows for the Period from February
24, 1995 to June 30, 1995 and the Years Ending June 30, 1996 and
1997
(2) Financial Statement Schedules:
(3) Exhibits:
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION OF DOCUMENTS
- - - ------------ ------------------------------------------------------------------------------------------------------------------
<C> <S>
3.1 Articles of Amendment and Restatement dated July 15, 1997. (incorporated by reference to Exhibit 3.1 filed with
the Company's Current Report on Form 8-K filed on July 21, 1997).
10.4 Registration Rights Agreement dated February 24, 1995 by and between Registrant and St. Joseph Medical Center,
Inc. and amendment thereto date December 1, 1995.*
10.5 Baltimore Medical Group, LLC Operating Agreement dated February 24, 1995.*
10.6 Agreement of Limited Partnership of Medical Holdings Limited Partnership*
10.8 Financing Transaction Agreement.*
10.9 Form of Exclusive Physician Participation Agreement.*
10.11 Amended and restated Physician Services Organization Agreement of Baltimore Medical Group, LLC.*
10.13 Form of Employment Agreement (Physician).*
10.14 Form of Specialist Physician Employment Agreement.*
10.17 Major Decision Agreement dated December 1, 1995 by and between the Registrant and Medical Mutual Liability
Insurance Society of Maryland.*
10.18 Promissory Note dated as of December 1, 1995 by and between the Registrant and Medical Mutual Liability Insurance
Society of Maryland.*
10.19 Non-negotiable, non-transferable Promissory Note dated February 24, 1995 by and between the Registrant and St.
Joseph Medical Center, Inc.*
10.20 Loan Agreement dated as of December 1, 1995 by and between the Registrant and NationsBank, N.A.*
10.24 Employment Agreement dated as of April 1, 1995 by and between the Registrant and Paul A. Serini and amendment
thereto dated January 1, 1996.*
10.27 Form of Employment Agreement.*
10.28 Form of Practice Transfer Agreement.*
10.30 Free State Health Plan, Inc., IPA Service Agreement (subject to confidentiality request for certain portions of
the exhibit.)*
10.31 Binding Letter of Intent with Health Care Corporation of the Mid-Atlantic for Medicare Risk Service Agreement
(subject to confidentiality request for certain portions of the exhibit).*
10.32 Binding Letter of Intent with Chesapeake Health Plan for Medicare Risk Service Agreement (subject to
confidentiality request for certain portions of the exhibit).*
10.33 Memorandum of Understanding with NYLCare of the Mid-Atlantic dated September 10, 1997 (filed herewith) (subject to
confidentiality request for certain portions of the exhibit).**
10.34 Amended and Restated Physician Services Organization Agreement of Carroll Medical Group, LLC.*
</TABLE>
60
<PAGE>
<TABLE>
<C> <S>
10.35 Amended and Restated Physician Services Organization Agreement with Cumberland Valley Medical Group, LLC.*
10.36 Physician Services Organization Agreement with Doctors Health Montgomery, LLC.*
10.37 Stock Purchase Agreement between the Registrant and Genesis Health Ventures, Inc. dated September 4, 1996, as
amended.*
10.38 Registration Rights Agreement between the Registrant and Genesis Health Ventures, Inc., dated September 4, 1996.*
10.40 IPA Percentage of Premium Service Agreement with Chesapeake Health Plan, dated as of June 1, 1996 (subject to
confidentiality request for certain portions of the exhibit).*
10.43 Employment Agreement dated as of May 1, 1996 between the Registrant and John R. Dwyer, Jr.*
10.44 Primary Care Limited Participation Agreement.*
10.45 Medicare HMO--Primary Care Limited Participation Agreement.*
10.46 Preferred Stock Purchase Agreement dated July 7, 1997 by and between the Registrant and The Beacon Group
III--Focus Value Fund, L.P. (incorporated by reference to Exhibit 10.1 filed with the Company's Current Report on
Form 8-K filed on July 21, 1997).
10.47 Amendment to Stock Purchase Agreement, dated as of July 15, 1997, by and between the Registrant and The Beacon
Group III--Focus Value Fund, L.P. (incorporated by reference to Exhibit 10.2 filed with the Company's Current
Report on Form 8-K filed on July 21, 1997).
10.48 Amended and Restated Stock Purchase Agreement dated July 9, 1997, as amended July 15, 1997, by and among the
Registrant, UniversityCare L.L.C., Genesis Health Ventures, Inc., and MedLantic Management Services, Inc.
(incorporated by reference to Exhibit 10.3 filed with the Company's Current Report on Form 8-K filed on July 21,
1997).
10.49 Shareholders' and Voting Agreement, dated July 15, 1997, by and among the Registrant, The Beacon
Group III--Focus Value Fund and other shareholder signatories. (incorporated by reference to Exhibit 10.4 filed
with the Company's Current Report on Form 8-K filed on July 21, 1997).
10.50 Amended and Restated Employment Agreement with Scott Rifkin dated July 15, 1997 (filed herewith)
10.51 Amended and Restated Employment Agreement with Alan Kimmel dated July 15, 1997 (filed herewith)
10.52 Amended and Restated Employment Agreement with Stewart B. Gold dated July 15, 1997 (filed herewith)
10.53 Registration Rights Agreement with the Beacon Group III Focus Value Fund, L.P. dated July 15, 1997 (filed herewith)
10.54 Employment Agreement with Paul Serini dated April 1, 1995 as amended on January 1, 1996 (incorporated by reference
to Exhibit 10.24 filed with the Registrant's Registration Statement on Form S-1 Registration Number 333-1926)
11 Computation of Earnings Per Common and Common Equivalent Share (filed herewith)
21 Subsidiaries of the Registrant (filed herewith)
23.1 Consent of Grant Thornton, LLP (filed herewith)
23.2 Consent of Arthur Andersen, LLP (filed herewith)
27 Financial Data Schedule. (filed herewith)
</TABLE>
- - - ---------------
*Incorporated by reference to the exhibits to the Registrant's Registration
Statement on Form S-1, Registration Number 333-1926, at the exhibit number
set forth opposite such exhibit's description above.
**Registrant has requested confidential treatment from the Securities and
Exchange Commission for portions of this exhibit, which confidential portions
have been filed separately.
(b) Reports on Form 8-K. The Registrant filed the following current Reports on
Form 8-K during the quarter ended June 30, 1997 and through September 22,
1997:
<TABLE>
<CAPTION>
DATE OF REPORT ITEMS REPORTED
- - - ----------------------------- --------------
<S> <C>
June 2, 1997 4
July 21, 1997 5
</TABLE>
61
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
DOCTORS HEALTH, INC.
(Registrant)
By: /s/ Stewart B. Gold
-----------------------
Stewart B. Gold
President and
Chief Executive Officer
Date: September 26, 1997
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, this report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated:
<TABLE>
<S> <C> <C>
DATE SIGNATURE CAPACITY
- - - ------------------- --------------------------------------------- ----------------------------------
September 26, 1997 /s/ Stewart B. Gold Principal Executive Officer
--------------------------------------------- Chief Executive Officer
Stewart B. Gold
September 26, 1997 /s/ John R. Dwyer, Jr. Principal Financial Officer
--------------------------------------------- Executive Vice President and
John R. Dwyer, Jr. Chief Financial Officer
September 26, 1997 /s/ Kyle Miller Principal Accounting Officer
--------------------------------------------- Vice President of Finance
Kyle Miller
September 26, 1997 /s/ Scott Rifkin, M.D. Chairman and
--------------------------------------------- Executive Vice President
Scott Rifkin, M.D.
September 26, 1997 /s/ Alan Kimmel, M.D. Executive Vice President and
--------------------------------------------- Director
Alan Kimmel, M.D.
September 26, 1997 /s/ Paul A. Serini Executive Vice President and
--------------------------------------------- Director
Paul A. Serini
September 26, 1997 /s/ Robert A. Barish, M.D. Director
---------------------------------------------
Robert A. Barish, M.D.
September , 1997 --------------------------------------------- Director
Richard L. Diamond, M.D.
September 26, 1997 /s/ Mark H. Eig, M.D. Director
---------------------------------------------
Mark H. Eig, M.D.
</TABLE>
62
<PAGE>
<TABLE>
<S> <C> <C>
September , 1997 --------------------------------------------- Director
John Prout
September 26, 1997 /s/ Albert Herrera, M.D. Director
---------------------------------------------
Albert Herrera, M.D.
September , 1997 --------------------------------------------- Director
Robert G. Graw, Jr., M.D.
September 26, 1997 /s/ Richard R. Howard Director
---------------------------------------------
Richard R. Howard
September 26, 1997 /s/ William D. Lamm, M.D. Director
---------------------------------------------
William D. Lamm, M.D.
September 26, 1997 /s/ Peter J. LoPresti, D.O. Director
---------------------------------------------
Peter J. LoPresti, D.O.
September 26, 1997 /s/ Thomas Mendell Director
---------------------------------------------
Thomas Mendell
September , 1997 --------------------------------------------- Director
J. David Nagel, M.D.
September 26, 1997 /s/ D. Alexander Rocha, M.D. Director
---------------------------------------------
D. Alexander Rocha, M.D.
September 26, 1997 /s/ Eric R. Wilkinson Director
---------------------------------------------
Eric R. Wilkinson
</TABLE>
63
<PAGE>
DOCTORS HEALTH, INC. AND SUBSIDIARIES
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
<TABLE>
<CAPTION>
BALANCE AT CHARGED TO CHARGED TO BALANCE
BEGINNING OF COSTS AND OTHER DEDUCTIONS AT END
DESCRIPTION PERIOD EXPENSES ACCOUNTS (WRITEOFFS) OF PERIOD
- - - ---------------------------------------------------------- ------------ ---------- ---------- --------- ----------
<S> <C> <C> <C> <C> <C>
YEAR ENDED JUNE 30, 1996
Allowance for doubtful receivables...................... $ 43,425 $ 281,096 $-- $ -- $ 324,521
Valuation allowances on deferred tax assets............. 770,000 2,152,000 -- -- 2,922,000
YEAR ENDED JUNE 30, 1997
Allowance for doubtful receivables...................... $ 324,521 $ 70,000 $-- $(124,000) $ 270,521
Valuation allowances on deferred tax assets............. 2,922,000 5,204,000 -- -- 8,126,000
</TABLE>
II-1
Note: Certain portions of this exhibit have been omitted and filed separately
with the Securities and Exchange Commission pursuant to a Request for
Confidential Treatment.
MEMORANDUM OF UNDERSTANDING
NYLCare Health Plans of the Mid-Atlantic, Inc. ("NYLCare Mid-Atlantic")
and
Doctors Health, Inc. ("Doctors Health")
CREATION OF RELATIONSHIP
1. OVERALL SCOPE. Doctors Health and NYLCare Mid-Atlantic have been discussing
ways to work more closely together in Medicare risk contracting, and have
agreed to create a relationship in which NYLCare Mid-Atlantic would shift the
financial risks of managing certain of its Medicare HMO enrollees to Doctors
Health and Doctors Health would become both clinically and financially
responsible for all or most of NYLCare Mid-Atlantic's Medicare HMO enrollees
in Maryland, Virginia and the District of Columbia. In pursuing such
discussions, the parties acknowledge that NYLCare Mid-Atlantic will retain
exclusively the role of the licensed HMO authorized to market the NYLCare
Mid-Atlantic Medicare risk product known as NYLCare 65. As such, NYLCare
Mid-Atlantic will retain responsibility for services set forth in Section 7
and will remain in a supervisory position over responsibilities delegated to
Doctors Health hereunder to the extent necessary for NYLCare Mid-Atlantic to
fulfill its regulatory obligations. NYLCare Mid-Atlantic retains the right to
determine whether and how the Medicare risk product is to be marketed.
2. NYLCare 65 NETWORK MANAGER. NYLCare Mid-Atlantic and Doctors Health would on
October 1, 1997 enter into a three (3) year Network Management Agreement,
under which NYLCare Mid-Atlantic would for the duration of the term appoint
Doctors Health as its Medicare HMO Network Manager for an area as designated
hereinafter as the "DOCTORS HEALTH SERVICE AREA," and "DOCTORS HEALTH
PHYSICIANS" and "NETWORK MANAGEMENT PHYSICIANS." "Doctors Health Physicians"
shall mean those primary care specialist physicians who have entered into a
participation agreement with Doctors Health and who are managed by Doctors
Health to provide health care services to Medicare enrollees. "Network
Management Physicians" shall mean those primary care and specialist
physicians who have entered into a participation agreement with NYLCare
Mid-Atlantic, except those in the District of Columbia and Prince George's
County, to provide health care services to NYLCare 65 enrollees and who will
be managed by Doctors Health under the Network Management Agreement. At the
end of the three (3) year initial term, the Network Management Agreement
would be renewed for additional one (1) year terms unless terminated earlier
as permitted under the Network Management Agreement. The Network Management
Agreement would include a ninety (90) day with cause termination provision;
provided, however, each party retains the option to terminate the Network
Management Agreement immediately in the event of one of the following:
1
<PAGE>
a. in the event of a liquidating distribution to the other party's
shareholders (or similar event); a combination, consolidation or merger
where the other party is not the survivor; any sale or issuance of the
other party's securities that places a majority of the voting power of
shares in the control of persons or entities not having such control on
September 30, 1997; any sale, exchange or other disposition of all or
substantially all of the other party's assets; or any significant change
in the management of the other party;
b. in the event that the other party proposes to act as a provider sponsored
network or conducts itself in such a manner as to compete with the
non-breaching party; and
c. in the event that the other party conducts itself in such a way as to
reflect negatively on the reputation of the non-breaching party.
NYLCare Mid-Atlantic retains the option to terminate the Network Management
Agreement immediately in the event that Doctors Health seeks to obtain in its
own right or through an affiliate an HMO license.
Additional with cause conditions will be defined in the Network Management
Agreement.
If the Network Management Agreement is terminated, the parties would extend
the terms of the Network Management Agreement for a period of ninety (90)
days until the enrollees can be transferred to other NYLCare Mid-Atlantic
participating providers. The Doctors Health Service Area would initially
consist of all Maryland counties other than Prince George's County, and all
Virginia counties in which NYLCare Mid-Atlantic is authorized to offer the
NYLCare 65 product, and could be expanded by NYLCare Mid-Atlantic and Doctors
Health during the term. Within the Doctors Health Service Area in Virginia,
any NYLCare 65 enrollees who select a primary care physician who has entered
into a participation agreement with Inova Integrated Services, Inova Health
System, or an affiliated LLC (described on EXHIBIT A) would be excluded from
the exclusive appointment for so long as such physician's contractual
obligation to Inova Integrated Services continues.
3. DOCTORS HEALTH PHYSICIANS. All physicians who are or who at any time become
affiliated with Doctors Health or one of its affiliated medical groups or
IPAs (i.e., those physicians with respect to whom Doctors Health has Medicare
risk contracting rights) would always be included as part of the Doctors
Health Physicians, including primary care physicians whose practices are or
become owned or affiliated with the Avanti Group (regardless of ownership of
the Avanti Group, as long as the Avanti Group is a participating NYLCare
Mid-Atlantic provider), through NYLCare Mid-Atlantic or directly with Doctors
Health, at the Avanti Group's election. This occurs regardless of whether the
Avanti Group becomes
2
<PAGE>
controlled by or under common control with Georgetown University Hospital or
the Georgetown Faculty Practice and regardless of whether they are in Prince
George's County or the District of Columbia, etc.). It is expected that by
December 31, 1997 that all such Doctors Health Physicians will become NYLCare
65 participating physicians.
4. PHYSICIAN RECRUITMENT. Doctors Health would be responsible for the clinical
care and would bear the full financial risk of utilization of services (as
described below) for all NYLCare 65 enrollees who as of September 30, 1997
have selected a Network Management Physician as their primary care physician
within the Doctors Health Service Area. It is recognized that Doctors Health
may recruit physicians in Prince George's County or the District of Columbia,
or physicians previously associated with one of the Inova practices. NYLCare
Mid-Atlantic will transfer a Network Management Physician who becomes a
Doctors Health Physician effective within thirty (30) days of notification
from Doctors Health or the physician.
5. EXISTING NYLCare MID-ATLANTIC PARTICIPATING PHYSICIANS. Subject to the HMO
role retained by NYLCare Mid-Atlantic in Section 1 and certain contractual
limitations in Section 6, Doctors Health will have full financial
responsibility and full clinical network management oversight for all NYLCare
65 enrollees within the Doctors Health Service Area. The Network Management
Agreement will provide that each of these physicians will be informed by
NYLCare Mid-Atlantic of Doctors Health's role as Network Manager and the
duties associated therewith. Doctors Health and NYLCare Mid-Atlantic each
agree that it is their intention to maintain and expand the Network
Management Physician and Doctors Health Physician primary care panel, and
that every reasonable effort will be made to keep all participating NYLCare
65 physicians in the panel and to avoid transfers of patients whenever
possible. It is understood by both parties that the intent of the Network
Management Agreement is to retain the Network Management Physician panel as
currently configured and that no currently participating provider will be
terminated from the Network Management Physician panel except for cause or at
the request of the provider.
6. DELEGATION OF MEDICAL MANAGEMENT. As Medicare HMO Network Manager, Doctors
Health will under the Network Management Agreement receive from NYLCare
Mid-Atlantic a full delegation of all medical management and related care
management decisions related to any of Doctors Health's NYLCare 65 enrollees
in accordance with NCQA standards. Such delegation of responsibility will be
subject to regulatory restrictions and contractual limitations regarding
exclusivity and utilization programs set forth in particular current
contracts with NYLCare Mid-Atlantic specialty providers. Doctors Health will,
at least until the termination of the current service year in effect and/or
any NYLCare Mid-Atlantic contracts in effect, agree to use NYLCare
Mid-Atlantic's existing provider agreements (at NYLCare Mid-Atlantic's prices
and rates) where Doctors Health has no provider agreement in place. Where
both NYLCare Mid-Atlantic and Doctors Health each have a provider agreement
in place (including an agreement with a hospital or other
3
<PAGE>
institution), Doctors Health may, subject to contractual and regulatory
limitations, if any, contained in the provider agreements, recruit such
provider in its network under the terms of either arrangement. Doctors Health
will in all events retain the right to make selective and/or focused
referrals within the network and to precertify referrals within the network,
in its discretion. NYLCare Mid-Atlantic will cooperate with Doctors Health in
its attempts to enforce physician compliance with Doctors Health programs and
procedures implemented under the Network Management Agreement.
7. ADDITIONAL RESPONSIBILITIES. NYLCare Mid-Atlantic will under the Network
Management Agreement remain responsible for defining the Medicare risk
product, serving as the direct resource to enrollees including but not
limited to administering NYLCare Mid-Atlantic's standard Medicare appeals and
grievances process, generating provider directories, defining standards for
professional liability insurance and credentialing and approving
credentialing of all Network Management Physicians in accordance with NCQA
standards (by means of a delegated credentialing agreement with Doctors
Health), and performing all TPA functions, including all claims payments to
providers, claims adjudication, member and provider services, and network
contracting. Where permissible by contract and regulation, NYLCare
Mid-Atlantic will agree to pay all claims, including, specifically, all
hospital claims, at the lowest of the NYLCare Mid-Atlanic fee schedule, the
Doctors Health fee schedule, or the maximum allowable Medicare payment, as
applicable. In the event more innovative and creative payments mechanisms are
arranged by Doctors Health, NYLCare Mid-Atlantic and Doctors Health will work
together to ensure that proper administration and payment of claims is made
by NYLCare Mid-Atlantic (at no additional cost to Doctors Health). NYLCare
Mid-Atlantic and Doctors Health will cooperate in customizing all systems,
processes and communications with providers and enrollees, to accommodate the
integration of Doctor Health's medical management and care management
functions with NYLCare Mid-Atlantic's retained administrative and payment
functions. The Network Management Agreement will clearly define the scope and
roles of each of NYLCare Mid-Atlantic and of Doctors Health.
8. PAYMENT AND RESERVE REQUIREMENT. Doctors Health will until October 1, 2000 be
paid by NYLCare Mid-Atlantic an amount each month equal to % of premium
(i.e., the applicable AAPCC adjusted annually by HCFA for each enrollee, plus
any subscriber or employer premiums) then in effect. Doctors Health will be
responsible for funding any necessary stop-loss arrangements in order to
comply with Physician Incentive Plan regulations. All payments will be made
by NYLCare Mid-Atlantic by the 10th day of each month during the term,
beginning on October 10, 1997. Claims payments to providers will be made by
charging such amounts against the capitation payment due to Doctors Health.
With respect to Virginia enrollees residing in the counties attached on
EXHIBIT B, NYLCare Mid-Atlantic will through June 30, 1998 pay Doctors Health
** ***** $*** PMPM, regardless of the AAPCC and/or premium then in effect.
With respect to Virginia enrollees
4
<PAGE>
elsewhere in Virginia, NYLCare Mid-Atlantic will through December 31, 1997
pay Doctors Health ** ***** $*** PMPM, regardless of the AAPCC and/or premium
then in effect. "PMPM" will be applied as the monthly total of eligible
NYLCare 65 enrollees who have selected a primary care Network Management
Physician within the Doctors Health Service Area.
Doctors Health will, within thirty (30) days of the effective date of the
Network Management Agreement, provide NYLCare Mid-Atlantic with an
Irrevocable Standby Letter of Credit at a financial institution acceptable to
NYLCare Mid-Atlantic in the initial notional amount of $*** ******* dollars,
such terms of the Letter of Credit to be agreed upon in the Network
Management Agreement. The notional amount of the Letter of Credit will be
increased: i) in the sixtieth (60th) day following the effective date of the
Network Management Agreement, to $*** ******* dollars; and ii) on each
anniversary of the effective date of the Network Management Agreement, to an
amount equal to sixty (60) days of average claims for the immediately
preceding twelve (12) month period, based on the beginning of the contract
year in question; provided, however, that in the event of any termination of
the Network Management Agreement by NYLCare Mid-Atlantic for cause, or a
termination of the Network Management Agreement at the end of the term, the
Letter of Credit will remain in effect for at least one hundred eighty (180)
days following termination. The Network Management Agreement will require
that Doctors Health maintain a Letter of Credit conforming to the above terms
at all times during the term of the Network Management Agreement.
TIME FRAME FOR DOCUMENTATION
1. PREPARATION OF NETWORK MANAGEMENT AGREEMENT. Doctors Health and NYLCare
Mid-Atlantic agree that time is of the essence in completing the
documentation necessary to implement the foregoing relationship. To this end,
each agrees to use its good faith best efforts to CONSUMMATE A FINAL
AGREEMENT(S) ON OR BEFORE TUESDAY, SEPTEMBER 30, 1997, such final agreement
to include all of the terms contained herein, and to commit such appropriate
time and resources to the completion and negotiation of the Network
Management Agreement and other related schedules and documents as may be
necessary to conduct a formal signing on or before Tuesday, September 30,
1997. Such process required to consummate a final agreement shall include
successful completion of a due diligence evaluation as described on EXHIBIT
C, which evaluation constitutes each party's determination as to the other
party's ability to assume the responsibilities established hereunder. Doctors
Health will use its best efforts to prepare and distribute to NYLCare
Mid-Atlantic an initial draft of a Network Management Agreement (and any
other related documents) on or before Monday, September 22, 1997.
Representatives of each of NYLCare Mid-Atlantic and Doctors Health will meet
on Thursday, September 25, 1997 to receive comments and use their respective
best efforts to finalize the
5
<PAGE>
agreement(s) in time for a signing on September 30, 1997. The parties agree
that any controversy, dispute or claim arising out of or relating to the
Network Management Agreement will be subject to binding arbitration.
2. NO CONSENTS. NYLCare Mid-Atlantic and Doctors Health both confirm to the
other that, to the best of their knowledge, no consents or approvals, other
than Board of Director approvals and regulatory approval as required, is
necessary to enter into the arrangements described above and/or to execute
the Network Management Agreement. Provided, however, if an amendment to the
Network Management Agreement is required based on regulatory mandate and such
amendment involves a modification which is substantially burdensome on either
party and which was not contemplated by the burdened party as of the Network
Management Agreement's date of execution, such burdened party may terminate
the Network Management Agreement upon ninety (90) days written notice to the
other party without penalty.
EXCLUSIVITY AND PUBLICITY
1. NON-SOLICITATION. NYLCare Mid-Atlantic understands that Doctors Health will
be expending considerable time, effort and capital in preparing to assume the
obligations to NYLCare Mid-Atlantic set forth herein, including, possibly,
the leasing of additional space, hiring of addition personnel, and the
engagement of attorneys and other advisors. NYLCare Mid-Atlantic therefor
agrees, until October 30, 1997, to use its best efforts to complete the
arrangements with Doctors Health set forth herein as soon as practicable and
agrees that it will not solicit nor enter into any discussions with other
provider groups, IPA management groups or any other person or entity to
provide any of the Network Services that are the subject of this Memorandum
of Understanding. With respect to marketing the NYLCare 65 product in the
District of Columbia and Prince George's County, Maryland, NYLCare
Mid-Atlantic shall have the right to enter into a similar network management
arrangement with a third party after first determining whether Doctors Health
is willing or able to assume such responsibilities in these areas upon terms
acceptable to NYLCare Mid-Atlantic.
2. JOINT PRESS RELEASE. NYLCare Mid-Atlantic and Doctors Health each agree that,
except as may be required by applicable law or regulation, no disclosure of
the financial arrangements described in this Memorandum of Understanding
shall be made by either without the consent of the other. Notwithstanding the
foregoing, it is the intent of NYLCare Mid-Atlantic and Doctors Health to
issue a joint press release promptly upon execution of this Memorandum of
Understanding and prior to execution of formal documents on September 30,
1997.
6
<PAGE>
MISCELLANEOUS
1. CONTRACTUAL OBLIGATIONS. Doctors Health and NYLCare Mid-Atlantic agree that
the provisions of paragraphs 1 and 2 of the Section entitled "TIME FRAME FOR
NEGOTIATION" and paragraphs 1 and 2 of the Section entitled "EXCLUSIVITY AND
PUBLICITY" are meant to create contractual obligations for each of NYLCare
Mid-Atlantic and Doctors Health. The balance of the provisions contained in
this Memorandum of Understanding are meant to express understandings reached
to date, and, other than each party's agreement to use its good faith best
efforts to consummate a transaction along the line described herein on or
before September 30, 1997, are not meant to create contractually binding
obligations. Neither party may assign or delegate any responsibilities
hereunder without the prior written consent of the other party.
2. CHOICE OF LAW. Where necessary, this Memorandum of Understanding shall be
subject to the provisions of Maryland law.
*****
ACCEPTED AND AGREED:
Doctors Health, Inc.
By: /s/ Stewart B. Gold Date: September 26, 1997
------------------- ------------------
Stewart B. Gold
Chief Executive Officer
NYLCare Health Plans of the Mid-Atlantic, Inc.
By: /s/ Jeff D. Emerson Date: September 10, 1997
------------------- -----------------
Jeff D. Emerson
President and Chief Executive Officer
7
<PAGE>
Exhibit A
Limited Liability Corporations affiliated with Inova Integrated Services and/or
Inova Health System:
Premier Health Services, LLC
United Health Services, LLC
8
<PAGE>
Exhibit B
For the period January 1, 1998 through June 30, 1998, NYLCare Mid-Atlantic will
pay Doctors Health ** ***** $*** PMPM for NYLCare 65 enrollees residing in the
following counties and cities in Virginia:
********
***********
*********
*******
*******
**** ******
**** *******
******
*** ****
********
****** ******
************
********
************
******** *******
**************
********
**********
********
9
<PAGE>
Exhibit C
10
<PAGE>
NYLCARE VIRTUAL NETWORK
PRELIMINARY LEGAL
DUE DILIGENCE CHECKLIST
FOR ENTITY
Corporate
- - - ---------
1. Entity organizational chart.
2. Copies of current organizational documents for Entity and all affiliates
(including medical groups, PHOs, etc.)
3. Copy of certificates of good standing, if applicable.
4. List of incumbent shareholders, directors, officers, or trustees.
5. Copy of most recent Annual Report filed with the Secretary of
State/Corporation Division, if applicable.
6. Copies of business or strategic plans (as relevant).
7. Disclosure of any related entity, owned, controlled by or under common
ownership or control with the Entity or any provider associated with the
Network.
Financial
- - - ---------
8. Most recent audited financial statements.
9. Current year to date budgets and financial statements, if any.
10. Any investment interest in or financial arrangement with any health care
provider or supplier (other than stock in a publicly traded company).
Provider
- - - --------
11. List of all physicians and other providers who are employees of Entity and
those who are participating providers with Entity, but who are not employees
(jointly, the "Network").
12. Evidence of Board certification/eligibility for Network providers.
13. Sample Employment Agreements with physicians and other providers.
14. Participating Provider Agreements with non-employed physicians and other
providers.
15. Copies of all provider subcontracts so that NYLCare can review complete
contract chain from Entity to individual provider.
16. Billing and collection agreements, if applicable.
17. List of all agreements between Entity and third party payors.
18. Description of Entity's experience with global or full risk-sharing
arrangements.
19. Description of Entity's internal risk-sharing arrangements, including
whether physicians at substantial financial risk.
20. Copies of any disclosure statements prepared pursuant to physician incentive
plan rules.
21. Description of Entity's plans to qualify as a PSO or PSN or similar
organization.
22. Description of any noncompetition provisions in any agreements.
<PAGE>
23. Description of service area in which Network operates or intends to operate
(MD, DC, VA).
24. Disclosure of any arrangement with any IPA, physician-hospital organization,
management services organizations, third party payor, or health benefit plan
and of any joint venture arrangement for the provision of health services.
25. Marketing agreements and marketing materials used in connection with
Network.
26. Copy of all governmental approvals obtained in connection with the Network
(not individual physicians), including but not limited to:
o professional licenses and registrations
o DEA registrations
o State controlled substances registrations
o Clinical laboratory licensure
o Pharmacy license
o Health facility license
o Certificate of need
o HSCRC filings or waivers
27. Evidence of all insurance related to the Network, including liability,
stop-loss, and reinsurance.
28. Disclosure of:
i) any malpractice suit, claim (whether or not filed in court),
settlement, settlement allocation, judgment, verdict or decree against
Entity (or any practitioner associated with Entity);
ii) any disciplinary, peer review or professional review investigation,
proceeding or action instituted against Entity (or any practitioner
associated with Entity) by any licensure board, hospital, medical
school, health care facility or entity, professional society or
association, third party payor, peer review or professional review
committee or body, or governmental agency;
iii) any criminal complaint, indictment or criminal proceeding in which
Entity (or any practitioner associated with Entity) is or has been
named as a defendant;
iv) any investigation or proceeding, whether administrative, civil or
criminal, relating to an allegation against Entity (or any practitioner
associated with Entity) or filing false health care claims, violating
anti-kickback laws, or engaging in other billing improprieties;
v) any allegation, termination, suspension or restriction of any
agreement, right or privilege, or any investigation or proceeding based
on any allegation, against Entity (or any practitioner associated with
Entity) or violating professional ethics or standards, or engaging in
illegal, immoral or other professional misconduct (of any nature or
degree); and
vi) any denial or withdrawal or an application in any state for licensure,
for medical staff privileges at any hospital or other health care
entity, for board certification or recertification, for participation
in any third party payment program, for state or federal controlled
substances registration, or for malpractice insurance.
<PAGE>
Management Services
- - - -------------------
29. Copies of any management or delegation agreements to provide quality
assurance/quality improvement/risk management/credentialling (the "Delegated
Functions").
30. Copies of any regulatory review or correspondence regarding Delegated
Functions, including from NCQA.
31. Copies of all protocols, programs, policies, etc. used to managed Delegated
Functions.
32. Description of experience managing non-Network providers.
33. Name of MIS and other vendors, including any proposed subcontractors, to be
used in accomplishing Delegated Functions.
Other
- - - -----
34. Disclosure of other material agreements, obligations, liabilities and
contingent liabilities, and of other material transactions under
consideration.
35. Willingness to have NYLCare in control of document preparation.
<PAGE>
DOCTORS HEALTH
DUE DILIGENCE REQUEST
RE: NYLCARE MEDICARE AGREEMENT
o Provider Agreement (form) for
Specialist Provider
Carve-out (Exclusive) Provider
Hospital Provider
o Actual enrollment by zip code as of 9/1/97 (by county if zip code not
available)
o Utilization / cost information for prior year (9/97-9/98)
Inpatient Admissions:
# Admits/hospital, by DRG if available;
Avg. cost per case,
ALOS,
# Admits per thousand members
Outpatient Surgery:
#'s by DRG, locations
Pharmacy
Benefit language
Utilization and cost, (per region as available)
Data (type, format) provided by PBM
Home Health
Cost detail, regionally adjusted as available
o Provider Directory on disk
o Data dictionaries (hard copy and disk) for NYLCare's:
provider database
referral database
eligibility database
fee schedule database
o NYLCare fee schedule, incl. NYLC contracted rates w/hospitals, home health
providers, subacute facilities, ASCs, ancillary providers
o Benefit plans / table
o Health Risk Assessment data / status
o Provider Policy and Procedure Manual, and any other pertinent policy and
procedure manuals
EXHIBIT 10.50
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
AMENDED AND RESTATED EMPLOYMENT AGREEMENT, entered into on
December 9, 1994 (the "Signing Date"), amended on February 24, 1995, October 11,
1996, April 21, 1997 and July 15, 1997 and dated as of the 1st day of July, 1994
(the "Effective Date"), between DOCTORS HEALTH, INC. (formerly Doctors Health
System, Inc.), a Maryland corporation (the "Company") and SCOTT M. RIFKIN (the
"Physician Executive").
-------------
BACKGROUND
-------------
The Company is engaged, directly or through service contracts
with others, in the business of (i) negotiating contracts to provide health care
services and products, (ii) managing health care providers, and (iii) providing
health care services and products (the "Business").
The Physician Executive is a primary care physician with
substantial skills and knowledge in the management and development of physician
practices, and is experienced in creating and expanding a physician run equity
model group practice working with hospitals, managed care organizations and
other physicians.
The Executive and the Company previously entered into an
Amended and Restated Employment Agreement dated April 21, 1997, a copy of which
is attached hereto (the "Prior Agreement"), and each desires to amend and
restate the Prior Agreement in its entirety to incorporate certain additional
matters.
The Company desires to hire the Physician Executive, and the
Physician Executive desires to work for the Company, on the terms and conditions
set forth in this Agreement.
1. EMPLOYMENT, DUTIES AND ACCEPTANCE.
1.1 EMPLOYMENT. (a) Effective upon the Effective
Date, the Company shall employ the Physician Executive as its Executive
Vice President and Director of Development. In such capacities, the
Physician Executive shall have the duty, responsibility and authority
for designing and implementing medical and non-medical policies and
procedures, and investigating, structuring and negotiating on behalf of
the Company and its Subsidiaries the
1
<PAGE>
purchase of primary care physician practices, and shall assist with the
creation of, contractual relationships with hospitals, physician
specialists, medical institutions and providers, negotiating managed
care and other contracts, and related matters involving the growth and
development of the Business, all after consultation with the Company's
Executive Vice President and Director of Medical Affairs and subject to
the guidelines, policies and control of the Company's Chief Executive
Officer and Board of Directors (the "Board"), to whom he shall report.
The Physician Executive shall perform such other duties within these
general parameters as the Chief Executive Officer or the Board may from
time to time designate. The Physician Executive shall perform his duties
faithfully and to the best of his abilities. The Physician Executive
shall also serve (A) during the Term, as a director of the Company
(subject to the power of the Board and the Shareholders of the Company
to remove him as set forth in the Company's Bylaws), (B) as a director
of all of the Company's Subsidiaries (as defined in SECTION 5.2), and
(C) until the "Financing Date" (as defined in SECTION 3.1(B)), as the
Chairman of the Board, all without any additional compensation.
(b) The Physician Executive shall
devote a significant portion of his working time and creative energies
to the performance of his duties hereunder and will at such times devote
such efforts as are reasonably sufficient for fulfilling the significant
responsibilities entrusted to him. So long as such activities, in the
aggregate, do not interfere with the performance by the Physician
Executive of his duties hereunder: (i) the Physician Executive shall be
permitted a reasonable amount of time to engage in the practice of
medicine as an employee of Baltimore Medical Group, Inc. and to
supervise his personal, passive, investments; (ii) the Physician
Executive shall be permitted a reasonable amount of time to participate
(as board member, officer or volunteer) in civic, political and
charitable activities; (iii) the Physician Executive shall be permitted
to deliver lectures to and teach at educational institutions and
business organizations; and (iv) subject to the provisions of SECTION 5
hereof, the Physician Executive may serve as a director or trustee of
one or more corporations not affiliated with the Company.
1.2 PLACE OF EMPLOYMENT. The Physician Executive's
principal place of employment shall be in the Baltimore, Maryland metropolitan
area, subject to such travel as may be reasonably required by his
employment pursuant to the terms hereof. The Physician Executive shall
not be required to relocate outside of the Baltimore, Maryland
metropolitan area during the Term, except by mutual agreement.
2. TERM OF EMPLOYMENT. The term of the Physician Executive's
employment under this Agreement (the "Term") shall commence on the Effective
Date and shall end on April 1, 2000 unless sooner terminated, or later extended,
as herein provided. Not later than February 1, 2000 (and each February 1 of each
calendar year during any Extension Period (defined below)), the Company and the
Physician Executive shall enter into good faith negotiations to determine
whether and on what terms to extend or renew this Agreement
2
<PAGE>
beyond April 1 of such calendar year. If by October 15, 1999 (and
October 15 of any calendar year occurring during an Extension Period)
either party gives written notice to the other of its desire to
terminate this Agreement as of April 1, then this Agreement shall so
terminate, and the Physician Executive shall be permitted a reasonable
amount of time during the balance of the Term within which to explore
alternative employment opportunities. If no such written notice to
terminate is given by either party by October 15, 1999 (or by October 15
of any calendar year occurring during an Extension Period), then the
Term shall, without further act or deed, automatically be extended upon
the same terms and conditions as previously in effect, for an additional
12 month period, commencing on April 1 of the applicable calendar year
and ending on March 31 of the immediately following calendar year. Each
such 12 month extension during the Term is referred to herein as an
"Extension Period", and shall constitute a part of the Term of this
Agreement for all purposes, including the provisions regarding
extensions contained in this Section 2.
3. COMPENSATION.
3.1 SALARY. As compensation for all services to be
rendered pursuant to this Agreement, the Company shall pay to the
Physician Executive, during the Term, a "Base Salary" (as defined in
this SECTION 3.1) less such deductions as shall be required to be
withheld by applicable laws and regulations. The "Base Salary" from July
1, 1997 to December 31, 1997 shall be a salary of $187,500 per annum,
subject to upward adjustment as determined by the Executive Committee of
the Board of Directors of the Company. The amount of the Base Salary has
been established based upon the mutual assumption by the Company and the
Physician Executive that the Physician Executive shall devote
approximately seventy-five percent (75%) of his working time and
creative energies to the performance of his duties hereunder. The
Company and the Physician Executive acknowledge and agree that because
the performance by the Physician Executive of his duties hereunder will
be of critical importance to the growth and prosperity of the Company,
the Company shall from time to time, in its reasonable discretion,
evaluate and determine the working time and creative energies that the
Physician Executive has devoted to the performance of his duties
hereunder during any preceding three (3) month period (it being
understood and agreed that the Physician Executive's use of permitted
vacation hereunder shall not be included in such determination). If the
Company determines that the Physician Executive has devoted
significantly more or significantly less of his working time and
creative energies to his duties hereunder during any such period, his
Base Salary will be adjusted, up or down, by the Company (in the
exercise of its reasonable discretion) on each such occasion, commencing
with the beginning of the fiscal quarter of the Company immediately
following the Signing Date. The Base Salary shall accrue from and after
the Effective Date, and shall be payable in arrears in equal monthly
installments each year.
3
<PAGE>
3.2 BONUS. The Physician Executive shall be eligible to
receive an annual bonus based upon the extent to which the Physician
Executive's performance meets or exceeds agreed upon performance
standards or the Physician Executive otherwise performs in an exemplary
manner, all in the sole discretion of the President and the Compensation
Committee of the Board of Directors of the Company.
3.3 STOCK; OPTION GRANT.
(a) The Company has transferred to the Physician
Executive twenty-five (25) shares of the voting common stock of the
Company. As a result of duly adopted resolutions of the Company's
directors and shareholders, and the filing with the Maryland SDAT of
Amended Articles of Incorporation of the Company, such 25 shares of
voting common stock have been reclassified and a stock dividend
declared, so that the Physician Executive on the date hereof is the
registered owner of 100,000 shares of the Company's Class A Common Stock
(the "Class A Common Stock"). On August 10, 1995, the Company issued to
the Physician Executive, in addition to the Stock, an option (the
"Option") to purchase an additional 100,000 shares of its Class A Common
Stock (the "Additional Stock").
(b) So long as the Physician Executive's employment
hereunder has not been earlier terminated by the Company pursuant to
the provisions of SECTION 4.3(A) hereof, the Option shall vest in full
upon the earlier to occur of (i) a Change in Control of the Company, or
(ii) twenty-four (24) months from the Signing Date, or (iii) termination
of the Physician Executive's employment pursuant to SECTION 4.3(B) or
SECTION 4.4 (such earlier date, the "Vesting Date"). The option price
for the Additional Shares shall be $25 in the aggregate; to the extent
the number of shares, or the class, or designation, of the Stock is
changed as the result of a reclassification, stock split, stock dividend
or other similar event, the number and/or class of shares of Additional
Stock issuable under the Option shall be adjusted accordingly. The
Option may not be exercised within one year of the Vesting Date, except
upon an earlier Change in Control of the Company.
(c) All Stock and Additional Stock transferred to
the Physician Executive hereunder is and shall remain subject to any
transfer restrictions and other protections as are set forth in the
Company's Charter, By-laws, or in any Shareholder's Agreement, and the
certificates or other instruments representing such stock shall bear or
contain a legend or statement regarding such transfer restrictions.
(d) "Change in Control" shall mean the earlier to
occur of (i) a liquidating distribution to Company's shareholders (or
similar event); (ii) a contribution, consolidation or merger where Company is
not the survivor; (iii) any sale, exchange or other disposition of all, or
substantially all of Company's assets; (iv) any public offering of
4
<PAGE>
Company's securities at a company value of at least $25,000,000 with
proceeds to Company of at least $15,000,000.
3.4. WITHHOLDING. The Company is authorized to withhold
from the amount of any Salary and Bonuses and any other things of value
paid to or for the benefit of the Physician Executive (other than
transfers of Stock), all sums authorized by the Physician Executive or
required to be withheld by law, court decree, or Physician Executive
order, including (but not limited to) such things as income taxes,
employment taxes, and employee contributions to fringe benefit plans
sponsored by the Company.
3.5 PARTICIPATION IN PHYSICIAN EXECUTIVE BENEFIT PLANS.
The Physician Executive shall be permitted during the Term, if and to
the extent eligible, to participate in any group life, hospitalization
or disability insurance plan, health program, automobile allowance,
pension plan or similar benefit plan of the Company which may be
available to other comparable executives and professional employees of
the Company, generally on the same terms as such other executives.
3.6 VACATION. The Physician Executive will receive at
least 4 weeks vacation per year, to be scheduled and taken at the
Physician Executive's option at such times as his duties may permit.
Should the Company's policy provide for more vacation to comparable
Physician Executives the Physician Executive will be accorded such
higher vacation. Unused vacation time shall not be cumulated or carried
over nor shall the Physician Executive receive any compensation for
unused vacation time.
3.7 EXPENSES. Subject to such policies as may from time
to time be established by the Board, the Company shall pay or reimburse
the Physician Executive for all ordinary, necessary and reasonable
expenses (including, without limitation, travel, meetings, dues,
subscriptions, fees, educational expenses, computer equipment and the
like) actually incurred or paid by the Physician Executive during the
Term in the performance of the Physician Executive's services under this
Agreement (including, without limitation, expenses incident to
attendance at board or management meetings of the Company, or its
Subsidiaries or Affiliates), upon presentation of expense statements or
vouchers or such other supporting information as the Board may require.
3.8 DEFERRED COMPENSATION. As soon as practicable
following execution of this Agreement, the Company shall pay the
Physician Executive $75,000 in full satisfaction of all deferred
compensation obligations of the Company to him for services performed
from the Signing Date to June 30, 1997.
4. TERMINATION.
5
<PAGE>
4.1 TERMINATION UPON DEATH. If the Physician
Executive dies during the Term, the Physician Executive's employment
shall terminate as of the date of death of the Physician Executive.
4.2 TERMINATION UPON DISABILITY. Notwithstanding any
other provision of this Agreement (except the other provisions of this
Section 4.2), if during the Term the Physician Executive becomes
physically, mentally or emotionally disabled, whether totally or
partially, as determined by an independent qualified physician, so that
the Physician Executive is, in the good faith determination of the
Board, substantially unable to perform his services hereunder for (i) a
period of three consecutive months, or (ii) shorter periods aggregating
three months during any twelve month period, the Company may (a)
continue the Physician Executive's employment hereunder until one (1)
year following the end of the Term at a Base Salary equal to the Base
Salary in effect at the time of the determination of the disability, or
(b) by written notice to the Physician Executive, terminate the
Physician Executive's employment hereunder as of the date of such
written notice and pay the Physician Executive as severance an amount
equal to the amount he would have been paid (at the Base Salary that is
in effect on the date of termination) for the period from the date of
termination until one (1) year following the end of the Term if his
employment had not been terminated. The preceding sentence shall be in
effect only until, and shall terminate upon, the occurrence of any of
the following events: (a) the cessation of the Company's business, (b)
the bankruptcy, liquidation, receivership, or dissolution of, or
assignment for the benefit of creditors by, the Company, (c) any Change
in Control of the Company (as defined in the Company's Amended and
Restated Stockholders Agreement, as it may be amended from time to
time), or (d) the consummation of any public offering of the Company's
capital stock (the "Extraordinary Events"). If any Extraordinary Event
occurs and thereafter the Physician Executive becomes physically,
mentally or emotionally disabled, whether totally or partially, as
determined by an independent qualified physician, so that the Physician
Executive is, in the good faith determination of the Board,
substantially unable to perform his services hereunder for (i) a period
of three consecutive months, or (ii) shorter periods aggregating three
months during any twelve month period, the Company may at any time after
the last day of the three consecutive months of disability or on the
last day of the shorter period aggregating three months of disability,
by written notice to the Physician Executive, terminate the Physician
Executive's employment hereunder as of the date such written notice
becomes effective.
4.3 TERMINATION AT ELECTION OF COMPANY.
(a) Notwithstanding any other
provision of this Agreement, the Company may terminate the Physician
Executive's employment hereunder at any time upon: (i) the continued
failure or refusal by, or manifest inability of, the Physician Executive
to perform his duties after reasonable prior notice to the Physician
Executive; (ii) the Physician
6
<PAGE>
Executive engaging in any acts or omissions involving dishonesty or acts or
omissions that demonstrate a lack of integrity; (iii) the conviction of the
Physician Executive of a felony; (iv) the Physician Executive engaging in acts
or omissions that demonstrably and materially injure the business and affairs
of the Company, monetarily or otherwise; and/or (v) any knowing material
misrepresentation made by the Physician Executive to the Company or any
material breach by the Physician Executive of his obligations hereunder.
(b) In addition to the Company's
right to terminate the Physician Executive's employment pursuant to
SECTION 4.3(A), and notwithstanding any other provision of this
Agreement, the Company may, for any or for no reason, terminate the
Physician Executive's employment upon 60 days prior written notice to
the Physician Executive.
4.4 TERMINATION BY THE PHYSICIAN EXECUTIVE.
(a) Provided that the Physician
Executive has delivered to the Board at least sixty (60) days prior
written notice setting forth in reasonable detail any alleged material
breach by the Company of this Agreement or other acts or omissions
engaged in by the Company constituting "constructive termination" of the
Physician Executive's employment with the Company, which breach, acts or
omissions have not been cured by the Company as of the end of such
period to the reasonable satisfaction of the Physician Executive, then,
notwithstanding any other provision of this Agreement, the Physician
Executive shall be entitled to terminate his employment for such
reasons, effective immediately upon the delivery by the Physician
Executive to the Board of a notice to the effect that such breach, acts
or omissions have not been cured to the reasonable satisfaction of the
Physician Executive; provided, however, that if such constructive
termination is caused by the Physician Executive's incapacity or
inability to serve due to a disability of the type described in SECTION
4.2 above and the Company elects to terminate the Physician Executive
pursuant to the provisions of SECTION 4.2, the Physician Executive
shall, for purposes of this Agreement, be deemed to have been terminated
pursuant to the provisions of SECTION 4.2 and not of this SECTION 4.4.
(b) For purposes of this SECTION
4.4, "constructive termination" shall be limited to those circumstances
where (i) the Company creates working conditions that a reasonable
person in the Physician Executive's position would consider unreasonable
or intolerable which is not remedied by the Company sixty (60) days
after notice thereof given by the Physician Executive;; and (ii) such
working conditions are not generally applicable to other Physician
executives of the Company.
4.5 COMPENSATION AND BENEFITS FOLLOWING
TERMINATION OF EMPLOYMENT.
(a) In the event of termination
of the Physician Executive's employment for any reason other than a
termination pursuant to SECTION 4.3(B) or SECTION 4.4
7
<PAGE>
(or a termination caused merely by the expiration of the Term): (i) all
compensation and other benefits payable or provided hereunder shall
cease as of the date of termination; and (ii) Base Salary (if any) then
payable or accrued through the date of termination and all accrued
benefits (if any) then payable to the Physician Executive pursuant to
the terms of any plans or arrangements referred to in SECTION 3.5 shall
be paid to the Physician Executive (or to his heirs, legatees and/or
legal representatives) through the date of termination.
(b) In the event of termination
of the Physician Executive's employment pursuant to SECTION 4.3(B)
or SECTION 4.4, the Physician Executive (or, in the event of the
Physician Executive's subsequent death or disability, his heirs,
legatees and/or legal representatives) shall receive, when and as the
same would have been payable hereunder if the Physician Executive's
employment had not been so terminated, each of the following payments
and benefits:
(i) all accrued
benefits (if any) then payable to the Physician Executive pursuant
to the terms of any plans or arrangements referred to in SECTION 3.5;
(ii) with respect to any
periods after June 30, 1996, 50% of the Base Salary which would have
been due to the Physician Executive from July 1, 1996 through the
remainder of the Term, at the times such payments would otherwise be
made, all as if this Agreement were still in effect; and
(iii) subject to the
provisions of the Company's Amended and Restated Articles, By-laws, the
Shareholder's Agreement, and the Option Agreement all of the shares of
Additional Stock issuable under the Option pursuant to SECTION 3.3 shall
be issued to the Physician Executive free of any restrictions.
(c) In the event of termination
under SECTION 4.2 (disability), the Physician Executive or his legal
representative, as the case may be, shall, in addition to such other
payments as may be due hereunder, be entitled to receive the proceeds of
any disability policies maintained by the Company and payable to the
Physician Executive.
8
<PAGE>
5. CERTAIN COVENANTS OF THE PHYSICIAN EXECUTIVE.
5.1 NECESSITY FOR COVENANTS. The Physician
Executive acknowledges that (i) the Company, its Subsidiaries and its
Affiliates (as defined in SECTION 5.2) are engaged in the Business, and
will in the future be engaged in the Business; (ii) his work and
providing management services to health care entities for the Company
and its Affiliates will give him access to customers and suppliers of,
and trade secrets of and confidential information concerning, the
Company, its Subsidiaries and its Affiliates; and (iii) the agreements
and covenants contained in this SECTION 5 are essential to protect the
business and goodwill of the Company, its Subsidiaries and its
Affiliates. In order to induce the Company to enter into this Agreement
and pay the compensation and other benefits at the levels requested by
the Physician Executive, the Physician Executive enters into the
following covenants:
5.2 DEFINITIONS.
(a) For purposes of SECTIONS 5.3
through 5.8 only, the term "Company" shall include the Company and
all of the Company's, Subsidiaries and Affiliates.
(b) "Provider" shall mean any health
care service provider or Affiliate thereof to whom the Company provided
management or other services.
(c) "Payor" means any insurer,
employer, health maintenance organization, preferred provider
organization, health benefit plan or other entity or organization to
which, or to whose members, insured's, employees, enrollees,
beneficiaries or other persons affiliated with it (collectively
"Beneficiaries"), the Company provides services or products.
(d) "Service Area" means the
geographic area in which the Company provides health care services and
in which the Beneficiaries of those services generally reside, which
shall include all areas within a 25 mile radius of the site of any
Provider's office.
(e) "Subsidiary" means any
person or entity in which the Company owns, beneficially or
otherwise, an equity interest of more than 50%.
(f) "Affiliate" means a
Subsidiary of the Company; a person or entity which is owned,
controlled, or operated by the Company; any person owning an equity
interest in the Company; any person who has appointed the Company as its
exclusive agent for the provision of professional services and the
collection of revenues therefrom; and any partner, member, employee,
owner or agent of any Affiliate and any person or entity which is under
common ownership, control or operation with the specified person or
entity.
9
<PAGE>
5.3 RESTRICTIONS. During the Term and,
unless the Physician Executive's employment is terminated other than
pursuant to SECTIONS 4.3(B) or 4.4 hereof, for a period of twelve (12)
months after the Physician Executive's employment hereunder is
terminated (the "Termination Date") (the "Restricted Period"), the
Physician Executive shall not, directly or indirectly, for himself or on
behalf of any other person, firm, corporation or other entity, whether
as a principal, agent, employee, stockholder, partner, officer, member,
director, sole proprietor, or otherwise:
(a) call upon or solicit any
Provider for the purpose of persuading the Provider to engage the
Physician Executive or any other person, firm, corporation or other
entity to provide services which are the same or similar to those the
Company provided to the Provider;
(b) call upon or solicit any
Payor for the purpose of persuading the Payor to engage any person or
entity other than the Company to provide health care services to the
Payor with respect to any of its Beneficiaries in the Service Area;
(c) solicit, participate in or
promote the solicitation of any person who was employed by the Company
or a Provider at any time during the twelve (12) months preceding the
Termination Date to leave the employ of the Company, or hire or engage
any of those persons;
(d) make any disparaging remarks
about the Company's business, services or personnel;
(e) interfere in any way with
the Company's business, prospects or personnel; or
(f) become affiliated with or render
services to any person engaged in any business that competes with the
Business within the Service Area, directly or indirectly, in any
capacity, including, without limitation, as an individual, partner,
shareholder, officer, director, principal, agent, employee, trustee or
consultant; provided, however, that the Physician Executive may own,
directly or indirectly, solely as an investment, securities which are
publicly traded if the Physician Executive (a) is not a controlling
person of, or a member of a group which controls, the issuer and (b)
does not, directly or indirectly, own 5% or more of any class of
securities of the issuer.
5.4 TRADE SECRETS AND CONFIDENTIAL INFORMATION
5.4.1 TRADE SECRETS DEFINED.
The term "Trade Secrets," as used in this Agreement, includes,
without limitation, (i) all information concerning billing practices and
10
<PAGE>
procedures of the Company, (ii) the rates and amounts that the Company
pays to its personnel, (iii) information about the Company's contracts
with insurers, health maintenance organizations, employers, and other
payors, (iv) all formulae, compilations, programs, devices, lists,
methods, techniques or processes of the Company, and (v) all other
information of the Company that would be deemed to be "trade secrets"
within the meaning of the Maryland Uniform Trade Secrets Act (the
"Act").
5.4.2 CONFIDENTIAL INFORMATION
DEFINED. Any other information not qualifying as a Trade Secret, but
relating to the business of the Company which is disclosed by the
Company to the Physician Executive, or is discovered by the Physician
Executive in the course of employment, is Confidential Information.
5.4.3 DUTY TO MAINTAIN SECRECY
AND CONFIDENTIALITY. During the Period of the Physician Executive's
employment with the Company, the Physician Executive shall maintain the
secrecy and confidentiality of the Trade Secrets and the Confidential
Information and shall not (i) divulge, furnish or make accessible to
anyone or in any way or use, for his own benefit or for the benefit of
any other individual firm or entity (other than in the ordinary course
of the Company's business), any Trade Secret or Confidential
Information; (ii) take or permit any action to be taken which would
reduce the value of the Trade Secrets or Confidential Information to the
Company; or (iii) otherwise misappropriate or suffer the
misappropriation of the Trade Secrets or the Confidential information,
within the meaning of the Act. After the Termination Date, Physician
Executive shall continue to maintain the secrecy and confidentiality of
such information, but only to the extent that the Physician Executive is
prohibited from directly or indirectly competing with Company pursuant
to the provisions of SECTION 5.3.
5.4.4 INFORMATION WHICH IS
PUBLICLY KNOWN. Notwithstanding anything herein to the contrary,
the obligations of secrecy and confidentiality set forth herein shall
not apply to any information which is now generally publicly known or
which subsequently becomes generally publicly known other than as a
direct or indirect result of the breach of this Agreement by the
Physician Executive, or which is required by law or order of any court
to be disclosed.
5.5 PROPERTY OF THE COMPANY. All
memoranda, notes, lists, records and other documents or papers (and
all copies thereof), including but not limited to, such items stored in
computer memories, on microfiche or by any other means, made or compiled
by or on behalf of the Physician Executive, or made available to the
Physician Executive concerning the Business, are and shall be the
property of the Company and shall be delivered to the Company promptly
upon the termination of the Physician Executive's employment with the
Company or at any other time on request; provided however, that the
Physician Executive may inspect during normal business hours such
records as shall be necessary for the purpose
11
<PAGE>
of assisting the Physician Executive to file, or prepare for an audit
of, his personal income tax returns.
5.6 PHYSICIAN EXECUTIVE'S IDEAS, ETC.
All inventions, prototypes, discoveries, improvements, innovations
and the like ("Inventions") and all works of original authorship or
images that are fixed in any tangible medium of expression and all
copies thereof ("Works") which are designed, created or developed by
Physician Executive, solely or in conjunction with others, in the course
of performance of the Physician Executive's duties which relate to the
Business, shall be made or conceived for the exclusive benefit of and
shall be the exclusive property of the Company. The Physician Executive
shall immediately notify the Company upon the design, creation or
development of all Inventions and Works. At any time thereafter, the
Physician Executive, at the request and expense of the Company, shall
execute and deliver to the Company all documents or instruments which
may be necessary to secure or perfect the Company's title to or interest
in the Inventions and Works, including but not limited to applications
for letters of patent, and extensions, continuations or reissues
thereof, applications for copyrights and documents or instruments of
assignment or transfer. All Works are agreed and stipulated to be "works
made for hire," as that term is used and understood within the Copyright
Act of 1976, as amended. To the extent any Works are not deemed to be
works made for hire as defined above, and to the extent that title to or
ownership of any Invention or Work and all other rights therein are not
otherwise vested exclusively in the Company, the Physician Executive
shall, without further consideration but at the expense of the Company,
assign and transfer to the Company the Physician Executive's entire
right, title and interest (including copyrights and patents) in or to
those Inventions and Works.
5.7 RIGHTS AND REMEDIES UPON BREACH. If
the Physician Executive breaches, or threatens to commit a breach of,
any of the provisions of SECTIONS 5.1 through 5.6 (the "Restrictive
Covenants"), the Company shall, in addition to its right immediately to
terminate this Agreement, have the right and remedy (which right and
remedy shall be independent of others and severally enforceable, and
which shall be in addition to, and not in lieu of, any other rights and
remedies available to the Company under law or in equity) to have the
Restrictive Covenants specifically enforced by any court having equity
jurisdiction, it being acknowledged and agreed that any such breach or
threatened breach could cause irreparable injury to the Company or its
Affiliates and that money damages may not provide adequate remedy to the
Company.
5.8 COVENANTS CURRENTLY BINDING
PHYSICIAN EXECUTIVE. The Physician Executive warrants that his
employment by the Company will not (a) violate any non-disclosure
agreements, covenants against competition, or other restrictive
covenants made by the Physician Executive to or for the benefit of any
previous employer or partner, or (b) violate or constitute a breach or
default under, any statute, law, judgment, order, decree, writ,
12
<PAGE>
injunction, deed, instrument, contract, lease, license or permit to
which the Physician Executive is a party or by which the Physician
Executive is bound.
5.9 LITIGATION. There is no litigation,
proceeding or investigation of any nature (either civil or criminal)
which is pending or, to the best of the Physician Executive's knowledge,
threatened against or affecting the Physician Executive or which would
adversely affect his ability to substantially perform the duties herein.
5.10 REVIEW. The Physician Executive
has received or been given the opportunity to review the provisions of
this Agreement, and the meaning and effect of each provision, with
independent legal counsel of the Physician Executive's choosing.
5.11 SEVERABILITY OF COVENANTS. The
Physician Executive acknowledges and agrees that the Restrictive
Covenants are reasonable and valid in geographical and temporal scope
and in all respects. If any court determines that any of the Restrictive
Covenants, or any part thereof, is invalid or unenforceable, the
remainder of the Restrictive Covenants shall not thereby be affected and
shall be given full effect, without regard to the invalid portions.
5.12 BLUE-PENCILING. If any court
determines that any of the Restrictive Covenants, or any part thereof,
is unenforceable because of the duration or geographic scope of such
provision, such court shall have the power to reduce the duration or
scope of such provision, as the case may be, and, in its reduced form,
such provision shall then be enforceable and shall be enforced. If any
such court declines to so revise such covenant, the parties agree to
negotiate in good faith a modification that will make such duration or
scope enforceable.
5.13 ENFORCEABILITY IN JURISDICTIONS.
The parties intend to and hereby confer jurisdiction to enforce the
Restrictive Covenants upon the courts of any jurisdiction within the
geographical scope of such Covenants. If the courts of any one or more
of such jurisdictions hold any Restrictive Covenant unenforceable by
reason of the breadth of such scope or otherwise, it is the intention of
the parties that such determination not bar or in any way affect the
Company's right to the relief provided above in the courts of any other
jurisdiction within the geographical scope of such Covenants, as to
breaches of such Covenants in such other respective jurisdictions, such
Covenants as they relate to each jurisdiction being, for this purpose,
severable into diverse and independent covenants.
5.14 EXTENSION. If the Physician
Executive violates any Restrictive Covenant, the Company shall not be
deprived of the full benefit of the period of the covenant. Accordingly,
the duration of that covenant shall be extended by the period of any
violation of that covenant.
13
<PAGE>
5.15 REMEDIES. The Company shall be
entitled to injunctive or other equitable relief because it will be
caused irreparable injury and damage by a breach of the provisions of
any of the Restrictive Covenants. The right to injunctive relief shall
include the right to both preliminary and permanent injunctions. The
Company shall not be required to post a bond or other similar assurance
if it brings an action to enforce the provisions of any of the
Restrictive Covenants. The Company's right to equitable relief shall not
preclude any other rights or remedies which the Company may have, all of
which rights and remedies are cumulative.
6. DISPUTE RESOLUTION.
6.1 COSTS OF LITIGATION. If either party
files suit or brings an arbitration proceeding to enforce its rights
under this Agreement, the prevailing party shall be entitled to recover
from the other party all expenses incurred by it in preparing for and in
trying the case, including, but not limited to, investigative costs,
court costs and reasonable attorney's fees.
6.2 CONSENT TO JURISDICTION. The
parties submit to the jurisdiction and venue of the courts of the
State of Maryland.
6.3 NO JURY TRIAL. NEITHER PARTY SHALL
ELECT A TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM
ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT.
6.4 ARBITRATION. Any dispute between
the Company and the Physician Executive concerning any part of the
Physician Executive's compensation arising under SECTION 3 or SECTION 4
hereof shall be resolved by binding arbitration pursuant to the terms of
SCHEDULE 6.4, attached hereto as a part hereof.
7. OTHER PROVISIONS.
7.1 NOTICES. Any notice or other
communication required or which may be given hereunder shall be in
writing and shall be delivered personally, telegraphed, telexed, sent by
facsimile transmission or sent by certified, registered or express mail,
postage paid, and shall be deemed given when so delivered personally,
telegraphed, telexed or sent by facsimile transmission or, if mailed,
four days after the date of mailing, as follows:
14
<PAGE>
(i) if to the Company, to:
Doctors Health System, Inc.
10451 Mill Run Circle
10th Floor
Owings Mills, Maryland 21117
Attention: President
Doctors Health System, Inc.
10451 Mill Run Circle
10th Floor
Owings Mills, Maryland 21117
Attention: Director of Legal Services
(ii) if to the Physician Executive, to:
Scott M. Rifkin
Doctors Health System, Inc.
10451 Mill Run Circle
10th Floor
Owings Mills, Maryland 21117
Any party may by notice given in accordance with this Section
to the other party designate another address or person for receipt of notices
hereunder.
7.2 ENTIRE AGREEMENT. This Agreement
contains the entire agreement between the parties with respect to the
subject matter hereof and supersedes all prior agreements and
understandings, written or oral, with respect thereto, including the
Prior Agreement.
7.3 WAIVERS AND AMENDMENTS. This
Agreement may be amended, modified, superseded, canceled, renewed
or extended, and the terms and conditions hereof may be waived, only by
a written instrument signed by the Physician Executive and a duly
authorized officer of the Company (each, in such capacity, a party) or,
in the case of a waiver, by the party waiving compliance. No delay on
the part of any party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof, nor shall any waiver on the
15
<PAGE>
part of any party of any right, power or privilege hereunder, nor any
single or partial exercise of any right, power or privilege hereunder,
preclude any other or further exercise thereof or the exercise of any
other right, power or privilege hereunder.
7.4 GOVERNING LAW. This Agreement
has been negotiated and is to be performed in the State of Maryland,
and shall be governed and construed in accordance with the laws of the
State of Maryland applicable to agreements made and to be performed
entirely within such State.
7.5 COUNTERPARTS. This Agreement may
be executed in two or more counterparts, each of which shall be
deemed an original but all of which together shall constitute one and
the same instrument.
7.6 CONFIDENTIALITY. Neither party
shall disclose the contents of this Agreement or of any other agreement
they have simultaneously entered into to any person, firm or entity,
except the agents or representatives of the parties, or except as
required by law.
7.7 WORD FORMS. Whenever used herein,
the singular shall include the plural and the plural shall include the
singular. The use of any gender, tense or conjugation shall include all
genders, tenses and conjugations.
7.8 HEADINGS. The Section headings have
been included for convenience only, are not part of this Agreement,
and are not to be used to interpret any provision hereof.
7.9 BINDING EFFECT AND BENEFIT. This
Agreement shall be binding upon and inure to the benefit of the
parties, their successors, heirs, personal representatives and other
legal representatives. This Agreement may be assigned by the Company to
any entity which buys substantially all of the Company's assets.
However, the Physician Executive may not assign this Agreement without
the prior written consent of the Company.
7.10 SEPARABILITY. The covenants
contained in this Agreement are separable, and if any court of
competent jurisdiction declares any of them to be invalid or
unenforceable, that declaration of invalidity or unenforceability shall
not affect the validity or enforceability of any of the other covenants,
each of which shall remain in full force and effect.
7.11 CONSENT OR APPROVAL. Whenever under
the terms of this Agreement the approval or consent of the Company is
required or the Company must make any determination, the Company, unless
this Agreement specifically requires otherwise, may not unreasonably
withhold or delay that consent or approval.
7.12 BACKGROUND. The Background is a part of this
Agreement.
16
<PAGE>
[SIGNATURES ON NEXT PAGE]
17
<PAGE>
IN WITNESS WHEREOF, the parties, intending to be legally
bound, have executed this Agreement or caused it to be executed and attested by
their duly authorized officers as a document under seal on the day and year
first above written.
ATTEST/WITNESS: DOCTORS HEALTH, INC.
/s/ Paul Serini By: /s/ Stewart B. Gold
___________________, Secretary _________________________(SEAL)
Stewart B. Gold, President
PHYSICIAN EXECUTIVE:
/s/ Thomas Mapp /s/ Scott M. Rifkin
___________________ _________________________(SEAL)
Scott M. Rifkin
18
<PAGE>
SCHEDULE 6.4
ARBITRATION PROCEDURE
1. INSTITUTION OF ARBITRATION PROCEEDING.
1.1. Any party to this Agreement (an "Initiating Party") may initiate
an arbitration proceeding (the "Proceeding") to resolve a dispute subject to
resolution under this Schedule (a "Dispute") by giving written notice (the
"Dispute Notice") to the other party (the "Responding Party") to such Dispute.
The Dispute Notice shall describe the substance of the Dispute with sufficient
specificity to give the Responding Party adequate notice of its nature. Unless
otherwise specified, time periods specified in this Schedule 6.4 shall be
calculated from the date of the Dispute Notice (the "Commencement Date").
2. SELECTION OF ARBITRAL PANEL.
2.1. The Arbitral Panel (the "Panel") shall consist of three
arbitrators, two of whom (the "Party Designated Arbitrators") shall be selected
by the parties pursuant to Section 2.2 hereof. The third arbitrator shall be a
"Neutral Arbitrator" selected by the Party Designated Arbitrators pursuant to
Section 2.3 hereof.
2.2. The Initiating Party shall designate its Party Designated
Arbitrator in the Dispute Notice. Within fifteen days of the Commencement Date,
the Responding Party shall designate its Party Designated Arbitrator.
2.3. Within forty-five days of the Commencement Date, the two Party
Designated Arbitrators shall agree upon and appoint a Neutral Arbitrator who
shall be an accountant and a partner in an international, "Big Six" accounting
firm.
2.4. Each party agrees promptly to disclose to the other party any
circumstances known to it which would cause reasonable doubt regarding the
impartiality of an individual under consideration or appointed as the Neutral
Arbitrator and any such individual shall also promptly disclose to the parties
any such circumstances.
2.5. During the process of selecting the Neutral Arbitrator and
thereafter during the course of this Proceeding, ex parte communications with
the Neutral Arbitrator or any individual under consideration as the Neutral
Arbitrator are prohibited and shall be disclosed by the party making any ex
parte communication, the Neutral Arbitrator or any individual under
consideration as a Neutral Arbitrator immediately upon discovery.
19
<PAGE>
3. PRE-HEARING PROCEDURES.
3.1. Within fifteen days of the appointment of the Neutral Arbitrator,
the Panel may convene a Pre-Hearing Conference to, inter alia, familiarize the
Neutral Arbitrator with the nature of the Dispute between the Parties, determine
the need for and the nature of discovery and establish a procedural schedule for
the further conduct of the Proceeding.
4. DISCOVERY.
4.1. Discovery, appropriately limited by the nature of the Dispute, is
expressly contemplated and permitted. However, the Parties acknowledge and agree
that one of the benefits of resolving Disputes through arbitration is the
opportunity reasonably to limit discovery. The Parties further agree that they
will endeavor to agree upon procedures and a schedule for discovery that will
result in a prompt and fair hearing under these procedures.
4.2. Discovery requests and responses need not be served upon the Panel
but the Panel shall promptly convene upon motion of either party to resolve
discovery disputes, if any.
4.3. Discovery will be completed within sixty days of the Pre-Hearing
Conference.
5. SUBMISSION OF EVIDENCE AND HEARING.
5.1. The Panel may receive evidence in the form of written statements
filed prior to Hearing for cross-examination on such statements or may receive
oral testimony at Hearing. Each party shall be entitled to submit rebuttal
testimony. The Panel may also permit opening and closing statements of counsel
at Hearing.
5.2. The Panel shall convene for Hearing the evidence and argument of
the parties at a time and place to be established by the Panel. The Hearing
shall be held no later than thirty days after the close of discovery or thirty
days after the Pre-Hearing Conference if there is no discovery.
5.3. At the Hearing, and for all other purposes related to the
Proceeding, the Initiating Party shall be deemed the party seeking affirmative
relief, shall go first and shall bear the burdens of proof and of persuasion.
5.4. The Hearing shall be transcribed.
6. POST-HEARING PROCEDURES.
20
<PAGE>
6.1. The Panel may request Post-Hearing briefs and, if it does so,
shall establish a schedule for submission of such briefs at the close of
Hearing.
6.2. Within thirty days of the later of the close of the Hearing or its
receipt of Post-Hearing briefs, the Panel shall issue a written Decision and
Award which shall include findings of fact and explain the reasons for the
Decision.
7. CONFIDENTIALITY.
7.1. Unless otherwise agreed, the Proceeding and all information and
documents relating to it shall be kept confidential by the Parties, the Panel,
witnesses and all other persons involved with the Proceeding. Specifically, but
without limitation, the Confidential Information of the parties shall be
safeguarded and maintained as confidential by all participants in the
Proceeding.
8. COSTS.
8.1. The Neutral Arbitrator's fees and expenses, and all expenses of
the Pre-Hearing Conference, Hearing or any other aspect of the Proceeding not
directly attributable to either party, such as the cost of transcription of
Panel Hearings and rental of Hearing rooms, shall be borne equally by the
parties.
8.2. The Panel shall in its Decision and Award determine whether and to
what extent either party is a prevailing party and entitled to an award of its
costs, including attorneys' fees.
9. MISCELLANEOUS.
9.1. The parties may agree at any time to depart from these procedures,
including the time periods herein established. Although not favored, the Panel
may also permit departures from these procedures and time periods absent
agreement of the parties to prevent a miscarriage of justice.
9.2. Until the Neutral Arbitrator is appointed, any issue relating to
the Proceeding that is not provided for in these procedures shall be governed by
the Commercial Arbitration Rules of the American Arbitration Association. Once
the Neutral Arbitrator is appointed, the Panel is empowered to resolve all
issues not contemplated by these procedures and upon which the parties cannot
agree.
9.3. The Panel may grant any remedy or relief that it deems just and
equitable and within the scope of the agreement of the parties, including, but
not limited to, specific performance of a contract, injunctive relief or other
equitable relief.
21
<PAGE>
9.4. These procedures contemplate a two-party Proceeding. If there are
more than two parties to a Proceeding, and they are unable by unanimous
agreement to align themselves as two parties, each party shall be entitled to
all the rights of a party hereunder, including specifically but without
limitation the right to appoint a Party Designated Arbitrator, and the Neutral
Arbitrator shall have a number of votes as to all matters decided by the Panel
equal to the sum of (i) the votes of all Party Designated Arbitrators, and (ii)
one.
9.5. The Panel may, in its discretion, convene and act by conference
call for all purposes other than taking oral testimony.
22
Exhibit 10.51
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
AMENDED AND RESTATED EMPLOYMENT AGREEMENT, entered into on
December 9, 1994 (the "Signing Date"), amended on February 24, 1995 and July 15,
1997, and dated as of the 1st day of July, 1994 (the "Effective Date"), between
DOCTORS HEALTH, INC. (formerly Doctors Health System, Inc.), a Maryland
corporation (the "Company") and ALAN KIMMEL (the " Physician Executive").
-------------
BACKGROUND
-------------
The Company is engaged, directly or through service contracts
with others, in the business of (i) negotiating contracts to provide health care
services and products, (ii) managing health care providers, and (iii) providing
health care services and products (the "Business").
The Physician Executive is a primary care physician with
substantial skills and knowledge in the management and development of physician
practices, and is experienced in creating and expanding a physician run equity
model group practice working with hospitals, managed care organizations and
other physicians.
The Executive and the Company previously entered into an
Amended and Restated Employment Agreement dated February 24, 1995, a copy of
which is attached hereto (the "Prior Agreement"), and each desires to amend and
restate the Prior Agreement in its entirety to incorporate certain additional
matters.
The Company desires to hire the Physician Executive, and the
Physician Executive desires to work for the Company, on the terms and conditions
set forth in this Agreement.
1. EMPLOYMENT, DUTIES AND ACCEPTANCE.
1.1 EMPLOYMENT. (a) Effective upon the
Effective Date, the Company shall employ the Physician Executive as its
Treasurer, Secretary and Executive Vice President and Director of Medical
Affairs. In such capacities, the Physician Executive have the duty,
responsibility and authority for designing and implementing medical and
non-medical policies
<PAGE>
and procedures, and for the supervision and coordination of: credentialling
processes, prospective quality assurance and clinical utilization, disease
management strategies, alignment of clinical and financial performance,
primary/specialty care balance, incentive based physician compensation, group
malpractice issues, medical resource management, clinical operational changes
for managed primary care systems, professional dispute mediation, patient
ombudsman issues relating to disputes with medical staff care, and transition
strategies from illness care to well care, all after consultation with the
Company's Executive Vice President and Director of Development and subject to
the guidelines, policies and control of the Company's Chief Executive Officer
and Board of Directors (the "Board"), to whom he shall report. The Physician
Executive shall perform such other duties within these general parameters as the
Chief Executive Officer or the Board may from time to time designate. The
Physician Executive shall perform his duties faithfully and to the best of his
abilities. The Physician Executive shall also serve (A) as a director of the
Company (subject to the power of the Board and the Shareholders of the Company
to remove him as set forth in the Company's Bylaws) and, (B) as a director of
all of the Company's Subsidiaries (as defined in SECTION 5.2).
(b) The Physician Executive shall devote a significant portion
of his working time and creative energies to the performance of his duties
hereunder and will at such times devote such efforts as are reasonably
sufficient for fulfilling the significant responsibilities entrusted to him. So
long as such activities, in the aggregate, do not interfere with the performance
by the Physician Executive of his duties hereunder: (i) the Physician Executive
shall be permitted a reasonable amount of time to engage in the practice of
medicine as an employee of Baltimore Medical Group, Inc. and to supervise his
personal, passive, investments; (ii) the Physician Executive shall be permitted
a reasonable amount of time to participate (as board member, officer or
volunteer) in civic, political and charitable activities; (iii) the Physician
Executive shall be permitted to deliver lectures to and teach at educational
institutions and business organizations; and (iv) subject to the provisions of
SECTION 5 hereof, the Physician Executive may serve as a director or trustee of
one or more corporations not affiliated with the Company.
1.2 PLACE OF EMPLOYMENT. The Physician
Executive's principal place of employment shall be in the Baltimore, Maryland
metropolitan area, subject to such travel as may be reasonably required by his
employment pursuant to the terms hereof. The Physician Executive shall not be
required to relocate outside of the Baltimore, Maryland metropolitan area during
the Term except by mutual agreement.
2. TERM OF EMPLOYMENT. The term of the Physician Executive's
employment under this Agreement (the "Term") shall commence on the Effective
Date and shall end on April 1, 2000, unless sooner terminated, or later
extended, as herein provided. Not later than February 1, 2000 (and each February
1 of each calendar year during any Extension Period (defined below)), the
Company and the Physician Executive shall enter into good faith
2
<PAGE>
negotiations to determine whether and on what terms to extend or renew this
Agreement beyond June 30 of such calendar year. If by October 15, 1999 (and
October 15 of any calendar year occurring during an Extension Period) either
party gives written notice to the other of its desire to terminate this
Agreement as of April 1, then this Agreement shall so terminate, and the
Physician Executive shall be permitted a reasonable amount of time during the
balance of the Term within which to explore alternative employment
opportunities. If no such written notice to terminate is given by either party
by October 15, 1999 (or by October 15 of any calendar year occurring during an
Extension Period), then the Term shall, without further act or deed,
automatically be extended upon the same terms and conditions as previously in
effect, for an additional 12 month period, commencing on April 1 of the
applicable calendar year and ending on March 31 of the immediately following
calendar year. Each such 12 month extension during the Term is referred to
herein as an "Extension Period", and shall constitute a part of the Term of this
Agreement for all purposes, including the provisions regarding extensions
contained in this Section 2.
3. COMPENSATION.
3.1 SALARY. As compensation for all services
to be rendered pursuant to this Agreement, the Company shall pay to the
Physician Executive, during the Term, a "Base Salary" (as defined in this
SECTION 3.1) less such deductions as shall be required to be withheld by
applicable laws and regulations. The "Base Salary" from July 1, 1997 to December
31, 1997 shall be a salary of $125,000 per annum, subject to upward adjustment
as determined by the Executive Committee or the Board of Directors of the
Company. The amount of the Base Salary has been established based upon the
mutual assumption by the Company and the Physician Executive that the Physician
Executive shall devote approximately fifty percent (50%) of his working time and
creative energies to the performance of his duties hereunder. The Company and
the Physician Executive acknowledge and agree that because the performance by
the Physician Executive of his duties hereunder will be of critical importance
to the growth and prosperity of the Company, the Company shall from time to
time, in its reasonable discretion, evaluate and determine the working time and
creative energies that the Physician Executive has devoted to the performance of
his duties hereunder during any preceding three (3) month period (it being
understood and agreed that the Physician Executive's use of permitted vacation
hereunder shall not be included in such determination). If the Company
determines that the Physician Executive has devoted significantly more or
significantly less of his working time and creative energies to his duties
hereunder during any such period, his Base Salary will be adjusted, up or down,
by the Company (in the exercise of its reasonable discretion) on each such
occasion, commencing with the beginning of the fiscal quarter of the Company
immediately following the Signing Date. The Base Salary shall accrue from and
after the Effective Date in equal monthly installments.
3
<PAGE>
3.2 BONUS. The Physician Executive shall be
eligible to receive an annual bonus based upon the extent to which the Physician
Executive's performance meets or exceeds agreed upon performance standards or
the Physician Executive otherwise performs in an exemplary manner, all in the
sole discretion of the President and Compensation Committee of the Board of
Directors of the Company.
3.3 STOCK.
(a) All Shares of the Company's Class
A Common Stock (the "Stock") transferred to the Physician Executive hereunder
is and shall remain subject to any transfer restrictions and other protections
as are set forth in the Company's Charter, By-laws, or in any Shareholder's
Agreement, and the certificates or other instruments representing such stock
shall bear or contain a legend or statement regarding such transfer
restrictions.
3.4. WITHHOLDING. The Company is authorized to
withhold from the amount of any Salary and Bonuses and any other things of value
paid to or for the benefit of the Physician Executive (other than transfers of
Stock), all sums authorized by the Physician Executive or required to be
withheld by law, court decree, or Physician Executive order, including (but not
limited to) such things as income taxes, employment taxes, and employee
contributions to fringe benefit plans sponsored by the Company.
3.5 PARTICIPATION IN PHYSICIAN EXECUTIVE
BENEFIT PLANS. The Physician Executive shall be permitted during the Term,
if and to the extent eligible, to participate in any group life, hospitalization
or disability insurance plan, health program, automobile allowance, pension plan
or similar benefit plan of the Company which may be available to other
comparable executives and professional employees of the Company, generally on
the same terms as such other executives.
3.6 VACATION. The Physician Executive will
receive at least 4 weeks vacation per year, to be scheduled and taken at the
Physician Executive's option at such times as his duties may permit. Should the
Company's policy provide for more vacation to comparable Physician Executives
the Physician Executive will be accorded such higher vacation. Unused vacation
time shall not be cumulated or carried over nor shall the Physician Executive
receive any compensation for unused vacation time.
3.7 EXPENSES. Subject to such policies as may
from time to time be established by the Board, the Company shall pay or
reimburse the Physician Executive for all ordinary, necessary and reasonable
expenses (including, without limitation, travel, meetings, dues, subscriptions,
fees, educational expenses, computer equipment and the like) actually incurred
or paid by the Physician Executive during the Term in the performance of the
Physician Executive's services under this Agreement (including, without
limitation, expenses
4
<PAGE>
incident to attendance at board or management meetings of the Company, or its
Subsidiaries or Affiliates), upon presentation of expense statements or vouchers
or such other supporting information as the Board may require.
3.8 DEFERRED COMPENSATION. As soon as
practicable following execution of this Agreement, the Company shall pay the
Executive $60,000 in full satisfaction of all deferred compensation obligations
of the Company to him for services performed during fiscal 1995, 1996 and 1997
in the amount of $60,000.
4. TERMINATION.
4.1 TERMINATION UPON DEATH. If the Physician
Executive dies during the Term, the Physician Executive's employment shall
terminate as of the date of death of the Physician Executive.
4.2 TERMINATION UPON DISABILITY.
Notwithstanding any other provision of this Agreement, if during the Term
the Physician Executive becomes physically, mentally or emotionally disabled,
whether totally or partially, as determined by an independent qualified
physician, so that the Physician Executive is, in the good faith determination
of the Board, substantially unable to perform his services hereunder for (i) a
period of three consecutive months, or (ii) shorter periods aggregating three
months during any twelve month period, the Company may at any time after the
last day of the three consecutive months of disability or on the last day of the
shorter period aggregating three months of disability, by written notice to the
Physician Executive, terminate the Physician Executive's employment hereunder as
of the date such written notice becomes effective.
4.3 TERMINATION AT ELECTION OF COMPANY.
(a) Notwithstanding any other provision
of this Agreement, the Company may terminate the Physician Executive's
employment hereunder at any time upon: (i) the continued failure or refusal by,
or manifest inability of, the Physician Executive to perform his duties after
reasonable prior notice to the Physician Executive; (ii) the Physician Executive
engaging in any acts or omissions involving dishonesty or acts or omissions that
demonstrate a lack of integrity; (iii) the conviction of the Physician Executive
of a felony; (iv) the Physician Executive engaging in acts or omissions that
demonstrably and materially injure the business and affairs of the Company,
monetarily or otherwise; and/or (v) any knowing material misrepresentation made
by the Physician Executive to the Company or any material breach by the
Physician Executive of his obligations hereunder.
(b) In addition to the Company's right
to terminate the Physician Executive's employment pursuant to SECTION 4.3(A),
and notwithstanding any other provision
5
<PAGE>
of this Agreement, the Company may, for any or for no reason, terminate the
Physician Executive's employment upon 60 days prior written notice to the
Physician Executive.
4.4 TERMINATION BY THE PHYSICIAN EXECUTIVE.
(a) Provided that the Physician
Executive has delivered to the Board at least sixty (60) days prior written
notice setting forth in reasonable detail any alleged material breach by the
Company of this Agreement or other acts or omissions engaged in by the Company
constituting "constructive termination" of the Physician Executive's employment
with the Company, which breach, acts or omissions have not been cured by the
Company as of the end of such period to the reasonable satisfaction of the
Physician Executive, then, notwithstanding any other provision of this
Agreement, the Physician Executive shall be entitled to terminate his employment
for such reasons, effective immediately upon the delivery by the Physician
Executive to the Board of a notice to the effect that such breach, acts or
omissions have not been cured to the reasonable satisfaction of the Physician
Executive; provided, however, that if such constructive termination is caused by
the Physician Executive's incapacity or inability to serve due to a disability
of the type described in SECTION 4.2 above and the Company elects to terminate
the Physician Executive pursuant to the provisions of SECTION 4.2, the Physician
Executive shall, for purposes of this Agreement, be deemed to have been
terminated pursuant to the provisions of SECTION 4.2 and not of this SECTION
4.4.
(b) For purposes of this SECTION 4.4,
"constructive termination" shall be limited to those circumstances where (i) the
Company creates working conditions that a reasonable person in the Physician
Executive's position would consider unreasonable or intolerable which is not
remedied by the Company within sixty (60) days after notice thereof given by the
Physician Executive; and (ii) such working conditions are not generally
applicable to other Physician executives of the Company.
4.5 COMPENSATION AND BENEFITS FOLLOWING
TERMINATION OF EMPLOYMENT.
(a) In the event of termination of the
Physician Executive's employment for any reason other than a termination
pursuant to SECTION 4.3(B) or SECTION 4.4 (or a termination caused merely by the
expiration of the Term): (i) all compensation and other benefits payable or
provided hereunder shall cease as of the date of termination; (ii) Base Salary
(if any) then payable or accrued through the date of termination; and (iii) all
accrued benefits (if any) then payable to the Physician Executive pursuant to
the terms of any plans or arrangements referred to in SECTION 3.5 shall be paid
to the Physician Executive (or to his heirs, legatees and/or legal
representatives) through the date of termination.
(b) In the event of termination of the
Physician Executive's employment pursuant to SECTION 4.3(B) or SECTION 4.4,
the Physician Executive (or, in the
6
<PAGE>
event of the Physician Executive's subsequent death or disability, his heirs,
legatees and/or legal representatives) shall receive, when and as the same would
have been payable hereunder if the Physician Executive's employment had not been
so terminated, each of the following payments and benefits:
(i) all accrued benefits (if
any) then payable to the Physician Executive pursuant to the terms of any
plans or arrangements referred to in SECTION 3.5; and
(ii) with respect to any periods
after June 30, 1996, 50% of the Base Salary which would have been due to the
Physician Executive from July 1, 1996 through the remainder of the Term, at the
times such payments would otherwise be made, all as if this Agreement were still
in effect.
(c) In the event of termination under
SECTION 4.2 (disability), the Physician Executive or his legal
representative, as the case may be, shall, in addition to such other payments as
may be due hereunder, be entitled to receive the proceeds of any disability
policies maintained by the Company and payable to the Physician Executive.
5. CERTAIN COVENANTS OF THE PHYSICIAN EXECUTIVE.
5.1 NECESSITY FOR COVENANTS. The Physician Executive
acknowledges that (i) the Company, its Subsidiaries and its Affiliates (as
defined in SECTION 5.2) are engaged in the Business, and will in the future be
engaged in the Business; (ii) his work and providing management services to
health care entities for the Company and its Affiliates will give him access to
customers and suppliers of, and trade secrets of and confidential information
concerning, the Company, its Subsidiaries and its Affiliates; and (iii) the
agreements and covenants contained in this SECTION 5 are essential to protect
the business and goodwill of the Company, its Subsidiaries and its Affiliates.
In order to induce the Company to enter into this Agreement and pay the
compensation and other benefits at the levels requested by the Physician
Executive, the Physician Executive enters into the following covenants:
5.2 DEFINITIONS.
(a) For purposes of SECTIONS 5.3 through
5.8 only, the term "Company" shall include the Company and all of the
Company's, Subsidiaries and Affiliates.
(b) "Provider" shall mean any health care
service provider or Affiliate thereof to whom the Company provided management or
other services.
(c) "Payor" means any insurer,
employer, health maintenance organization, preferred provider organization,
health benefit plan or other entity or organization
7
<PAGE>
to which, or to whose members, insured's, employees, enrollees, beneficiaries or
other persons affiliated with it (collectively "Beneficiaries"), the Company
provides services or products.
(d) "Service Area" means the geographic area
in which the Company provides health care services and in which the
Beneficiaries of those services generally reside, which shall include all areas
within a 25 mile radius of the site of any Provider's office.
(e) "Subsidiary" means any person or
entity in which the Company owns, beneficially or otherwise, an equity
interest of more than 50%.
(f) "Affiliate" means a Subsidiary of
the Company; a person or entity which is owned, controlled, or operated by the
Company; any person owning an equity interest in the Company; any person who has
appointed the Company as its exclusive agent for the provision of professional
services and the collection of revenues therefrom; and any partner, member,
employee, owner or agent of any Affiliate and any person or entity which is
under common ownership, control or operation with the specified person or
entity.
5.3 RESTRICTIONS. During the Term and, unless
the Physician Executive's employment is terminated other than pursuant to
SECTIONS 4.3(B) or 4.4 hereof, for a period of twelve (12) months after the
Physician Executive's employment hereunder is terminated (the "Termination
Date") (the "Restricted Period"), the Physician Executive shall not, directly or
indirectly, for himself or on behalf of any other person, firm, corporation or
other entity, whether as a principal, agent, employee, stockholder, partner,
officer, member, director, sole proprietor, or otherwise:
(a) call upon or solicit any Provider
for the purpose of persuading the Provider to engage the Physician Executive
or any other person, firm, corporation or other entity to provide services which
are the same or similar to those the Company provided to the Provider;
(b) call upon or solicit any Payor for
the purpose of persuading the Payor to engage any person or entity other that
the Company to provide health care services to the Payor with respect to any of
its Beneficiaries in the Service Area;
(c) solicit, participate in or promote
the solicitation of any person who was employed by the Company or a Provider
at any time during the twelve (12) months preceding the Termination Date to
leave the employ of the Company, or hire or engage any of those persons;
8
<PAGE>
(d) make any disparaging remarks about
the Company's business, services or personnel;
(e) interfere in any way with the
Company's business, prospects or personnel; or
(f) become affiliated with or render
services to any person engaged in any business that competes with the Business
within the Service Area, directly or indirectly, in any capacity, including,
without limitation, as an individual, partner, shareholder, officer, director,
principal, agent, employee, trustee or consultant; provided, however, that the
Physician Executive may own, directly or indirectly, solely as an investment,
securities which are publicly traded if the Physician Executive (a) is not a
controlling person of, or a member of a group which controls, the issuer and (b)
does not, directly or indirectly, own 5% or more of any class of securities of
the issuer.
5.4 TRADE SECRETS AND CONFIDENTIAL INFORMATION
5.4.1 TRADE SECRETS DEFINED. The term
"Trade Secrets," as used in this Agreement, includes, without limitation,
(i) all information concerning billing practices and procedures of the Company,
(ii) the rates and amounts that the Company pays to its personnel, (iii)
information about the Company's contracts with insurers, health maintenance
organizations, employers, and other payors, (iv) all formulae, compilations,
programs, devices, lists, methods, techniques or processes of the Company, and
(v) all other information of the Company that would be deemed to be "trade
secrets" within the meaning of the Maryland Uniform Trade Secrets Act (the
"Act").
5.4.2 CONFIDENTIAL INFORMATION DEFINED.
Any other information not qualifying as a Trade Secret, but relating to the
business of the Company which is disclosed by the Company to the Physician
Executive, or is discovered by the Physician Executive in the course of
employment, is Confidential Information.
5.4.3 DUTY TO MAINTAIN SECRECY AND
CONFIDENTIALITY. During the Period of the Physician Executive's employment
with the Company, the Physician Executive shall maintain the secrecy and
confidentiality of the Trade Secrets and the Confidential Information and shall
not (i) divulge, furnish or make accessible to anyone or in any way or use, for
his own benefit or for the benefit of any other individual firm or entity (other
than in the ordinary course of the Company's business), any Trade Secret or
Confidential Information; (ii) take or permit any action to be taken which would
reduce the value of the Trade Secrets or Confidential information to the
Company; or (iii) otherwise misappropriate or suffer the misappropriation of the
Trade Secrets or the Confidential information, within the meaning of the Act.
After the Termination Date, Physician Executive shall continue to maintain the
9
<PAGE>
secrecy and confidentiality of such information, but only to the extent that the
Physician Executive is prohibited from directly or indirectly competing with
Company pursuant to the provisions of SECTION 5.3.
5.4.4 INFORMATION WHICH IS PUBLICLY
KNOWN. Notwithstanding anything herein to the contrary, the obligations
of secrecy and confidentiality set forth herein shall not apply to any
information which is now generally publicly known or which subsequently becomes
generally publicly known other than as a direct or indirect result of the breach
of this Agreement by the Physician Executive, or which is required by law or
order of any court to be disclosed.
5.5 PROPERTY OF THE COMPANY. All memoranda,
notes, lists, records and other documents or papers (and all copies thereof),
including but not limited to, such items stored in computer memories, on
microfiche or by any other means, made or compiled by or on behalf of the
Physician Executive, or made available to the Physician Executive concerning the
Business, are and shall be the property of the Company and shall be delivered to
the Company promptly upon the termination of the Physician Executive's
employment with the Company or at any other time on request; provided however,
that the Physician Executive may inspect during normal business hours such
records as shall be necessary for the purpose of assisting the Physician
Executive to file, or prepare for an audit of, his personal income tax returns.
5.6 PHYSICIAN EXECUTIVE'S IDEAS, ETC. All
inventions, prototypes, discoveries, improvements, innovations and the like
("Inventions") and all works of original authorship or images that are fixed in
any tangible medium of expression and all copies thereof ("Works") which are
designed, created or developed by Physician Executive, solely or in conjunction
with others, in the course of performance of the Physician Executive's duties
which relate to the Business, shall be made or conceived for the exclusive
benefit of and shall be the exclusive property of the Company. The Physician
Executive shall immediately notify the Company upon the design, creation or
development of all Inventions and Works. At any time thereafter, the Physician
Executive, at the request and expense of the Company, shall execute and deliver
to the Company all documents or instruments which may be necessary to secure or
perfect the Company's title to or interest in the Inventions and Works,
including but not limited to applications for letters of patent, and extensions,
continuations or reissues thereof, applications for copyrights and documents or
instruments of assignment or transfer. All Works are agreed and stipulated to be
"works made for hire," as that term is used and understood within the Copyright
Act of 1976, as amended. To the extent any Works are not deemed to be works made
for hire as defined above, and to the extent that title to or ownership of any
Invention or Work and all other rights therein are not otherwise vested
exclusively in the Company, the Physician Executive shall, without further
consideration but at the expense of the Company, assign and transfer to the
Company the Physician Executive's
10
<PAGE>
entire right, title and interest (including copyrights and patents) in or to
those Inventions and Works.
5.7 RIGHTS AND REMEDIES UPON BREACH. If the
Physician Executive breaches, or threatens to commit a breach of, any of the
provisions of SECTIONS 5.1 through 5.6 (the "Restrictive Covenants"), the
Company shall, in addition to its right immediately to terminate this Agreement,
have the right and remedy (which right and remedy shall be independent of others
and severally enforceable, and which shall be in addition to, and not in lieu
of, any other rights and remedies available to the Company under law or in
equity) to have the Restrictive Covenants specifically enforced by any court
having equity jurisdiction, it being acknowledged and agreed that any such
breach or threatened breach could cause irreparable injury to the Company or its
Affiliates and that money damages may not provide adequate remedy to the
Company.
5.8 COVENANTS CURRENTLY BINDING PHYSICIAN
EXECUTIVE. The Physician Executive warrants that his employment by the Company
will not (a) violate any non-disclosure agreements, covenants against
competition, or other restrictive covenants made by the Physician Executive to
or for the benefit of any previous employer or partner, or (b) violate or
constitute a breach or default under, any statute, law, judgment, order, decree,
writ, injunction, deed, instrument, contract, lease, license or permit to which
the Physician Executive is a party or by which the Physician Executive is bound.
5.9 LITIGATION. There is no litigation,
proceeding or investigation of any nature (either civil or criminal) which is
pending or, to the best of the Physician Executive's knowledge, threatened
against or affecting the Physician Executive or which would adversely affect his
ability to substantially perform the duties herein.
5.10 REVIEW. The Physician Executive has
received or been given the opportunity to review the provisions of this
Agreement, and the meaning and effect of each provision, with independent legal
counsel of the Physician Executive's choosing.
5.11 SEVERABILITY OF COVENANTS. The
Physician Executive acknowledges and agrees that the Restrictive Covenants
are reasonable and valid in geographical and temporal scope and in all respects.
If any court determines that any of the Restrictive Covenants, or any part
thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants
shall not thereby be affected and shall be given full effect, without regard to
the invalid portions.
5.12 BLUE-PENCILING. If any court determines
that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographic scope of such provision, such court shall
have the power to reduce the duration or scope of such
11
<PAGE>
provision, as the case may be, and, in its reduced form, such provision shall
then be enforceable and shall be enforced. If any such court declines to so
revise such covenant, the parties agree to negotiate in good faith a
modification that will make such duration or scope enforceable.
5.13 ENFORCEABILITY IN JURISDICTIONS. The
parties intend to and hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of
such Covenants. If the courts of any one or more of such jurisdictions hold any
Restrictive Covenant unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the parties that such determination not bar or
in any way affect the Company's right to the relief provided above in the courts
of any other jurisdiction within the geographical scope of such Covenants, as to
breaches of such Covenants in such other respective jurisdictions, such
Covenants as they relate to each jurisdiction being, for this purpose, severable
into diverse and independent covenants.
5.14 EXTENSION. If the Physician Executive
violates any Restrictive Covenant, the Company shall not be deprived of the
full benefit of the period of the covenant. Accordingly, the duration of that
covenant shall be extended by the period of any violation of that covenant.
5.15 REMEDIES. The Company shall be entitled to
injunctive or other equitable relief because it will be caused irreparable
injury and damage by a breach of the provisions of any of the Restrictive
Covenants. The right to injunctive relief shall include the right to both
preliminary and permanent injunctions. The Company shall not be required to post
a bond or other similar assurance if it brings an action to enforce the
provisions of any of the Restrictive Covenants. The Company's right to equitable
relief shall not preclude any other rights or remedies which the Company may
have, all of which rights and remedies are cumulative.
6. DISPUTE RESOLUTION.
6.1 COSTS OF LITIGATION. If either party files suit
or brings an arbitration proceeding to enforce its rights under this Agreement,
the prevailing party shall be entitled to recover from the other party all
expenses incurred by it in preparing for and in trying the case, including, but
not limited to, investigative costs, court costs and reasonable attorney's fees.
6.2 CONSENT TO JURISDICTION. The parties
submit to the jurisdiction and venue of the courts of the State of Maryland.
12
<PAGE>
6.3 NO JURY TRIAL. NEITHER PARTY SHALL ELECT A
TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM ARISING OUT OF
OR IN ANY WAY CONNECTED WITH THIS AGREEMENT.
6.4 ARBITRATION. Any dispute between the
Company and the Physician Executive concerning any part of the Physician
Executive's compensation arising under SECTION 3 or SECTION 4 hereof shall be
resolved by binding arbitration pursuant to the terms of SCHEDULE 6.4, attached
hereto as a part hereof.
7. OTHER PROVISIONS.
7.1 NOTICES. Any notice or other communication
required or which may be given hereunder shall be in writing and shall be
delivered personally, telegraphed, telexed, sent by facsimile transmission or
sent by certified, registered or express mail, postage paid, and shall be deemed
given when so delivered personally, telegraphed, telexed or sent by facsimile
transmission or, if mailed, four days after the date of mailing, as follows:
(i) if to the Company, to:
Doctors Health, Inc.
10451 Mill Run Circle, 10th Floor
Owings Mills, Maryland 21117
Attention: President
with copy to:
Doctors Health, Inc.
10451 Mill Run Circle, 10th Floor
Owings Mills, Maryland 21117
Attention: Director of Legal Services
(ii) if to the Physician Executive, to:
Alan Kimmel
Two Park Center Court
Owings Mills, Maryland 21117
13
<PAGE>
Any party may by notice given in accordance with this Section
to the other party designate another address or person for receipt of notices
hereunder.
7.2 ENTIRE AGREEMENT. This Agreement
contains the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements and understandings, written or
oral, with respect thereto, including the Prior Agreement.
7.3 WAIVERS AND AMENDMENTS. This Agreement
may be amended, modified, superseded, canceled, renewed or extended, and the
terms and conditions hereof may be waived, only by a written instrument signed
by the Physician Executive and a duly authorized officer of the Company (each,
in such capacity, a party) or, in the case of a waiver, by the party waiving
compliance. No delay on the part of any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof, nor shall any waiver on
the part of any party of any right, power or privilege hereunder, nor any single
or partial exercise of any right, power or privilege hereunder, preclude any
other or further exercise thereof or the exercise of any other right, power or
privilege hereunder.
7.4 GOVERNING LAW. This Agreement has been
negotiated and is to be performed in the State of Maryland, and shall be
governed and construed in accordance with the laws of the State of Maryland
applicable to agreements made and to be performed entirely within such State.
7.5 COUNTERPARTS. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument.
7.6 CONFIDENTIALITY. Neither party shall
disclose the contents of this Agreement or of any other agreement they have
simultaneously entered into to any person, firm or entity, except the agents or
representatives of the parties, or except as required by law.
7.7 WORD FORMS. Whenever used herein, the
singular shall include the plural and the plural shall include the singular. The
use of any gender, tense or conjugation shall include all genders, tenses and
conjugations.
7.8 HEADINGS. The Section headings have been
included for convenience only, are not part of this Agreement, and are not to
be used to interpret any provision hereof.
7.9 BINDING EFFECT AND BENEFIT. This Agreement
shall be binding upon and inure to the benefit of the parties, their successors,
heirs, personal representatives and other legal representatives. This Agreement
may be assigned by the Company to any entity which
14
<PAGE>
buys substantially all of the Company's assets. However, the Physician Executive
may not assign this Agreement without the prior written consent of the Company.
7.10 SEPARABILITY. The covenants contained in
this Agreement are separable, and if any court of competent jurisdiction
declares any of them to be invalid or unenforceable, that declaration of
invalidity or unenforceability shall not affect the validity or enforceability
of any of the other covenants, each of which shall remain in full force and
effect.
7.11 CONSENT OR APPROVAL. Whenever under the terms
of this Agreement the approval or consent of the Company is required or the
Company must make any determination, the Company, unless this Agreement
specifically requires otherwise, may not unreasonably withhold or delay that
consent or approval.
7.12 BACKGROUND. The Background is a part of this
Agreement.
15
<PAGE>
IN WITNESS WHEREOF, the parties, intending to be legally
bound, have executed this Agreement or caused it to be executed and attested by
their duly authorized officers as a document under seal on the day and year
first above written.
ATTEST/WITNESS: DOCTORS HEALTH, INC.
/s/ Paul Serini , Secretary By: /s/ Stewart Gold (SEAL)
___________________ _________________________
Stewart Gold, President
PHYSICIAN EXECUTIVE:
/s/ George Kohutiak /s/ Alan Kimmel (SEAL)
___________________ __________________________________
Alan Kimmel
Attorney-In-Fact
16
<PAGE>
SCHEDULE 6.4
ARBITRATION PROCEDURE
1. INSTITUTION OF ARBITRATION PROCEEDING.
1.1. Any party to this Agreement (an "Initiating Party") may initiate
an arbitration proceeding (the "Proceeding") to resolve a dispute subject to
resolution under this Schedule (a "Dispute") by giving written notice (the
"Dispute Notice") to the other party (the "Responding Party") to such Dispute.
The Dispute Notice shall describe the substance of the Dispute with sufficient
specificity to give the Responding Party adequate notice of its nature. Unless
otherwise specified, time periods specified in this Schedule 6.4 shall be
calculated from the date of the Dispute Notice (the "Commencement Date").
2. SELECTION OF ARBITRAL PANEL.
2.1. The Arbitral Panel (the "Panel") shall consist of three
arbitrators, two of whom (the "Party Designated Arbitrators") shall be selected
by the parties pursuant to Section 2.2 hereof. The third arbitrator shall be a
"Neutral Arbitrator" selected by the Party Designated Arbitrators pursuant to
Section 2.3 hereof.
2.2. The Initiating Party shall designate its Party Designated
Arbitrator in the Dispute Notice. Within fifteen days of the Commencement Date,
the Responding Party shall designate its Party Designated Arbitrator.
2.3. Within forty-five days of the Commencement Date, the two Party
Designated Arbitrators shall agree upon and appoint a Neutral Arbitrator who
shall be an accountant and a partner in an international, "Big Six" accounting
firm.
2.4. Each party agrees promptly to disclose to the other party any
circumstances known to it which would cause reasonable doubt regarding the
impartiality of an individual under consideration or appointed as the Neutral
Arbitrator and any such individual shall also promptly disclose to the parties
any such circumstances.
2.5. During the process of selecting the Neutral Arbitrator and
thereafter during the course of this Proceeding, ex parte communications with
the Neutral Arbitrator or any individual under consideration as the Neutral
Arbitrator are prohibited and shall be disclosed by the party making any ex
parte communication, the Neutral Arbitrator or any individual under
consideration as a Neutral Arbitrator immediately upon discovery.
17
<PAGE>
3. PRE-HEARING PROCEDURES.
3.1. Within fifteen days of the appointment of the Neutral Arbitrator,
the Panel may convene a Pre-Hearing Conference to, inter alia, familiarize the
Neutral Arbitrator with the nature of the Dispute between the Parties, determine
the need for and the nature of discovery and establish a procedural schedule for
the further conduct of the Proceeding.
4. DISCOVERY.
4.1. Discovery, appropriately limited by the nature of the Dispute, is
expressly contemplated and permitted. However, the Parties acknowledge and agree
that one of the benefits of resolving Disputes through arbitration is the
opportunity reasonably to limit discovery. The Parties further agree that they
will endeavor to agree upon procedures and a schedule for discovery that will
result in a prompt and fair hearing under these procedures.
4.2. Discovery requests and responses need not be served upon the Panel
but the Panel shall promptly convene upon motion of either party to resolve
discovery disputes, if any.
4.3. Discovery will be completed within sixty days of the Pre-Hearing
Conference.
5. SUBMISSION OF EVIDENCE AND HEARING.
5.1. The Panel may receive evidence in the form of written statements
filed prior to Hearing for cross-examination on such statements or may receive
oral testimony at Hearing. Each party shall be entitled to submit rebuttal
testimony. The Panel may also permit opening and closing statements of counsel
at Hearing.
5.2. The Panel shall convene for Hearing the evidence and argument of
the parties at a time and place to be established by the Panel. The Hearing
shall be held no later than thirty days after the close of discovery or thirty
days after the Pre-Hearing Conference if there is no discovery.
5.3. At the Hearing, and for all other purposes related to the
Proceeding, the Initiating Party shall be deemed the party seeking affirmative
relief, shall go first and shall bear the burdens of proof and of persuasion.
5.4. The Hearing shall be transcribed.
6. POST-HEARING PROCEDURES.
18
<PAGE>
6.1. The Panel may request Post-Hearing briefs and, if it does so,
shall establish a schedule for submission of such briefs at the close of
Hearing.
6.2. Within thirty days of the later of the close of the Hearing or its
receipt of Post-Hearing briefs, the Panel shall issue a written Decision and
Award which shall include findings of fact and explain the reasons for the
Decision.
7. CONFIDENTIALITY.
7.1. Unless otherwise agreed, the Proceeding and all information and
documents relating to it shall be kept confidential by the Parties, the Panel,
witnesses and all other persons involved with the Proceeding. Specifically, but
without limitation, the Confidential Information of the parties shall be
safeguarded and maintained as confidential by all participants in the
Proceeding.
8. COSTS.
8.1. The Neutral Arbitrator's fees and expenses, and all expenses of
the Pre-Hearing Conference, Hearing or any other aspect of the Proceeding not
directly attributable to either party, such as the cost of transcription of
Panel Hearings and rental of Hearing rooms, shall be borne equally by the
parties.
8.2. The Panel shall in its Decision and Award determine whether and to
what extent either party is a prevailing party and entitled to an award of its
costs, including attorneys' fees.
9. MISCELLANEOUS.
9.1. The parties may agree at any time to depart from these procedures,
including the time periods herein established. Although not favored, the Panel
may also permit departures from these procedures and time periods absent
agreement of the parties to prevent a miscarriage of justice.
9.2. Until the Neutral Arbitrator is appointed, any issue relating to
the Proceeding that is not provided for in these procedures shall be governed by
the Commercial Arbitration Rules of the American Arbitration Association. Once
the Neutral Arbitrator is appointed, the Panel is empowered to resolve all
issues not contemplated by these procedures and upon which the parties cannot
agree.
9.3. The Panel may grant any remedy or relief that it deems just and
equitable and within the scope of the agreement of the parties, including, but
not limited to, specific performance of a contract, injunctive relief or other
equitable relief.
19
<PAGE>
9.4. These procedures contemplate a two-party Proceeding. If there are
more than two parties to a Proceeding, and they are unable by unanimous
agreement to align themselves as two parties, each party shall be entitled to
all the rights of a party hereunder, including specifically but without
limitation the right to appoint a Party Designated Arbitrator, and the Neutral
Arbitrator shall have a number of votes as to all matters decided by the Panel
equal to the sum of (i) the votes of all Party Designated Arbitrators, and (ii)
one.
9.5. The Panel may, in its discretion, convene and act by conference
call for all purposes other than taking oral testimony.
Exhibit 10.52
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
AMENDED AND RESTATED EMPLOYMENT AGREEMENT, entered into on
November 4, 1994 (the "Signing Date"), amended on February 24, 1995 and July 15,
1997, and dated as of the 1st day of July, 1994 (the "Effective Date"), between
DOCTORS HEALTH, INC. (formerly Doctors Health System, Inc.), a Maryland
corporation (the "Company") and STEWART GOLD (the "Executive").
-------------
BACKGROUND
-------------
The Company is engaged, directly or through service contracts
with others, in the business of (i) negotiating contracts to provide health care
services and products, (ii) managing health care providers and (iii) providing
health care services and products (the "Business").
The Executive is experienced in creating new business
opportunities that take advantage of inefficiencies in existing markets,
managing health care organizations and in raising capital.
The Executive and the Company previously entered into an
Amended and Restated Employment Agreement dated February 24, 1995, a copy of
which is attached hereto (the "Prior Agreement"), and each desires to amend and
restate the Prior Agreement in its entirety to incorporate certain additional
matters.
The Company desires to hire Executive, and the Executive
desires to work for the Company, on the terms and conditions set forth in this
Agreement.
1. EMPLOYMENT, DUTIES AND ACCEPTANCE.
1.1 EMPLOYMENT. (a) Effective upon the
Effective Date, the Company shall employ the Executive as its President and
Chief Executive Officer. In such capacities, the Executive shall have
responsibility and authority for directing and managing the operations of the
Company and its Subsidiaries within such guidelines, policies and directions as
the board of directors of the Company (the "Board") may from
<PAGE>
time to time adopt. The Executive's duties shall include raising capital,
creating new business opportunities, creating the Company's infrastructure,
supervising billings and collections, engaging auditors, attorneys and other
consultants, negotiating managed care and other contracts, and implementing and
designing non-medical policies and procedures, in each case subject to the
guidelines and policies of the Board. The Executive shall perform his duties
faithfully and to the best of his abilities. The Executive shall also serve
during the Term as a director of the Company (subject to the power of the Board
and the Shareholders of the Company to remove him as set forth in the Company's
Bylaws), and shall serve during the Term as a director of all of the Company's
Subsidiaries (as defined in SECTION 5.2), all without any additional
compensation.
(b) The Executive shall devote his full working time and
creative energies to the performance of his duties hereunder and will at all
times devote such additional time and efforts as are reasonably sufficient for
fulfilling the significant responsibilities entrusted to him. So long as such
activities, in the aggregate, do not interfere with the performance by the
Executive of his duties hereunder: (i) the Executive shall be permitted a
reasonable amount of time to supervise his personal, passive, investments; (ii)
the Executive shall be permitted a reasonable amount of time to participate (as
board member, officer or volunteer) in civic, political and charitable
activities; (iii) the Executive shall be permitted to deliver lectures to and
teach at educational institutions and business organizations; and (iv) subject
to the provisions of SECTION 5 hereof, the Executive may serve as a director or
trustee of one or more corporations not affiliated with the Company.
1.2 PLACE OF EMPLOYMENT. The Executive's
principal place of employment shall be in the Baltimore, Maryland metropolitan
area, subject to such travel as may be reasonably required by his employment
pursuant to the terms hereof. The Executive shall not be required to relocate
outside of the Baltimore, Maryland metropolitan area during the Term unless the
Company provides relocation benefits acceptable to the Executive in his sole
discretion.
2. TERM OF EMPLOYMENT. The term of the Executive's employment
under this Agreement (the "Term") shall commence on the Effective Date and shall
end on April 1, 2000, unless sooner terminated, or later extended, as herein
provided. Not later than February 1, 2000 (and each February 1 of each calendar
year during any Extension Period (defined below)), the Company and the Executive
shall enter into good faith negotiations to determine whether and on what terms
to extend or renew this Agreement beyond April 1 of such calendar year. If by
October 15, 1999 (and October 15 of any calendar year occurring during an
Extension Period) either party gives written notice to the other of its desire
to terminate this Agreement as of April 1, then this Agreement shall so
terminate, and the Executive shall be permitted a reasonable
2
<PAGE>
amount of time during the balance of the Term within which to explore
alternative employment opportunities. If no such written notice to terminate is
given by either party by October 15, 1999 (or by October 15 of any calendar year
occurring during an Extension Period), then the Term shall, without further act
or deed, automatically be extended upon the same terms and conditions as
previously in effect, for an additional 12 month period, commencing on April 1
of the applicable calendar year and ending on March 31 of the immediately
following calendar year. Each such 12 month extension during the Term is
referred to herein as an "Extension Period", and shall constitute a part of the
Term of this Agreement for all purposes, including the provisions regarding
extensions contained in this Section 2.
3. COMPENSATION.
3.1 SALARY. As compensation for all services
to be rendered pursuant to this Agreement, the Company shall pay to the
Executive, during the Term, a "Base Salary" (as defined in this SECTION 3.1)
less such deductions as shall be required to be withheld by applicable laws and
regulations. The "Base Salary" from July 1, 1997 to December 31, 1997 shall be a
salary of $280,000 per annum, subject to upward adjustment as determined by the
Executive Comittee or the Board of Directors of the Company. The Base Salary
shall accrue from and after the Effective Date, and shall be payable in arrears
in equal monthly installments.
3.2 BONUS. The Executive shall be eligible to
receive an annual bonus based upon the extent to which the Executive's
performance meets or exceeds agreed upon performance standards or the Executive
otherwise performs in an exemplary manner, all in the sole discretion of the
Compensation Committee of the Board of Directors of the Company.
3.3 STOCK. The Executive holds 600,000
Shares of the Company's Class A Common Stock, all of which are vested in the
Executive and not subject to forfeiture. All Shares of the Company's Class A
Common Stock (the "Stock") held by the Executive hereunder is and shall remain
subject to the transfer restrictions and other protections as are set forth in
the Company's Amended and Restated Articles, By-laws, or in any Shareholder's
Agreement, and the certificates or other instruments representing such stock
shall bear or contain a legend or statement regarding such transfer
restrictions.
3.4. WITHHOLDING. Except for the payment
contemplated under SECTION 3.1(A), the Company is authorized to withhold from
the amount of any Salary and Bonuses and any other things of value paid to or
for the benefit of the Executive (other than transfers of Stock), all sums
authorized by the Executive or required to be withheld by law, court decree, or
executive order, including (but not limited to) such
3
<PAGE>
things as income taxes, employment taxes, and employee contributions to fringe
benefit plans sponsored by the Company.
3.5 PARTICIPATION IN EXECUTIVE BENEFIT PLANS.
The Executive shall be permitted during the Term, if and to the extent
eligible, to participate in any group life, hospitalization or disability
insurance plan, health program, automobile allowance, pension plan or similar
benefit plan of the Company which may be available to other comparable
executives or professional employees, including physicians, of the Company
generally on the same terms as such other executives.
3.6 VACATION. The Executive will receive at
least 4 weeks vacation per year, to be scheduled and taken at the Executive's
option at such times as his duties may permit. Should the Company's policy
provide for more vacation to comparable executives the Executive will be
accorded such higher vacation. Unused vacation time shall not be cumulated or
carried over nor shall the Executive receive any compensation for unused
vacation time.
3.7 EXPENSES. Subject to such policies as may
from time to time be established by the Board, the Company shall pay or
reimburse the Executive for all ordinary, necessary and reasonable expenses
(including, without limitation, travel, meetings, dues, subscriptions, fees,
educational expenses, computer equipment and the like) actually incurred or paid
by the Executive during the Term in the performance of the Executive's services
under this Agreement (including, without limitation, expenses incident to
attendance at board or management meetings of the Company, or its Subsidiaries
or Affiliates), upon presentation of expense statements or vouchers or such
other supporting information as the Board may require.
3.8 DEFERRED COMPENSATION. As soon as
practicable following execution of this Agreement, the Company shall pay the
Executive $75,000 in full satisfaction of all deferred compensation obligations
to him for services performed from the Signing Date to June 30, 1997.
4. TERMINATION.
4.1 TERMINATION UPON DEATH. If the Executive dies
during the Term, the Executive's employment shall terminate as of the date of
death of the Executive.
4.2 TERMINATION UPON DISABILITY.
Notwithstanding any other provision of this Agreement, if during the Term
the Executive becomes physically, mentally or emotionally disabled, whether
totally or partially, as determined by an independent qualified physician, so
that the Executive is, in the good faith determination
4
<PAGE>
of the Board, substantially unable to perform his services hereunder for (i) a
period of three consecutive months, or (ii) shorter periods aggregating three
months during any twelve month period, the Company may at any time after the
last day of the three consecutive months of disability or on the last day of the
shorter period aggregating three months of disability, by written notice to the
Executive, terminate the Executive's employment hereunder as of the date such
written notice becomes effective.
4.3 TERMINATION AT ELECTION OF COMPANY.
(a) Notwithstanding any other
provision of this Agreement, the Company may terminate the Executive's
employment hereunder at any time upon: (i) the continued failure or refusal by,
or manifest inability of, the Executive to perform his duties after reasonable
prior notice to the Executive; (ii) the Executive engaging in any acts or
omissions involving dishonesty or acts or omissions that demonstrate a lack of
integrity; (iii) the conviction of the Executive of a felony; (iv) the Executive
engaging in acts or omissions that demonstrably and materially injure the
business and affairs of the Company, monetarily or otherwise; and/or (v) any
knowing material misrepresentation made by the Executive to the Company or any
material breach by the Executive of his obligations hereunder.
(b) In addition to the Company's
right to terminate the Executive's employment pursuant to SECTION 4.3(A),
and notwithstanding any other provision of this Agreement, the Company may, for
any or for no reason, terminate the Executive's employment upon 60 days prior
written notice to the Executive.
4.4 TERMINATION BY THE EXECUTIVE.
(a) Provided that the Executive has
delivered to the Board at least sixty (60) days prior written notice setting
forth in reasonable detail any alleged material breach by the Company of this
Agreement or other acts or omissions engaged in by the Company constituting
"constructive termination" of the Executive's employment with the Company, which
breach, acts or omissions have not been cured by the Company as of the end of
such period to the reasonable satisfaction of the Executive, then,
notwithstanding any other provision of this Agreement, the Executive shall be
entitled to terminate his employment for such reasons, effective immediately
upon the delivery by the Executive to the Board of a notice to the effect that
such breach, acts or omissions have not been cured to the reasonable
satisfaction of the Executive; provided, however, that if such constructive
termination is caused by the Executive's incapacity or inability to serve due to
a disability of the type described in SECTION 4.2 above and the Company elects
to terminate the Executive pursuant to the provisions of SECTION 4.2, the
Executive shall, for purposes of this Agreement, be
5
<PAGE>
deemed to have been terminated pursuant to the provisions of SECTION 4.2 and not
of this SECTION 4.4.
(b) For purposes of this SECTION 4.4,
"constructive termination" shall be limited to those circumstances where (i)
the Company creates working conditions that a reasonable person in the
Executive's position would consider unreasonable or intolerable which is not
remedied by the Company within sixty (60) days after notice thereof given by the
Executive; and (ii) such working conditions are not generally applicable to
other executives of the Company.
4.5 COMPENSATION AND BENEFITS FOLLOWING
TERMINATION OF EMPLOYMENT.
(a) In the event of termination of
the Executive's employment for any reason other than a termination pursuant
to SECTION 4.3(B) or SECTION 4.4 (or a termination caused merely by the
expiration of the Term): (i) all compensation and other benefits payable or
provided hereunder shall cease as of the date of termination; (ii) Base Salary
(if any) then payable or accrued through the date of termination; (iii) all
accrued benefits (if any) then payable to the Executive pursuant to the terms of
any plans or arrangements referred to in SECTION 3.5 shall be paid to the
Executive (or to his heirs, legatees and/or legal representatives) through the
date of termination; and (iv) any shares of stock that remain unvested pursuant
to SECTION 3.3 shall immediately be forfeited to the Company.
(b) In the event of termination of the
Executive's employment pursuant to SECTION 4.3(B) or SECTION 4.4, the
Executive (or, in the event of the Executive's subsequent death or disability,
his heirs, legatees and/or legal representatives) shall receive, at the times
and as the same would have been payable hereunder if the Executive's employment
had not been so terminated, each of the following payments and benefits:
(i) all accrued benefits (if
any) then payable to the Executive pursuant to the terms of any plans or
arrangements referred to in SECTION 3.5; and
(ii) with respect to any periods
after June 30, 1996, 50% of the Base Salary which would have been due to the
Executive from July 1, 1996 through the remainder of the Term, at the times such
payments would otherwise be made, all as if this Agreement were still in effect.
(c) In the event of termination
under SECTION 4.2 (disability), the Executive or his legal representative, as
the case may be, shall, in
6
<PAGE>
addition to such other payments as may be due hereunder, be entitled to receive
the proceeds of any disability policies maintained by the Company and payable to
the Executive.
5. CERTAIN COVENANTS OF THE EXECUTIVE.
5.1 NECESSITY FOR COVENANTS. The Executive
acknowledges that (i) the Company, its Subsidiaries and its Affiliates (as
defined in SECTION 5.2) are engaged in the business, directly or through service
contracts with others, of providing primary and specialized medical and related
health care services and related products (the "Company Business"), and will in
the future be engaged in the Company Business; (ii) his work and providing
management services to health care entities for the Company and its Affiliates
will give him access to customers and suppliers of, and trade secrets of and
confidential information concerning, the Company, its Subsidiaries and its
Affiliates; and (iii) the agreements and covenants contained in this SECTION 5
are essential to protect the business and goodwill of the Company, its
Subsidiaries and its Affiliates. In order to induce the Company to enter into
this Agreement and pay the compensation and other benefits at the levels
requested by the Executive, the Executive enters into the following covenants:
5.2 DEFINITIONS.
(a) For purposes of SECTIONS 5.3
through 5.8 only, the term "Company" shall include the Company and all of the
Company's, Subsidiaries and Affiliates.
(b) "Provider" shall mean any health
care service provider or Affiliate thereof to whom the Company provided
management or other services.
(c) "Payor" means any insurer,
employer, health maintenance organization, preferred provider organization,
health benefit plan or other entity or organization to which, or to whose
members, insured's, employees, enrollees, beneficiaries or other persons
affiliated with it (collectively "Beneficiaries"), the Company provides services
or products.
(d) "Service Area" means the
geographic area in which the Company provides health care services and in
which the Beneficiaries of those services generally reside, which shall include
all areas within a 25 mile radius of the site of any Provider's office.
7
<PAGE>
(e) "Subsidiary" means any person or
entity in which the Company owns, beneficially or otherwise, an equity
interest of more than 50%.
(f) "Affiliate" means a Subsidiary of
the Company; a person or entity which is owned, controlled, or operated by
the Company; any person owning an equity interest in the Company; any person who
has appointed the Company as its exclusive agent for the provision of
professional services and the collection of revenues therefrom; and any partner,
member, employee, owner or agent of any Affiliate and any person or entity which
is under common ownership, control or operation with the specified person or
entity.
5.3 RESTRICTIONS. During the Term and,
unless the Executive's employment is terminated other than pursuant to
SECTIONS 4.3(B) or 4.4 hereof, for a period of twelve (12) months after the
Executive's employment hereunder is terminated (the "Termination Date") (the
"Restricted Period"), the Executive shall not, directly or indirectly, for
himself or on behalf of any other person, firm, corporation or other entity,
whether as a principal, agent, employee, stockholder, partner, officer, member,
director, sole proprietor, or otherwise:
(a) call upon or solicit any Provider
for the purpose of persuading the Provider to engage the Executive or any
other person, firm, corporation or other entity to provide services which are
the same or similar to those the Company provided to the Provider;
(b) call upon or solicit any Payor
for the purpose of persuading the Payor to engage any person or entity other
that the Company to provide health care services to the Payor with respect to
any of its Beneficiaries in the Service Area;
(c) solicit, participate in or promote
the solicitation of any person who was employed by the Company or a Provider at
any time during the twelve (12) months preceding the Termination Date to leave
the employ of the Company, or hire or engage any of those persons;
(d) make any disparaging remarks about
the Company's business, services or personnel;
(e) interfere in any way with the
Company's business, prospects or personnel; or
(f) become affiliated with or render
services to any person engaged in any business that competes with the Company
Business within the
8
<PAGE>
Service Area, directly or indirectly, in any capacity, including, without
limitation, as an individual, partner, shareholder, officer, director,
principal, agent, employee, trustee or consultant; provided, however, that the
Executive may own, directly or indirectly, solely as an investment, securities
which are publicly traded if the Executive (a) is not a controlling person of,
or a member of a group which controls, the issuer and (b) does not, directly or
indirectly, own 5% or more of any class of securities of the issuer.
5.4 TRADE SECRETS AND CONFIDENTIAL INFORMATION
5.4.1 TRADE SECRETS DEFINED. The term
"Trade Secrets," as used in this Agreement, includes, without limitation, (i)
all information concerning billing practices and procedures of the Company, (ii)
the rates and amounts that the Company pays to its personnel, (iii) information
about the Company's contracts with insurers, health maintenance organizations,
employers, and other payors, (iv) all formulae, compilations, programs, devices,
lists, methods, techniques or processes of the Company, and (v) all other
information of the Company that would be deemed to be "trade secrets" within the
meaning of the Maryland Uniform Trade Secrets Act (the "Act").
5.4.2 CONFIDENTIAL INFORMATION
DEFINED. Any other information not qualifying as a Trade Secret, but
relating to the business of the Company which is disclosed by the Company to the
Executive, or is discovered by the Executive in the course of employment, is
Confidential Information.
5.4.3 DUTY TO MAINTAIN SECRECY AND
CONFIDENTIALITY. During the Period of the Executive's employment with the
Company, the Executive shall maintain the secrecy and confidentiality of the
Trade Secrets and the Confidential Information and shall not (i) divulge,
furnish or make accessible to anyone or in any way or use, for his own benefit
or for the benefit of any other individual firm or entity (other than in the
ordinary course of the Company's business), any Trade Secret or Confidential
Information; (ii) take or permit any action to be taken which would reduce the
value of the Trade Secrets or Confidential information to the Company; or (iii)
otherwise misappropriate or suffer the misappropriation of the Trade Secrets or
the Confidential information, within the meaning of the Act. After Termination
Date, Executive shall continue to maintain the secrecy and confidentiality of
such information, but only to the extent that the Executive is prohibited from
directly or indirectly competing with Company pursuant to the provisions of
SECTION 5.3.
5.4.4 INFORMATION WHICH IS PUBLICLY
KNOWN. Notwithstanding anything herein to the contrary, the obligations of
secrecy and confidentiality set forth herein shall not apply to any information
which is now generally publicly known or which subsequently becomes generally
publicly known other than as
9
<PAGE>
a direct or indirect result of the breach of this Agreement by the Executive, or
which is required by law or order of any court to be disclosed.
5.5 PROPERTY OF THE COMPANY. All memoranda,
notes, lists, records and other documents or papers (and all copies thereof),
including but not limited to, such items stored in computer memories, on
microfiche or by any other means, made or compiled by or on behalf of the
Executive, or made available to the Executive concerning the Company Business,
are and shall be the property of the Company and shall be delivered to the
Company promptly upon the termination of the Executive's employment with the
Company or at any other time on request; provided however, that the Executive
may inspect during normal business hours such records as shall be necessary for
the purpose of assisting the Executive to file, or prepare for an audit of, his
personal income tax returns.
5.6 EXECUTIVE'S IDEAS, ETC. All
inventions, prototypes, discoveries, improvements, innovations and the
like ("Inventions") and all works of original authorship or images that are
fixed in any tangible medium of expression and all copies thereof ("Works")
which are designed, created or developed by Executive, solely or in conjunction
with others, in the course of performance of the Executive's duties which relate
to the Company Business, shall be made or conceived for the exclusive benefit of
and shall be the exclusive property of the Company. The Executive shall
immediately notify the Company upon the design, creation or development of all
Inventions and Works. At any time thereafter, the Executive, at the request and
expense of the Company, shall execute and deliver to the Company all documents
or instruments which may be necessary to secure or perfect the Company's title
to or interest in the Inventions and Works, including but not limited to
applications for letters of patent, and extensions, continuations or reissues
thereof, applications for copyrights and documents or instruments of assignment
or transfer. All Works are agreed and stipulated to be "works made for hire," as
that term is used and understood within the Copyright Act of 1976, as amended.
To the extent any Works are not deemed to be works made for hire as defined
above, and to the extent that title to or ownership of any Invention or Work and
all other rights therein are not otherwise vested exclusively in the Company,
the Executive shall, without further consideration but at the expense of the
Company, assign and transfer to the Company the Executive's entire right, title
and interest (including copyrights and patents) in or to those Inventions and
Works.
5.7 RIGHTS AND REMEDIES UPON BREACH. If the
Executive breaches, or threatens to commit a breach of, any of the provisions
of SECTIONS 5.1 through 5.6 (the "Restrictive Covenants"), the Company shall, in
addition to its right immediately to terminate this Agreement, have the right
and remedy (which right and remedy shall be independent of others and severally
enforceable, and which shall be in addition to, and not in lieu of, any other
rights and remedies available to the Company
10
<PAGE>
under law or in equity) to have the Restrictive Covenants specifically enforced
by any court having equity jurisdiction, it being acknowledged and agreed that
any such breach or threatened breach could cause irreparable injury to the
Company or its Affiliates and that money damages may not provide adequate remedy
to the Company.
5.8 COVENANTS CURRENTLY BINDING EXECUTIVE.
The Executive warrants that his employment by the Company will not (a)
violate any non-disclosure agreements, covenants against competition, or other
restrictive covenants made by the Executive to or for the benefit of any
previous employer or partner, or (b) violate or constitute a breach or default
under, any statute, law, judgment, order, decree, writ, injunction, deed,
instrument, contract, lease, license or permit to which the Executive is a party
or by which the Executive is bound.
5.9 LITIGATION. There is no litigation,
proceeding or investigation of any nature (either civil or criminal) which is
pending or, to the best of the Executive's knowledge, threatened against or
affecting the Executive or which would adversely affect his ability to
substantially perform the duties herein.
5.10 REVIEW. The Executive has received or
been given the opportunity to review the provisions of this Agreement, and the
meaning and effect of each provision, with independent legal counsel of the
Executive's choosing.
5.11 SEVERABILITY OF COVENANTS. The Executive
acknowledges and agrees that the Restrictive Covenants are reasonable and valid
in geographical and temporal scope and in all respects. If any court determines
that any of the Restrictive Covenants, or any part thereof, is invalid or
unenforceable, the remainder of the Restrictive Covenants shall not thereby be
affected and shall be given full effect, without regard to the invalid portions.
5.12 BLUE-PENCILING. If any court
determines that any of the Restrictive Covenants, or any part thereof, is
unenforceable because of the duration or geographic scope of such provision,
such court shall have the power to reduce the duration or scope of such
provision, as the case may be, and, in its reduced form, such provision shall
then be enforceable and shall be enforced. If any such court declines to so
revise such covenant, the parties agree to negotiate in good faith a
modification that will make such duration or scope enforceable.
5.13 ENFORCEABILITY IN JURISDICTIONS. The
parties intend to and hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of
such Covenants. If the courts of any one or more of such jurisdictions hold any
Restrictive Covenant unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the parties that such
11
<PAGE>
determination not bar or in any way affect the Company's right to the relief
provided above in the courts of any other jurisdiction within the geographical
scope of such Covenants, as to breaches of such Covenants in such other
respective jurisdictions, such Covenants as they relate to each jurisdiction
being, for this purpose, severable into diverse and independent covenants.
5.14 EXTENSION. If the Executive violates any
Restrictive Covenant, the Company shall not be deprived of the full benefit of
the period of the covenant. Accordingly, the duration of that covenant shall be
extended by the period of any violation of that covenant.
5.15 REMEDIES. The Company shall be entitled
to injunctive or other equitable relief because it will be caused irreparable
injury and damage by a breach of the provisions of any of the Restrictive
Covenants. The right to injunctive relief shall include the right to both
preliminary and permanent injunctions. The Company shall not be required to post
a bond or other similar assurance if it brings an action to enforce the
provisions of any of the Restrictive Covenants. The Company's right to equitable
relief shall not preclude any other rights or remedies which the Company may
have, all of which rights and remedies are cumulative.
6. DISPUTE RESOLUTION.
6.1 COSTS OF LITIGATION. If either party files suit
or brings an arbitration proceeding to enforce its rights under this Agreement,
the prevailing party shall be entitled to recover from the other party all
expenses incurred by it in preparing for and in trying the case, including, but
not limited to, investigative costs, court costs and reasonable attorney's fees.
6.2 CONSENT TO JURISDICTION. The parties
submit to the jurisdiction and venue of the courts of the State of Maryland.
6.3 NO JURY TRIAL. NEITHER PARTY SHALL ELECT A
TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR
IN ANY WAY CONNECTED WITH THIS AGREEMENT.
6.4 ARBITRATION. Any dispute between the
Company and the Executive concerning any part of the Executive's compensation
arising under SECTION 3 or SECTION 4 hereof shall be resolved by binding
arbitration pursuant to the terms of SCHEDULE 6.4, attached hereto as a part
hereof.
7. OTHER PROVISIONS.
12
<PAGE>
7.1 NOTICES. Any notice or other communication
required or which may be given hereunder shall be in writing and shall be
delivered personally, telegraphed, telexed, sent by facsimile transmission or
sent by certified, registered or express mail, postage paid, and shall be deemed
given when so delivered personally, telegraphed, telexed or sent by facsimile
transmission or, if mailed, four days after the date of mailing, as follows:
(i) if to the Company, to:
Doctors Health System, Inc.
10451 Mill Run Circle, 10th Floor
Owings Mills, Maryland 21117
Attention: Chairman
with copy to:
Doctors Health System, Inc.
10451 Mill Run Circle, 10th Floor
Owings Mills, Maryland 21117
Attention: Director of Legal Services
(ii) if to the Executive, to:
Stewart Gold
One Aston Court
Owings Mills, Maryland 21117-1437
Any party may by notice given in accordance with this Section
to the other party designate another address or person for receipt of notices
hereunder.
7.2 ENTIRE AGREEMENT. This Agreement contains
the entire agreement between the parties with respect to the subject matter
hereof and supersedes all prior agreements and understandings, written or oral,
with respect thereto, including the Prior Agreement.
7.3 WAIVERS AND AMENDMENTS. This Agreement may
be amended, modified, superseded, canceled, renewed or extended, and the terms
and conditions hereof may be waived, only by a written instrument signed by the
Executive and a duly authorized officer of the Company (each, in such capacity,
a party) or, in the case of a waiver, by the party waiving compliance. No delay
on the part of any party in
13
<PAGE>
exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or
privilege hereunder, nor any single or partial exercise of any right, power or
privilege hereunder, preclude any other or further exercise thereof or the
exercise of any other right, power or privilege hereunder.
7.4 GOVERNING LAW. This Agreement has been
negotiated and is to be performed in the State of Maryland, and shall be
governed and construed in accordance with the laws of the State of Maryland
applicable to agreements made and to be performed entirely within such State.
7.5 COUNTERPARTS. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument.
7.6 CONFIDENTIALITY. Neither party shall
disclose the contents of this Agreement or of any other agreement they have
simultaneously entered into to any person, firm or entity, except the agents or
representatives of the parties, or except as required by law.
7.7 WORD FORMS. Whenever used herein, the
singular shall include the plural and the plural shall include the singular.
The use of any gender, tense or conjugation shall include all genders, tenses
and conjugations.
7.8 HEADINGS. The Section headings have been
included for convenience only, are not part of this Agreement, and are not to
be used to interpret any provision hereof.
7.9 BINDING EFFECT AND BENEFIT. This Agreement
shall be binding upon and inure to the benefit of the parties, their successors,
heirs, personal representatives and other legal representatives. This Agreement
may be assigned by the Company to any entity which buys substantially all of the
Company's assets. However, the Executive may not assign this Agreement without
the prior written consent of the Company.
7.10 SEPARABILITY. The covenants contained in
this Agreement are separable, and if any court of competent jurisdiction
declares any of them to be invalid or unenforceable, that declaration of
invalidity or unenforceability shall not affect the validity or enforceability
of any of the other covenants, each of which shall remain in full force and
effect.
14
<PAGE>
7.11 CONSENT OR APPROVAL. Whenever under the
terms of this Agreement the approval or consent of the Company is required or
the Company must make any determination, the Company, unless this Agreement
specifically requires otherwise, may not unreasonably withhold or delay that
consent or approval.
7.12 BACKGROUND. The Background is a part of this
Agreement.
15
<PAGE>
IN WITNESS WHEREOF, the parties, intending to be legally
bound, have executed this Agreement or caused it to be executed and attested by
their duly authorized officers as a document under seal on the day and year
first above written.
ATTEST/WITNESS: DOCTORS HEALTH SYSTEM, INC.
/s/ Thomas Mapp By: /s/ Paul Serini
___________________ _______________________(SEAL)
Assistant Secretary
EXECUTIVE:
/s/ Thomas Mapp /s/ Stewart Gold
___________________ _____________________________(SEAL)
Stewart Gold
16
<PAGE>
SCHEDULE 6.4
ARBITRATION PROCEDURE
1. INSTITUTION OF ARBITRATION PROCEEDING.
1.1. Any party to this Agreement (an "Initiating Party") may initiate
an arbitration proceeding (the "Proceeding") to resolve a dispute subject to
resolution under this Schedule (a "Dispute") by giving written notice (the
"Dispute Notice") to the other party (the "Responding Party") to such Dispute.
The Dispute Notice shall describe the substance of the Dispute with sufficient
specificity to give the Responding Party adequate notice of its nature. Unless
otherwise specified, time periods specified in this Schedule 6.4 shall be
calculated from the date of the Dispute Notice (the "Commencement Date").
2. SELECTION OF ARBITRAL PANEL.
2.1. The Arbitral Panel (the "Panel") shall consist of three
arbitrators, two of whom (the "Party Designated Arbitrators") shall be selected
by the parties pursuant to Section 2.2 hereof. The third arbitrator shall be a
"Neutral Arbitrator" selected by the Party Designated Arbitrators pursuant to
Section 2.3 hereof.
2.2. The Initiating Party shall designate its Party Designated
Arbitrator in the Dispute Notice. Within fifteen days of the Commencement Date,
the Responding Party shall designate its Party Designated Arbitrator.
2.3. Within forty-five days of the Commencement Date, the two Party
Designated Arbitrators shall agree upon and appoint a Neutral Arbitrator who
shall be an accountant and a partner in an international, "Big Six" accounting
firm.
2.4. Each party agrees promptly to disclose to the other party any
circumstances known to it which would cause reasonable doubt regarding the
impartiality of an individual under consideration or appointed as the Neutral
Arbitrator and any such individual shall also promptly disclose to the parties
any such circumstances.
2.5. During the process of selecting the Neutral Arbitrator and
thereafter during the course of this Proceeding, ex parte communications with
the Neutral Arbitrator or any individual under consideration as the Neutral
Arbitrator are prohibited and shall be disclosed by the party making any ex
parte communication, the Neutral Arbitrator or any individual under
consideration as a Neutral Arbitrator immediately upon discovery.
17
<PAGE>
3. PRE-HEARING PROCEDURES.
3.1. Within fifteen days of the appointment of the Neutral Arbitrator,
the Panel may convene a Pre-Hearing Conference to, inter alia, familiarize the
Neutral Arbitrator with the nature of the Dispute between the Parties, determine
the need for and the nature of discovery and establish a procedural schedule for
the further conduct of the Proceeding.
4. DISCOVERY.
4.1. Discovery, appropriately limited by the nature of the Dispute, is
expressly contemplated and permitted. However, the Parties acknowledge and agree
that one of the benefits of resolving Disputes through arbitration is the
opportunity reasonably to limit discovery. The Parties further agree that they
will endeavor to agree upon procedures and a schedule for discovery that will
result in a prompt and fair hearing under these procedures.
4.2. Discovery requests and responses need not be served upon the Panel
but the Panel shall promptly convene upon motion of either party to resolve
discovery disputes, if any.
4.3. Discovery will be completed within sixty days of the Pre-Hearing
Conference.
5. SUBMISSION OF EVIDENCE AND HEARING.
5.1. The Panel may receive evidence in the form of written statements
filed prior to Hearing for cross-examination on such statements or may receive
oral testimony at Hearing. Each party shall be entitled to submit rebuttal
testimony. The Panel may also permit opening and closing statements of counsel
at Hearing.
5.2. The Panel shall convene for Hearing the evidence and argument of
the parties at a time and place to be established by the Panel. The Hearing
shall be held no later than thirty days after the close of discovery or thirty
days after the Pre-Hearing Conference if there is no discovery.
5.3. At the Hearing, and for all other purposes related to the
Proceeding, the Initiating Party shall be deemed the party seeking affirmative
relief, shall go first and shall bear the burdens of proof and of persuasion.
5.4. The Hearing shall be transcribed.
18
<PAGE>
6. POST-HEARING PROCEDURES.
6.1. The Panel may request Post-Hearing briefs and, if it does so,
shall establish a schedule for submission of such briefs at the close of
Hearing.
6.2. Within thirty days of the later of the close of the Hearing or its
receipt of Post-Hearing briefs, the Panel shall issue a written Decision and
Award which shall include findings of fact and explain the reasons for the
Decision.
7. CONFIDENTIALITY.
7.1. Unless otherwise agreed, the Proceeding and all information and
documents relating to it shall be kept confidential by the Parties, the Panel,
witnesses and all other persons involved with the Proceeding. Specifically, but
without limitation, the Confidential Information of the parties shall be
safeguarded and maintained as confidential by all participants in the
Proceeding.
8. COSTS.
8.1. The Neutral Arbitrator's fees and expenses, and all expenses of
the Pre-Hearing Conference, Hearing or any other aspect of the Proceeding not
directly attributable to either party, such as the cost of transcription of
Panel Hearings and rental of Hearing rooms, shall be borne equally by the
parties.
8.2. The Panel shall in its Decision and Award determine whether and to
what extent either party is a prevailing party and entitled to an award of its
costs, including attorneys' fees.
9. MISCELLANEOUS.
9.1. The parties may agree at any time to depart from these procedures,
including the time periods herein established. Although not favored, the Panel
may also permit departures from these procedures and time periods absent
agreement of the parties to prevent a miscarriage of justice.
9.2. Until the Neutral Arbitrator is appointed, any issue relating to
the Proceeding that is not provided for in these procedures shall be governed by
the Commercial Arbitration Rules of the American Arbitration Association. Once
the Neutral Arbitrator is appointed, the Panel is empowered to resolve all
issues not contemplated by these procedures and upon which the parties cannot
agree.
19
<PAGE>
9.3. The Panel may grant any remedy or relief that it deems just and
equitable and within the scope of the agreement of the parties, including, but
not limited to, specific performance of a contract, injunctive relief or other
equitable relief.
9.4. These procedures contemplate a two-party Proceeding. If there are
more than two parties to a Proceeding, and they are unable by unanimous
agreement to align themselves as two parties, each party shall be entitled to
all the rights of a party hereunder, including specifically but without
limitation the right to appoint a Party Designated Arbitrator, and the Neutral
Arbitrator shall have a number of votes as to all matters decided by the Panel
equal to the sum of (i) the votes of all Party Designated Arbitrators, and (ii)
one.
9.5. The Panel may, in its discretion, convene and act by conference
call for all purposes other than taking oral testimony.
Exhibit 10.53
REGISTRATION RIGHTS AGREEMENT
by and between
DOCTORS HEALTH SYSTEM, INC.
and
THE BEACON GROUP III - FOCUS VALUE FUND, L.P.
Dated as of July 15, 1997
<PAGE>
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT is made as of July 15, 1997, by and
between DOCTORS HEALTH SYSTEM, INC., a Maryland corporation (the "Company") and
THE BEACON GROUP III - FOCUS VALUE FUND, L.P., a Delaware limited partnership
("Beacon").
W I T N E S S E T H:
WHEREAS, simultaneously herewith, the Company and Beacon are entering
into a Preferred Stock Purchase Agreement (the "Purchase Agreement"), pursuant
to which the Company is issuing, and Beacon is purchasing, shares of Series D
Convertible Preferred Stock, $10.00 par value per share, of the Company ("Series
D Preferred"); and
WHEREAS, simultaneously herewith, the Company, Beacon and certain other
equity holders of the Company are entering into a Shareholders' and Voting
Agreement (the "Shareholders' Agreement"); and
WHEREAS, the execution and delivery of this Agreement is a condition to
the closing of the Purchase Agreement.
NOW, THEREFORE, in consideration of the premises and of the mutual
covenants and obligations hereinafter set forth, the parties hereto hereby agree
as follows:
1. Certain Definitions.
As used in this Agreement, the following terms shall have the meanings
ascribed to them below:
"Affiliate" means (i) with respect to any Person, any other Person
directly or indirectly controlling or controlled by or under direct or indirect
common control with such specified Person or (ii) with respect to any
individual, shall also mean the spouse, sibling, child, step-child, grandchild,
niece, nephew or parent of such Person, or the spouse thereof.
"Common Stock" means any and all classes of common stock, $.01 par
value per share, of the Company and any equity securities issued or issuable
with respect to such common stock in connection with a reclassification,
recapitalization, merger, consolidation or other reorganization.
"Conversion Shares" means the shares of Class C Common Stock or other
equity securities issued or issuable upon conversion of the Series D Preferred.
-1-
<PAGE>
"Holder" or "Holders" means any party who is a signatory to this
Agreement and any party who shall hereafter acquire and hold Registrable
Securities.
"IPO" means the initial underwritten offering pursuant to which the
Common Stock becomes registered under Section 12 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act").
"Major Holder" means with respect to any registration the Holder that,
together with its Affiliates, includes the largest number of Registrable
Securities in such registration.
"Person" means any individual, corporation, limited liability company,
limited or general partnership, joint venture, association, joint-stock company,
trust, unincorporated organization or government or any agency or political
subdivisions thereof.
"Registrable Securities" means any (i) shares of Series D Preferred
owned by Beacon, whether acquired on the date hereof or hereafter acquired, (ii)
shares of Common Stock owned by Beacon, whether acquired on the date hereof or
hereafter acquired, (iii) Conversion Shares owned by Beacon, (iv) shares of
Series D Preferred or Common Stock acquired by any Person after the date hereof
pursuant to rights granted to Beacon under the Purchase Agreement or the
Shareholders' Agreement, (v) Conversion Shares acquired by any Person after the
date hereof pursuant to rights granted to Beacon under the Purchase Agreement or
the Shareholders' Agreement and (vi) shares of Common Stock issued or issuable,
directly or indirectly, with respect to the Common Stock referenced in clauses
(ii), (iii), (iv) or (v) above by way of stock dividend, stock split or
combination of shares. As to any particular Registrable Securities, such
securities shall cease to be Registrable Securities when (i) a registration
statement with respect to the sale of such securities shall have been declared
effective under the Securities Act and such securities shall have been disposed
of in accordance with such registration statement, or (ii) such securities shall
have been sold (other than in a privately negotiated sale) pursuant to Rule 144
(or any successor provision) under the Securities Act.
"Requisite Percentage of Outstanding Holders" means the Holders of
Registrable Securities who, assuming conversion of all of the then outstanding
Series D Preferred into Conversion Shares, would hold 5% or more of the total
Conversion Shares that would then be outstanding.
"Requisite Percentage of Participating Holders" means Holders of
Registrable Securities participating in the registration who, assuming
conversion of all then outstanding Series D Preferred into Conversion Shares,
would hold a majority of the total Conversion Shares that would then be held by
all Holders participating in the registration.
"SEC" means the Securities and Exchange Commission.
-2-
<PAGE>
"Securities Act" means the Securities Act of 1933, as amended.
2. Registration Rights.
2.1. Demand Registrations.
(a) Request for Registration. Subject to Section 2.1(d),
at any time and from time to time after the earlier of (i) the date six months
after the closing of an IPO and (ii) two years after the date hereof, one or
more Holders of Registrable Securities representing the Requisite Percentage of
Outstanding Holders shall have the right to require the Company to file a
registration statement under the Securities Act covering all or any part of
their respective Registrable Securities, by delivering a written request
therefor to the Company specifying the number of Registrable Securities to be
included in such registration by such Holder(s) and the intended method of
distribution thereof. All such requests pursuant to this Section 2.1(a) are
referred to herein as "Demand Registration Requests," and the registrations so
requested are referred to herein as "Demand Registrations" (with respect to any
Demand Registration, the Holder(s) making such demand for registration being
referred to as the "Initiating Holder"). As promptly as practicable, but no
later than 15 days after receipt of a Demand Registration Request, the Company
shall give written notice (the "Demand Exercise Notice") of such Demand
Registration Request to all Holders of record of Registrable Securities.
(b) Registration of Other Securities. The Company shall
include in a Demand Registration (i) the Registrable Securities of the
Initiating Holder and (ii) the Registrable Securities of any other Holder that
shall have made a written request to the Company for inclusion thereof in such
registration (which request shall specify the maximum number of Registrable
Securities intended to be disposed of by such Holder(s)) within 30 days after
the receipt of the Demand Exercise Notice.
(c) Registration. The Company shall, as expeditiously as
possible following a Demand Registration Request, use its best efforts to (i)
effect such registration under the Securities Act (including, without
limitation, by means of a shelf registration pursuant to Rule 415 under the
Securities Act if so requested and if the Company is then eligible to use such a
registration) of the Registrable Securities that the Company has been so
requested to register, for distribution in accordance with such intended method
of distribution, and (ii) if requested by the Initiating Holder or Major Holder,
obtain acceleration of the effective date of the registration statement relating
to such registration.
(d) Limitations on Requested Registrations. The rights
of Holders of Registrable Securities to request Demand Registrations pursuant to
Section 2.1(a) are subject to the following limitations: (i) the Company shall
not be obligated to effect a Demand Registration within six months after the
effective date of any other registration of securities (other than pursuant to a
registration on Form S-8 or any successor or similar form that is then in
effect) and (ii) in no event shall the Company be required to
-3-
<PAGE>
effect, in the aggregate, without regard to the Holder of Registrable Securities
making such request, more than two Demand Registrations; provided that in the
event a Demand Registration is cancelled by the Requisite Percentage of
Outstanding Holders, such Demand Registration shall only be counted as a Demand
Registration for purposes of this Section 2.1(d)(ii) if the Requisite Percentage
of Outstanding Holders do not agree to pay all Expenses of such Demand
Registration notwithstanding their rights under Section 2.5.
(e) Cutbacks. If the managing underwriter of any
underwritten offering shall advise the Holders participating in a Demand
Registration that the Registrable Securities covered by the registration
statement cannot be sold in such offering within a price range acceptable to the
Requisite Percentage of Participating Holders, then the Holders representing the
Requisite Percentage of Participating Holders shall have the right to notify the
Company in writing that they have determined that the registration statement be
abandoned or withdrawn, in which event the Company shall abandon or withdraw
such registration statement. If the managing underwriter of any underwritten
offering shall advise the Company in writing that, in its opinion, the number of
securities requested to be included in a Demand Registration exceeds the number
that can be sold in such offering within a price range acceptable to the
Requisite Percentage of Participating Holders, the Company will include in such
registration, to the extent of the number that the Company is so advised can be
sold in such offering, Registrable Securities requested to be included in such
registration, pro rata among the Holders requesting such registration in
accordance with the number of Conversion Shares held by and issuable upon
conversion of Registrable Securities to each such Holder so requested to be
registered.
(f) Selection of Underwriters. The managing underwriter
or underwriters of each underwritten offering of the Registrable Securities so
to be registered shall be proposed by the Requisite Percentage of Participating
Holders (and shall be reasonably acceptable to the Company).
(g) Postponement. The Company shall be entitled once to
postpone for a reasonable period of time (but not to exceed 180 days) the filing
of any registration statement required to be prepared and filed by it pursuant
to this Section 2.1 if a nationally recognized investment bank (which investment
bank shall be selected by and mutually agreeable to both an investment bank
selected by the Company and an investment bank selected by the Requisite
Percentage of Participating Holders) shall advise the Company in writing that,
in its opinion, the Company is unable to effect an underwritten offering due to
then currently prevailing market conditions or due to circumstances affecting
the financial condition, business or operations of the Company. Promptly (but in
no event more than 30 days) after receipt of such opinion, the Company shall
give the participating Holders written notice of its determination to postpone
the filing of any registration statement, and an approximation of the
anticipated delay. If the Company shall so postpone the filing of a registration
statement, the participating Holders representing the Requisite Percentage of
Participating Holders shall have the right to withdraw the request for
registration by
-4-
<PAGE>
giving written notice to the Company within 20 days after receipt of the notice
of postponement and, in the event of such withdrawal, such request shall not be
counted toward the number of Demand Registrations (including for purposes of
paragraph (d) of this Section 2.1).
2.2. Piggyback Registrations.
(a) Piggyback Registrations. If, at any time, the
Company proposes or is required to register any of its equity securities under
the Securities Act (other than pursuant to (i) registrations on such form or
similar form(s) solely for registration of securities in connection with an
employee benefit plan or dividend reinvestment plan or a merger, consolidation
or acquisition or (ii) a Demand Registration under Section 2.1) on a
registration statement on Form S-1, Form S-2 or Form S-3 (or an equivalent
general registration form then in effect), whether or not for its own account,
the Company shall give prompt written notice of its intention to do so to each
of the Holders of record of Registrable Securities. Upon the written request of
any Holder, made within 15 days following the receipt of any such written notice
(which request shall specify the maximum number of Registrable Securities
intended to be disposed of by such Holder and the intended method of
distribution thereof), the Company shall use its best efforts to cause all such
Registrable Securities, the Holders of which have so requested the registration
thereof, to be registered under the Securities Act (with the securities that the
Company at the time proposes to register) to permit the sale or other
disposition by the Holders (in accordance with the intended method of
distribution thereof) of the Registrable Securities to be so registered. There
is no limitation on the number of such piggyback registrations pursuant to the
preceding sentence that the Company is obligated to effect. No registration
effected under this Section 2.2(a) shall relieve the Company of its obligations
to effect Demand Registrations.
(b) Abandonment or Delay. If, at any time after giving
written notice of its intention to register any equity securities and prior to
the effective date of the registration statement filed in connection with such
registration, the Company shall determine for any reason not to register or to
delay registration of such equity securities, the Company may, at its election,
give written notice of such determination to all Holders of record of
Registrable Securities and (i) in the case of a determination not to register,
shall be relieved of its obligation to register any Registrable Securities in
connection with such abandoned registration, without prejudice, however, to the
rights of Holders under Section 2.1, and (ii) in the case of a determination to
delay such registration of its equity securities, shall be permitted to delay
the registration of such Registrable Securities for the same period as the delay
in registering such other equity securities.
(c) Holder's Right to Withdraw. Any Holder shall have
the right to withdraw its request for inclusion of its Registrable Securities in
any registration statement pursuant to this Section 2.2 by giving written notice
to the Company of its request to withdraw; provided, however, that (i) such
request must be made in writing prior to the earlier of the execution of the
underwriting agreement or the execution of
-5-
<PAGE>
the custody agreement with respect to such registration and (ii) such withdrawal
shall be irrevocable and, after making such withdrawal, a Holder shall no longer
have any right to include Registrable Securities in the registration as to which
such withdrawal was made.
(d) Cutbacks. If the managing underwriter of any
underwritten offering shall inform the Company by letter of its belief that the
number of Registrable Securities requested to be included in a registration
under this Section 2.2 would materially adversely affect such offering, then the
Company will include in such registration, first, the securities proposed by the
Company to be sold for its own account and, second, the Registrable Securities
and all other securities of the Company to be included in such registration to
the extent of the number and type, if any, that the Company is so advised can be
sold in (or during the time of) such offering.
2.3. S-3 Registrations. If at any time (i) one or more Holders of
Registrable Securities representing the Registrable Percentage of Outstanding
Holders request that the Company file a registration statement on Form S-3 or
any successor thereto for a public offering of all or any portion of the shares
of Registrable Securities held by such Holder or Holders, the reasonably
anticipated aggregate price to the public of which would exceed $1,000,000, and
(ii) the Company is a registrant entitled to use Form S-3 or any successor
thereto to register such shares, then the Company shall use its best efforts to
register under the Securities Act on Form S-3 or any successor thereto, for
public sale in accordance with the method of disposition specified in such
notice, the number of shares of Registrable Securities specified in such notice.
Whenever the Company is required by this Section 2.3 to use its best efforts to
effect the registration of Registrable Securities, each of the procedures and
requirements of Section 2.1 (including but not limited to the requirement that
the Company notify all Holders of Registrable Securities from whom notice has
not been received and provide them with the opportunity to participate in the
offering) shall apply to such registration. Notwithstanding anything to the
contrary contained herein, (i) no request may be made under this Section 2.3
within six months after the effective date of a registration statement filed by
the Company covering a firm commitment underwritten public offering in which the
holders of Registrable Securities shall have been entitled to join pursuant to
Sections 2.1 and 2.2 in which there shall have been effectively registered all
shares of Registrable Securities as to which registration shall have been
requested registrations pursuant to this Section 2.3 and (ii) the Company shall
not be required to effect more than four registrations pursuant to this Section
2.3.
2.4. Registration Procedures. If and whenever the Company is
required by the provisions of this Agreement to use its best efforts to effect
or cause the registration of any Registrable Securities under the Securities Act
as provided in this Agreement, the Company shall, as expeditiously as possible:
(a) prepare and file with the SEC a registration
statement on an appropriate registration form of the SEC for the disposition of
such Registrable Securities in accordance with the intended method of
disposition thereof, which form (i)
-6-
<PAGE>
shall be selected by the Company and (ii) shall, in the case of a shelf
registration, be available for the sale of the Registrable Securities by the
selling Holders thereof and such registration statement shall comply as to form
in all material respects with the requirements of the applicable form and
include all financial statements required by the SEC to be filed therewith, and
the Company shall use its best efforts to cause such registration statement to
become effective (provided, however, that before filing a registration statement
or prospectus or any amendments or supplements thereto, or comparable statements
under securities or blue sky laws of any jurisdiction, the Company will furnish
to one counsel for the Holders participating in the planned offering (selected
by the Major Holder) and the underwriters, if any, copies of all such documents
proposed to be filed (including all exhibits thereto), which documents will be
subject to the reasonable review and, in the case of a registration pursuant to
Section 2.1 or Section 2.3, reasonable comment of such counsel, and the Company
shall not file any registration statement or amendment thereto or any prospectus
or supplement thereto pursuant to Sections 2.1 or 2.3 to which the holders of a
majority of the Registrable Securities covered by such registration statement or
the underwriters, if any, shall reasonably object in writing);
(b) in connection with any Demand Registration, prepare
and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection therewith as may be necessary to
keep such registration statement effective for such period (which shall not be
required to exceed 180 days) as any seller of Registrable Securities pursuant to
such registration statement shall request and to comply with the provisions of
the Securities Act with respect to the sale or other disposition of all
Registrable Securities covered by such registration statement in accordance with
the intended methods of disposition by the seller or sellers thereof set forth
in such registration statement;
(c) furnish, without charge, to each seller of such
Registrable Securities and each underwriter, if any, of the securities covered
by such registration statement such number of copies of such registration
statement, each amendment and supplement thereto (in each case including all
exhibits), and the prospectus included in such registration statement (including
each preliminary prospectus) in conformity with the requirements of the
Securities Act, and other documents, as such seller and underwriter may
reasonably request in order to facilitate the public sale or other disposition
of the Registrable Securities owned by such seller (the Company hereby
consenting to the use in accordance with applicable law of each such
registration statement (or amendment or post-effective amendment thereto) and
each such prospectus (or preliminary prospectus or supplement thereto) by each
such seller of Registrable Securities and the underwriters, if any, in
connection with the offering and sale of the Registrable Securities covered by
such registration statement or prospectus);
(d) use its best efforts to register or qualify the
Registrable Securities covered by such registration statement under such other
securities or "blue sky" laws of such jurisdictions as any sellers of
Registrable Securities or any managing underwriter,
-7-
<PAGE>
if any, shall reasonably request in writing, and do any and all other acts and
things that may be reasonably necessary or advisable to enable such sellers or
underwriter, if any, to consummate the disposition of the Registrable Securities
in such jurisdictions, except that in no event shall the Company be required to
qualify to do business as a foreign corporation in any jurisdiction where it
would not, but for the requirements of this paragraph (d), be required to be so
qualified, to subject itself to taxation in any such jurisdiction or to consent
to general service of process in any such jurisdiction;
(e) promptly notify each Holder selling Registrable
Securities covered by such registration statement and each managing underwriter,
if any: (i) when the registration statement, any pre-effective amendment, the
prospectus or any prospectus supplement related thereto or post-effective
amendment to the registration statement has been filed and, with respect to the
registration statement or any post-effective amendment, when the same has become
effective; (ii) of any request by the SEC or state securities authority for
amendments or supplements to the registration statement or the prospectus
related thereto or for additional information; (iii) of the issuance by the SEC
of any stop order suspending the effectiveness of the registration statement or
the initiation of any proceedings for that purpose; (iv) of the receipt by the
Company of any notification with respect to the suspension of the qualification
of any Registrable Securities for sale under the securities or blue sky laws of
any jurisdiction or the initiation of any proceeding for such purpose; (v) of
the existence of any fact of which the Company becomes aware that results in the
registration statement, the prospectus related thereto or any document
incorporated therein by reference containing an untrue statement of a material
fact or omitting to state a material fact required to be stated therein or
necessary to make any statement therein not misleading; and (vi) if at any time
the representations and warranties contemplated by Section 3 below cease to be
true and correct in all material respects; and, if the notification relates to
an event described in clause (v), the Company shall promptly prepare and furnish
to each such seller and each underwriter, if any, a reasonable number of copies
of a prospectus supplemented or amended so that, as thereafter delivered to the
purchasers of such Registrable Securities, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein in the light of
the circumstances under which they were made not misleading;
(f) comply with all applicable rules and regulations of
the SEC, and make generally available to its security holders, as soon as
reasonably practicable after the effective date of the registration statement
(and in any event within 16 months thereafter), an earnings statement (which
need not be audited) covering the period of at least twelve consecutive months
beginning with the first day of the Company's first calendar quarter after the
effective date of the registration statement, which earnings statement shall
satisfy the provisions of Section 11(a) of the Securities Act and Rule 158
thereunder;
(g) (i) cause all such Registrable Securities covered by
such registration statement to be listed on the principal securities exchange on
which similar
-8-
<PAGE>
securities issued by the Company are then listed (if any), if the listing of
such Registrable Securities is then permitted under the rules of such exchange,
or (ii) if no similar securities are then so listed, to either cause all such
Registrable Securities to be listed on a national securities exchange or to
secure designation of all such Registrable Securities as a National Association
of Securities Dealers, Inc. Automated Quotation System ("NASDAQ") "national
market system security" within the meaning of Rule 11Aa2-1 of the SEC or,
failing that, secure NASDAQ authorization for such shares and, without limiting
the generality of the foregoing, take all actions that may be required by the
Company as the issuer of such Registrable Securities in order to facilitate the
managing underwriter's arranging for the registration of at least two market
makers as such with respect to such shares with the National Association of
Securities Dealers, Inc. (the "NASD");
(h) provide and cause to be maintained a transfer agent
and registrar for all such Registrable Securities covered by such registration
statement not later than the effective date of such registration statement;
(i) enter into such customary agreements (including, if
applicable, an underwriting agreement) and take such other actions as the
Holders of a majority of the Registrable Securities or the Major Holder
participating in such offering shall reasonably request in order to expedite or
facilitate the disposition of such Registrable Securities;
(j) obtain an opinion from the Company's counsel and a
"cold comfort" letter from the Company's independent public accountants in
customary form and covering such matters as are customarily covered by such
opinions and "cold comfort" letters delivered to underwriters in underwritten
public offerings, which opinion and letter shall be reasonably satisfactory to
the underwriters, if any, and to the Major Holder participating in such
offering, and furnish to each Holder participating in the offering and to each
underwriter, if any, a copy of such opinion and letter addressed to such Holder
(in the case of the opinion) and underwriter (in the case of the opinion and the
"cold comfort" letter);
(k) deliver promptly to the Major Holder and counsel for
the selling Holders participating in the offering and each underwriter, if any,
copies of all correspondence between the Commission and the Company, its counsel
or auditors and any memoranda relating to discussions with the Commission or its
staff with respect to the registration statement, other than those portions of
any such memoranda that contain information subject to attorney-client privilege
with respect to the Company, and, upon receipt of such confidentiality
agreements as the Company may reasonably request, make reasonably available for
inspection by any seller of such Registrable Securities covered by such
registration statement, by any underwriter, if any, participating in any
disposition to be effected pursuant to such registration statement and by any
attorney, accountant or other agent retained by any such seller or any such
underwriter, all pertinent financial and other records, pertinent corporate
documents and properties of the Company, and cause all of the Company's
officers,
-9-
<PAGE>
directors and employees to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such
registration statement;
(l) use its best efforts to promptly obtain the
withdrawal of any order suspending the effectiveness of the registration
statement;
(m) provide a CUSIP number for all Registrable
Securities, not later than the effective date of the registration statement;
(n) make reasonably available its employees and personnel
and otherwise provide reasonable assistance to the underwriters (taking into
account the needs of the Company's businesses and the requirements of the
marketing process) in the marketing of Registrable Securities in any
underwritten offering;
(o) promptly prior to the filing of any document that is
to be incorporated by reference into the registration statement or the
prospectus (after the initial filing of such registration statement) provide
copies of such document to counsel for the selling holders of Registrable
Securities and to each managing underwriter, if any, and make the Company's
representatives reasonably available for discussion of such document and make
such changes in such document concerning the selling holders prior to the filing
thereof as counsel for such selling holders or underwriters may reasonably
request;
(p) furnish to each Holder participating in the offering
and the managing underwriter, without charge, at least one signed copy of the
registration statement and any post-effective amendments thereto, including
financial statements and schedules, all documents incorporated therein by
reference and all exhibits (including those incorporated by reference);
(q) cooperate with the selling Holders of Registrable
Securities and the managing underwriter, if any, to facilitate the timely
preparation and delivery of certificates not bearing any restrictive legends
representing the Registrable Securities to be sold, and cause such Registrable
Securities to be issued in such denominations and registered in such names in
accordance with the underwriting agreement prior to any sale of Registrable
Securities to the underwriters or, if not an underwritten offering, in
accordance with the instructions of the selling holders of Registrable
Securities at least three business days prior to any sale of Registrable
Securities; and
(r) take all such other commercially reasonable actions
as are necessary or advisable in order to expedite or facilitate the disposition
of such Registrable Securities.
The Company may require as a condition precedent to the
Company's obligations under this Section 2.4 that each seller of Registrable
Securities as to which any registration is being effected furnish the Company
such information regarding such
-10-
<PAGE>
seller and the distribution of such securities as the Company may from time to
time reasonably request; provided that such information shall be used only in
connection with such registration.
Each Holder of Registrable Securities agrees that upon receipt
of any notice from the Company of the happening of any event of the kind
described in clause (v) of paragraph (e) of this Section 2.4, such Holder will
discontinue such Holder's disposition of Registrable Securities pursuant to the
registration statement covering such Registrable Securities until such Holder's
receipt of the copies of the supplemented or amended prospectus contemplated by
paragraph (e) of this Section 2.4 and, if so directed by the Company, will
deliver to the Company (at the Company's expense) all copies, other than
permanent file copies, then in such Holder's possession of the prospectus
covering such Registrable Securities that was in effect at the time of receipt
of such notice. In the event the Company shall give any such notice, the
applicable period mentioned in paragraph (b) of this Section 2.4 shall be
extended by the number of days during such period from and including the date of
the giving of such notice to and including the date when each seller of any
Registrable Securities covered by such registration statement shall have
received the copies of the supplemented or amended prospectus contemplated by
paragraph (e) of this Section 2.4.
If any such registration statement or comparable statement
under "blue sky" laws refers to any Holder by name or otherwise as the Holder of
any securities of the Company, then such Holder shall have the right to require
(i) the insertion therein of language, in form and substance satisfactory to
such Holder and the Company, to the effect that the holding by such Holder of
such securities is not to be construed as a recommendation by such Holder of the
investment quality of the Company's securities covered thereby and that such
holding does not imply that such Holder will assist in meeting any future
financial requirements of the Company, or (ii) in the event that such reference
to such Holder by name or otherwise is not in the judgment of the Company, as
advised by counsel, required by the Securities Act or any similar federal
statute or any state "blue sky" or securities law then in force, the deletion of
the reference to such Holder.
2.5. Registration Expenses.
(a) "Expenses" shall mean any and all fees and expenses
incident to the Company's performance of or compliance with this Article 2,
including, without limitation: (i) SEC, stock exchange or NASD registration,
listing and filing fees and all listing fees and fees with respect to the
inclusion of securities in NASDAQ, (ii) fees and expenses of compliance with
state securities or "blue sky" laws and in connection with the preparation of a
"blue sky" survey, including without limitation, reasonable fees and expenses of
blue sky counsel, (iii) printing and copying expenses, (iv) messenger and
delivery expenses, (v) expenses incurred in connection with any road show, (vi)
fees and disbursements of counsel for the Company, (vii) with respect to each
registration, the reasonable fees and disbursements of one counsel for the
selling Holder(s)
-11-
<PAGE>
(selected by the Major Holder), (viii) fees and disbursements of all independent
public accountants (including the expenses of any audit and/or "cold comfort"
letter) and fees and expenses of other persons, including special experts,
retained by the Company, (ix) fees and expenses payable to a Qualified
Independent Underwriter, (x) fees and expenses payable to the investment banks
referred to in Section 2.1(g) and (xi) any other fees and disbursements of
underwriters, if any, customarily paid by issuers or sellers of securities
(collectively, "Expenses").
(b) The Company shall pay all Expenses with respect to
any Demand Registration, whether or not it becomes effective or remains
effective for the period contemplated by Section 2.4(b), and with respect to any
registration effected under Sections 2.2 or 2.3.
(c) Notwithstanding the foregoing, (x) the provisions of
this Section 2.5 shall be deemed amended to the extent necessary to cause these
expense provisions to comply with "blue sky" laws of each state in which the
offering is made and (y) in connection with any registration hereunder, each
Holder of Registrable Securities being registered shall pay all underwriting
discounts and commissions and any transfer taxes, if any, attributable to the
sale of such Registrable Securities, pro rata with respect to payments of
discounts and commissions in accordance with the number of shares sold in the
offering by such Holder, and (z) the Company shall, in the case of all
registrations under this Article 2, be responsible for all its internal expenses
(including, without limitation, all salaries and expenses of its officers and
employees performing legal or accounting duties).
2.6. Certain Limitations on Registration Rights. In the case of
any registration under Section 2.1 pursuant to an underwritten offering, or in
the case of a registration under Sections 2.2 or 2.3 if the Company has
determined to enter into an underwriting agreement in connection therewith, all
securities to be included in such registration shall be subject to an
underwriting agreement and no Person may participate in such registration unless
such Person agrees to sell such Person's securities on the basis provided
therein and completes and executes all reasonable questionnaires and other
documents (including custody agreements and powers of attorney) that must be
executed in connection therewith, and provides such other information to the
Company or the underwriter as may be necessary to register such Person's
securities.
2.7. Limitations on Sale or Distribution of Other Securities.
(a) To the extent requested in writing by a managing
underwriter, if any, of any registration effected pursuant to Section 2.1, each
Holder of Registrable Securities agrees not to sell, transfer or otherwise
dispose of, including any sale pursuant to Rule 144 under the Securities Act,
any Common Stock, or any other equity security of the Company or any security
convertible into or exchangeable or exercisable for any equity security of the
Company (other than as part of such underwritten public offering) during the
time period reasonably requested by the managing underwriter, not to exceed 180
days (and the Company hereby also so
-12-
<PAGE>
agrees (except that the Company may effect any sale or distribution of any such
securities pursuant to a registration on Form S-4 (if reasonably acceptable to
such managing underwriter) or Form S-8, or any successor or similar form that is
then in effect or upon the conversion, exchange or exercise of any then
outstanding Common Stock Equivalent) to use its reasonable best efforts to cause
each holder of any equity security or any security convertible into or
exchangeable or exercisable for any equity security of the Company purchased
from the Company at any time other than in a public offering so to agree). Each
managing underwriter shall be entitled to rely on the agreements of each Holder
of Registrable Securities set forth in this Section 2.7(a) and shall be a third
party beneficiary of the provisions of this Section 2.7(a).
(b) The Company hereby agrees that, if it shall
previously have received a request for registration pursuant to Section 2.1, 2.2
or 2.3, and if such previous registration shall not have been withdrawn or
abandoned, the Company shall not sell, transfer, or otherwise dispose of, any
Common Stock, or any other equity security of the Company or any security
convertible into or exchangeable or exercisable for any equity security of the
Company (other than as part of such underwritten public offering, a registration
on Form S-4 or Form S-8 or any successor or similar form that is then in effect
or upon the conversion, exchange or exercise of any then outstanding Common
Stock Equivalent), until a period of 180 days shall have elapsed from the
effective date of such previous registration; and the Company shall so provide
in any registration rights agreements hereafter entered into with respect to any
of its securities.
2.8. No Required Sale. Nothing in this Agreement shall be deemed
to create an independent obligation on the part of any Holder to sell any
Registrable Securities pursuant to any effective registration statement.
2.9. Indemnification.
(a) In the event of any registration of any securities of
the Company under the Securities Act pursuant to this Article 2, the Company
will, and hereby does, indemnify and hold harmless, to the fullest extent
permitted by law, each Holder of Registrable Securities, its directors,
officers, affiliates, employees, stockholders, members and partners (and the
directors, officers, affiliates, employees, stockholders, members and partners
thereof), each other Person who participates as an underwriter or a Qualified
Independent Underwriter, if any, in the offering or sale of such securities,
each officer, director, employee, stockholder, member or partner of such
underwriter or Qualified Independent Underwriter, and each other Person, if any,
who controls such seller or any such underwriter within the meaning of the
Securities Act, against any and all losses, claims, damages or liabilities,
joint or several, actions or proceedings (whether commenced or threatened) in
respect thereof ("Claims") and expenses (including reasonable fees of counsel
and any amounts paid in any settlement effected with the Company's consent,
which consent shall not be unreasonably withheld or delayed) to which each such
indemnified party may become subject under the Securities Act or otherwise,
insofar as such Claims or expenses arise out of or are
-13-
<PAGE>
based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement under which such securities were
registered under the Securities Act, together with the documents incorporated by
therein or the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, or (ii) any untrue statement or alleged untrue statement of a
material fact contained in any preliminary, final or summary prospectus or any
amendment or supplement thereto, together with the documents incorporated by
reference therein, or the omission or alleged omission to state therein a
material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading; provided, however, that the Company shall not be liable to
any such indemnified party in any such case to the extent such Claim or expense
arises out of or is based upon any untrue statement or alleged untrue statement
of a material fact or omission or alleged omission of a material fact made in
such registration statement or amendment thereof or supplement thereto or in any
such prospectus or any preliminary, final or summary prospectus in reliance upon
and in conformity with written information furnished to the Company by or on
behalf of such indemnified party specifically for use therein. Such indemnity
and reimbursement of expenses shall remain in full force and effect regardless
of any investigation made by as on behalf of such indemnified party and shall
survive the transfer of such securities by such seller.
(b) Each Holder of Registrable Securities that are
included in the securities as to which any registration under Section 2.1, 2.2
or 2.3 is being effected (and, if the Company requires as a condition to
including any Registrable Securities in any registration statement filed in
accordance with Section 2.1, 2.2 or 2.3, any underwriter and Qualified
Independent Underwriter, if any) shall, severally and not jointly, indemnify and
hold harmless (in the same manner and to the same extent as set forth in
paragraph (a) of this Section 2.9) to the extent permitted by law the Company,
its officers and directors, each Person controlling the Company within the
meaning of the Securities Act and all other prospective sellers and their
directors, officers, general and limited partners and respective controlling
Persons with respect to any untrue statement or alleged untrue statement of any
material fact in, or omission or alleged omission of any material fact from,
such registration statement, any preliminary, final or summary prospectus
contained therein, or any amendment or supplement thereto, if such statement or
alleged statement or omission or alleged omission was made in reliance upon and
in conformity with written information furnished to the Company or its
representatives by or on behalf of such Holder or underwriter or Qualified
Independent Underwriter, if any, specifically for use therein and reimburse such
indemnified party for any legal or other expenses reasonably incurred in
connection with investigating or defending any such Claim as such expenses are
incurred; provided, however, that the aggregate amount that any such Holder
shall be required to pay pursuant to this Section 2.9(b) and Sections 2.9(c) and
(e) shall in no case be greater than the amount of the net proceeds received by
such person upon the sale of the Registrable Securities pursuant to the
registration statement giving rise to such claim. Such indemnity and
reimbursement of expenses shall remain in full force and effect
-14-
<PAGE>
regardless of any investigation made by or on behalf of such indemnified party
and shall survive the transfer of such securities by such Holder.
(c) Indemnification similar to that specified in the
preceding paragraphs (a) and (b) of this Section 2.9 (with appropriate
modifications) shall be given by the Company and each seller of Registrable
Securities with respect to any required registration or other qualification of
securities under any state securities and "blue sky" laws.
(d) Any person entitled to indemnification under this
Agreement shall notify promptly the indemnifying party in writing of the
commencement of any action or proceeding with respect to which a claim for
indemnification may be made pursuant to this Section 2.9, but the failure of any
indemnified party to provide such notice shall not relieve the indemnifying
party of its obligations under the preceding paragraphs of this Section 2.9,
except to the extent the indemnifying party is materially prejudiced thereby and
shall not relieve the indemnifying party from any liability that it may have to
any indemnified party otherwise than under this Article 2. In case any action
or proceeding is brought against an indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate therein and, unless in the reasonable opinion of outside
counsel to the indemnified party a conflict of interest between such indemnified
and indemnifying parties may exist in respect of such claim, to assume the
defense thereof jointly with any other indemnifying party similarly notified, to
the extent that it chooses, with counsel reasonably satisfactory to such
indemnified party, and after notice from the indemnifying party to such
indemnified party that it so chooses, the indemnifying party shall not be liable
to such indemnified party for any legal or other expenses subsequently incurred
by such indemnified party in connection with the defense thereof other than
reasonable costs of investigation; provided, however, that (i) if the
indemnifying party fails to take reasonable steps necessary to defend diligently
the action or proceeding within 20 days after receiving notice from such
indemnified party that the indemnified party believes it has failed to do so; or
(ii) if such indemnified party who is a defendant in any action or proceeding
that is also brought against the indemnifying party reasonably shall have
concluded that there may be one or more legal defenses available to such
indemnified party that are not available to the indemnifying party; or (iii) if
representation of both parties by the same counsel is otherwise inappropriate
under applicable standards of professional conduct, then, in any such case, the
indemnified party shall have the right to assume or continue its own defense as
set forth above (but with no more than one firm of counsel for all indemnified
parties in each jurisdiction who shall be approved by the Major Holder of the
registration in respect of which such indemnification is sought), and the
indemnifying party shall be liable for any expenses therefor. No indemnifying
party shall, without the written consent of the indemnified party, effect the
settlement or compromise of, or consent to the entry of any judgment with
respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the
indemnified party is an actual or potential party to such action or claim)
unless such
-15-
<PAGE>
settlement, compromise or judgment (A) includes an unconditional release of the
indemnified party from all liability arising out of such action or claim and (B)
does not include a statement as to or an admission of fault, culpability or a
failure to act, by or on behalf of any indemnified party.
(e) If for any reason the foregoing indemnity is
unavailable or is insufficient to hold harmless an indemnified party under
Sections 2.9(a), (b) or (c), then each indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of any Claim in
such proportion as is appropriate to reflect the relative fault of the
indemnifying party, on the one hand, and the indemnified party, on the other
hand, with respect to such offering of securities. The relative fault shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the indemnifying party or the
indemnified party and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such untrue statement or
omission. If, however, the allocation provided in the second preceding sentence
is not permitted by applicable law, then each indemnifying party shall
contribute to the amount paid or payable by such indemnified party in such
proportion as is appropriate to reflect not only such relative faults but also
the relative benefits of the indemnifying party and the indemnified party as
well as any other relevant equitable considerations. The parties hereto agree
that it would not be just and equitable if contributions pursuant to this
Section 2.9(e) were to be determined by pro rata allocation or by any other
method of allocation that does not take account of the equitable considerations
referred to in the preceding sentences of this Section 2.9(e). The amount paid
or payable in respect of any Claim shall be deemed to include any legal or other
expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such Claim. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. Notwithstanding anything in this Section 2.9(e)
to the contrary, no indemnifying party (other than the Company) shall be
required pursuant to this Section 2.9(e) to contribute any amount in excess of
the net proceeds received by such indemnifying party from the sale of
Registrable Securities in the offering to which the losses, claims, damages or
liabilities of the indemnified parties relate, less the amount of any
indemnification payment made by such indemnifying party pursuant to Sections
2.9(b) and (c).
(f) The indemnity agreements contained herein shall be in
addition to any other rights to indemnification or contribution that any
indemnified party may have pursuant to law or contract and shall remain
operative and in full force and effect regardless of any investigation made or
omitted by or on behalf of any indemnified party and shall survive the transfer
of the Registrable Securities by any such party.
(g) The indemnification and contribution required by this
Section 2.9 shall be made by periodic payments of the amount thereof during the
course of the
-16-
<PAGE>
investigation or defense, as and when bills are received or expense, loss,
damage or liability is incurred.
3. Underwritten Offerings.
3.1. Requested Underwritten Offerings. If requested by the
underwriters for any underwritten offering by the Holders pursuant to a
registration requested under Section 2.1 or 2.3, the Company shall enter into a
customary underwriting agreement with the underwriters. Such underwriting
agreement shall be satisfactory in form and substance to the Major Holder and
shall contain such representations and warranties by, and such other agreements
on the part of, the Company and such other terms as are generally included in
the standard underwriting agreement of such underwriters, including, without
limitation, indemnities and contribution agreements. Any Holder participating
in the offering shall be a party to such underwriting agreement and may, at its
option, require that any or all of the representations and warranties by, and
the other agreements on the part of, the Company to and for the benefit of such
underwriters shall also be made to and for the benefit of such Holder and that
any or all of the conditions precedent to the obligations of such underwriters
under such underwriting agreement be conditions precedent to the obligations of
such Holder. Such underwriting agreement shall also contain such
representations and warranties by the participating Holders as are customary in
agreements of that type.
3.2. Piggyback Underwritten Offerings. In the case of a
registration pursuant to Section 2.2 hereof, if the Company shall have
determined to enter into an underwriting agreement in connection therewith, all
of the Holders' Registrable Securities to be included in such registration shall
be subject to such underwriting agreement. Any Holder participating in such
registration may, at its option, require that any or all of the representations
and warranties by, and the other agreements on the part of, the Company to and
for the benefit of such underwriters shall also be made to and for the benefit
of such Holder and that any or all of the conditions precedent to the
obligations of such underwriters under such underwriting agreement be conditions
precedent to the obligations of such Holder. Such underwriting agreement shall
also contain such representations and warranties by the participating Holders as
are customary in agreements of that type.
4. General.
4.1. Adjustments Affecting Registrable Securities. The Company
agrees that it shall not effect or permit to occur any combination or
subdivision of shares that would adversely affect the ability of the Holder of
any Registrable Securities to include such Registrable Securities in any
registration contemplated by this Agreement or the marketability of such
Registrable Securities in any such registration. The Company agrees that it
will take all reasonable steps necessary to effect a subdivision of shares if in
the reasonable judgment of (a) the Holder of Registrable Securities that makes a
Demand Registration Request or (b) the managing underwriter for the offering in
respect of such Demand Registration Request, such subdivision would enhance the
-17-
<PAGE>
marketability of the Registrable Securities. Each Holder agrees to vote all of
its shares of capital stock in a manner, and to take all other actions
necessary, to permit the Company to carry out the intent of the preceding
sentence including, without limitation, voting in favor of an amendment to the
Company's Articles of Incorporation in order to increase the number of
authorized shares of capital stock of the Company.
4.2. Rule 144. If the Company shall have filed a registration
statement pursuant to the requirements of Section 12 of the Exchange Act or a
registration statement pursuant to the requirements of the Securities Act in
respect of the Common Stock or securities of the Company convertible into or
exchangeable or exercisable for Common Stock, the Company covenants that (i) so
long as it remains subject to the reporting provisions of the Exchange Act, it
will timely file the reports required to be filed by it under the Securities Act
or the Exchange Act (including, but not limited to, the reports under Sections
13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1) of Rule 144
under the Securities Act), and (ii) will take such further action as any Holder
of Registrable Securities may reasonably request, all to the extent required
from time to time to enable such Holder to sell Registrable Securities without
registration under the Securities Act within the limitation of the exemptions
provided by (A) Rule 144 under the Securities Act, as such Rule may be amended
from time to time, or (B) any similar rule or regulation hereafter adopted by
the Commission. Upon the request of any Holder of Registrable Securities, the
Company will deliver to such Holder a written statement as to whether it has
complied with such requirements.
4.3. Amendments and Waivers. This Agreement may be amended,
modified, supplemented or waived only upon the written agreement of the Company
and the holders of not less than a majority of the shares of Registrable
Securities (treating all shares of Series D Preferred as having been converted
at the conversion ratio then in effect).
4.4. Notices. Except as otherwise provided in this Agreement, all
notices, requests, consents and other communications hereunder to any party
shall be deemed to be sufficient if contained in a written instrument delivered
in person or by telecopy, nationally recognized overnight courier or first class
registered or certified mail, return receipt requested, postage prepaid,
addressed to such party at the address set forth below or such other address as
may hereafter be designated in writing by such party to the other parties:
(i) if to the Company, to:
Doctors Health System, Inc.
10451 Mill Run Circle
Owings Mills, MD 21117
Telecopy: (410)
Attention:
-18-
<PAGE>
(ii) if to Beacon, to:
The Beacon Group III - Focus Value Fund, L.P.
399 Park Avenue
New York, NY 10022
Telecopy: (212) 339-9109
Attention: Eric R. Wilkinson
with a copy to:
Fried, Frank, Harris, Shriver & Jacobson
One New York Plaza
New York, NY 10004
Telecopy: (212) 859-8587
Attention: David N. Shine, Esq.
All such notices, requests, consents and other communications shall be deemed to
have been given when received.
4.5. No Inconsistent Agreements. Without the prior written consent
of Beacon, the Company will not, on or after the date of this Agreement, enter
into any agreement with respect to its securities that is inconsistent with the
rights granted in this Agreement or otherwise conflicts with the provisions
hereof, other than any lock-up agreement with the underwriters in connection
with any registered offering effected hereunder, pursuant to which the Company
shall agree not to register for sale, and the Company shall agree not to sell or
otherwise dispose of, Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock, for a specified period following
the registered offering.
4.6. Future Grants of Registration Rights. The Company shall not
grant any registration rights or similar rights with respect to its securities
without the consent of Beacon for so long as Beacon holds Registrable
Securities.
4.7. Miscellaneous.
(a) This Agreement shall be binding upon and inure to the
benefit of and be enforceable by the parties hereto and the respective
successors, personal representatives and assigns of the parties hereto, whether
so expressed or not. If any Person shall acquire Registrable Securities from
any Holder, in any manner, whether by operation of law or otherwise, such
transferee shall promptly notify the Company and such Registrable Securities
acquired from such Holder shall be held subject to all of the terms of this
Agreement, and by taking and holding such Registrable Securities such Person
shall be entitled to receive the benefits of and be conclusively deemed to have
agreed to be bound by and to perform all of the terms and provision of this
Agreement. If the Company shall so request, any such successor or assign shall
agree
-19-
<PAGE>
in writing to acquire and hold the Registrable Securities acquired from such
Holder subject to all of the terms hereof. If any Holder shall acquire
additional Registrable Securities, such Registrable Securities shall be subject
to all of the terms, and entitled to all the benefits, of this Agreement. No
Person other than a Holder shall be entitled to any benefits under this
Agreement, except as otherwise expressly provided herein.
(b) This Agreement (with the documents referred to herein
or delivered pursuant hereto) embodies the entire agreement and understanding
between the parties hereto and supersedes all prior agreements and
understandings relating to the subject matter hereof.
(c) This Agreement shall be construed and enforced in
accordance with and governed by the laws of the State of New York without giving
effect to the conflicts of law principles thereof.
(d) The headings in this Agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof. All
section references are to this Agreement unless otherwise expressly provided.
(e) This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
(f) Any term or provision of this Agreement that is
invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction.
(g) The parties hereto acknowledge that there would be no
adequate remedy at law if any party fails to perform any of its obligations
hereunder, and accordingly agree that each party, in addition to any other
remedy to which it may be entitled at law or in equity, shall be entitled to
injunctive relief, including specific performance, to enforce such obligations
without the posting of any bond, and, if any action should be brought in equity
to enforce any of the provisions of this Agreement, none of the parties hereto
shall raise the defense that there is an adequate remedy at law.
(h) Each party hereto shall do and perform or cause to be
done and performed all such further acts and things and shall execute and
deliver all such other agreements, certificates, instruments, and documents as
any other party hereto reasonably may request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.
-20-
<PAGE>
IN WITNESS WHEREOF, the undersigned have executed this Registration
Rights Agreement as of the date set forth above.
DOCTORS HEALTH SYSTEM, INC.
By: /s/ Stewart B. Gold
___________________
Name: Stewart B. Gold
Title: President
THE BEACON GROUP III -
FOCUS VALUE FUND, L.P.
By: Focus Value Investors, L.L.C.
By: Focus Value GP, Inc.
By: /s/ Eric R. Wilkinson
___________________
Name: Eric Wilkinson
Title: Managind Director
-21-
EXHIBIT 11
COMPUTATION OF (LOSS) EARNINGS PER COMMON SHARE
<TABLE>
<CAPTION>
Years Ended June 30,
1997 1996 1995
<S><C>
Weighted average of common shares outstanding during the period
(adjusted to reflect two-for-one stock split) 3,345,397 3,063,205 3,000,000
Net (loss) earnings $(14,800,050) $(6,612,113) $(1,755,685)
Dividends and issuance costs on Series A, B and C Redeemable, 1,382,083 552,531 113,300
Convertible Preferred
Net (loss) earnings as adjusted (16,182,133) (7,164,644) (1,868,985)
Net (loss) earnings per common share $(4.84) $(2.34) $(.62)
</TABLE>
All outstanding options and warrants as of June 30, 1997, 1996 and 1995 have
been excluded as they are anti-dilutive.
EXHIBIT 21
SUBSIDIARIES OF DOCTORS HEALTH, INC.
Doctors Health Primary Care IPA, Inc.
Doctors Health Medalie Equipment Corporation
Mishner Newco, Inc.
Williams Newco, Inc.
PCPA Newco, Inc.
WomanCare IPA, Inc.
Doctors Health of Virginia, Inc.
Montgomery Newco, Inc.
Anne Arundel Newco, Inc.
Medicap, Inc.
EXHIBIT 23.1
CONSENT
We have issued our report dated October 3, 1996, except for Note 20, which
is now incorporated into the second paragraph of Note 11 the date of which is
January 13, 1997, accompanying the consolidated financial statements and
schedules for the years ended June 30, 1996 and 1995 contained in the Annual
Report of Doctors Health, Inc. (formerly Doctors Health System, Inc.) on Form
10-K for the years ended June 30, 1997. We hereby consent to the use of the
aforementioned report in the Annual Report on Form 10-K, and to the use of our
name as it appears under the caption "Experts."
/s/ Grant Thornton LLP
Baltimore, Maryland
September 26, 1997
EXHIBIT 23.2
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation
by reference of our reports in this
Form 10-K, into the Company's previously filed S-1 Registration Statement File
No. 333-1926.
/s/ Arthur Andersen LLP
Baltimore, Maryland
September 26, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0001010005
<NAME> Doctors Health, Inc. 10-K
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-END> JUN-30-1997
<CASH> 4,737,828
<SECURITIES> 0
<RECEIVABLES> 5,279,801
<ALLOWANCES> 270,521
<INVENTORY> 0
<CURRENT-ASSETS> 11,543,753
<PP&E> 5,221,083
<DEPRECIATION> 1,015,551
<TOTAL-ASSETS> 24,478,642
<CURRENT-LIABILITIES> 16,616,631
<BONDS> 0
19,282,113
0
<COMMON> 34,552
<OTHER-SE> (19,576,731)
<TOTAL-LIABILITY-AND-EQUITY> 24,478,642
<SALES> 22,832,097
<TOTAL-REVENUES> 23,078,986
<CGS> 0
<TOTAL-COSTS> 22,823,613
<OTHER-EXPENSES> 14,273,459
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 781,964
<INCOME-PRETAX> (14,800,050)
<INCOME-TAX> 0
<INCOME-CONTINUING> (14,800,050)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (14,800,050)
<EPS-PRIMARY> (4.84)
<EPS-DILUTED> (4.84)
</TABLE>
